

JYU DISSERTATIONS 611

---

Rajanish Reddy Pallerla

# Studies Towards Synthesis of Favipiravir & Humilisin E

---



UNIVERSITY OF JYVÄSKYLÄ  
FACULTY OF MATHEMATICS  
AND SCIENCE

JYU DISSERTATIONS 611

---

**Rajanish Reddy Pallerla**

# **Studies Towards Synthesis of Favipiravir & Humilisin E**

Esitetään Jyväskylän yliopiston matemaattis-luonnontieteellisen tiedekunnan suostumuksella  
julkisesti tarkastettavaksi yliopiston Ylistönrinteen salissa Kem4  
maaliskuun 3. päivänä 2023 kello 12.

Academic dissertation to be publicly discussed, by permission of  
the Faculty of Mathematics and Science of the University of Jyväskylä,  
in Ylistönrinne, auditorium Kem4, on March 3, 2023 at 12 o'clock noon.



JYVÄSKYLÄN YLIOPISTO  
UNIVERSITY OF JYVÄSKYLÄ

JYVÄSKYLÄ 2023

Editors

Petri Pihko

Department of Chemistry, University of Jyväskylä

Ville Korkiakangas

Open Science Centre, University of Jyväskylä

Copyright © 2023, by author and University of Jyväskylä

ISBN 978-951-39-9305-4 (PDF)

URN:ISBN:978-951-39-9305-4

ISSN 2489-9003

Permanent link to this publication: <http://urn.fi/URN:ISBN:978-951-39-9305-4>

## ABSTRACT

Pallerla, Rajanish Reddy

Studies Towards Synthesis of Favipiravir & Humilisin E

Jyväskylä: University of Jyväskylä, 2023, 139 p.

(JYU Dissertations

ISSN 2489-9003; 611)

ISBN 978-951-39-9305-4 (PDF)

Synthetic organic chemistry has made human life easier by giving access to a variety of useful molecules. Be it academic research, industrial or medicinal applications, synthesis has paved way for accelerated growth in respective fields. The majority of drugs we use in our daily life are either natural products, analogues of natural products or mimic natural products in a certain way. Access to natural products from Nature can be laborious and inefficient, leading to a plethora of practical issues. Total synthesis bridges this gap by providing a way to access the required molecules from commercially available compounds.

The first chapter discusses the synthetic routes towards favipiravir, an antiviral with a large global demand. Motivated by COVID-19 pandemic, we became interested in addressing the chemical synthesis of this molecule. The chapter outlines the previously reported synthetic routes and describes the rationale behind the design of a shorter route.

The second chapter describes synthetic approaches towards the recently discovered tricyclic terpenoid humilisin E. Examples of natural products containing a bicyclo[3.2.0]heptane motif which constitutes the core of the humilisin E, and compiled examples from the literature for synthetic construction of this motif are reviewed. This discussion is followed by a detailed description of our own strategies to construct the bicyclo[3.2.0]heptane core of humilisin E, culminating in a successful stereocontrolled synthesis of the fully functionalized humilisin E core.

The entire thesis is summarized in chapter 3, and full experimental details are provided in chapter 4.

Keywords: total synthesis, natural products, terpenoids, pyrazines, cyclobutanes, cyclopentanes

# TIIVISTELMÄ

Pallerla, Rajanish Reddy

Faviripaviirin ja humilisiini E:n synteesiin tähtääviä tutkimuksia

Jyväskylä: Jyväskylän yliopisto, 2023, 139 s.

(JYU Dissertations

ISSN 2489-9003; 611)

ISBN 978-951-39-9305-4 (PDF)

Synteettinen orgaaninen kemia on helpottanut ihmisten elämää antamalla käsiimme erilaisia hyödyllisiä aineita. Sekä akateemisessa tutkimuksessa että teollisissa tai lääketieteen sovellutuksissa synteesikemia on ollut tärkeä tekijä alan kasvuun. Suuri osa päivittäisessä käytössä olevista lääkeaineista on joko luonnonaineita, niiden muunnelmia, tai luonnonaineiden toimintaa matkivia aineita. Tästä huolimatta luonnonaineita on usein vaikeaa ja kallista tuottaa luonnollisista lähteistään. Luonnonaineiden kokonaissynteesi tarjoaa onnistuessaan keinon tuottaa luonnonaineita kaupallisesti saatavista lähtöaineista.

Väitöskirjan ensimmäinen kappale käsittelee viruslääke faviripaviirin synteesiä. Faviripaviirin synteesiä motivoi COVID-19-pandemian eteneminen, koska tätä lääkeainetta kaavailtiin myös koronaviruslääkkeeksi. Tässä luvussa esitellään aiemmin julkaistuja faviripaviirin synteesimenetelmiä sekä omaa yritystämme kehittää lyhyempi ja tehokkaampi synteesimenetelmä faviripaviirille.

Toisessa kappaleessa kuvataan hiljattain eristetyn trisyklisen terpenoidin, humilisiini E:n, synteesiä. Kappaleessa esitellään kirjallisuudessa eri tapoja syntetisoida humilisiini E:n rakenteessa oleva bisyklo[3.2.0]heptaaniyksikkö tai sitä vastaava rakenne. Tämän jälkeen kappaleessa kuvataan omia synteesistrategioitamme ja lopulta onnistunutta humilisiini E:n ydinrakenteen stereokontrolloitua synteesiä.

Koko väitöskirjan yhteenveto esitellään luvussa 3, ja luku 4 sisältää kuvauksen väitöskirjan kokeellisesta työstä.

Avainsanat: kokonaissynteesi, luonnonaineet, terpenoidit, pyrasiinit, syklobutaanit, syklopentaanit

**Author**

Rajanish Reddy Pallerla  
Department of Chemistry  
P.O. Box 35  
FI-40014 University of Jyväskylä  
Finland  
rajanish.4.pallerla@jyu.fi

**Supervisors**

Professor Petri Pihko  
Department of Chemistry  
P.O. Box 35  
FI-40014 University of Jyväskylä  
Finland  
petri.pihko@jyu.fi

**Reviewers**

Prof. Edgars Suna  
Latvian Institute of Organic Synthesis  
Aizkraukles 21  
LV-1006, Riga  
Latvia

Prof. Pavel Kocovsky  
Department of Organic Chemistry  
Charles University  
Hlavova 2030/8  
1 28 43, Prague 2  
Czech Republic

**Opponent**

Prof. Trond Vidar Hansen  
Department of Pharmacy  
University of Oslo  
Sem Sælands vei 3  
Farmasibygningen  
0371, Oslo  
Norway

## ACKNOWLEDGEMENTS

The work presented in this dissertation was carried out at the Department of Chemistry, University of Jyväskylä. The work was financially supported by the Academy of Finland and the Faculty of Mathematics and Science Doctoral School.

I would like to express my sincere gratitude to my supervisor Professor Petri Pihko for giving me the opportunity to do research under his guidance. The journey over the years from our first meeting to the end of my doctoral studies has been enlightening and fascinating. Thank you for teaching me the ways of problem solving in organic chemistry required in research.

I am thankful for Professor Edgars Suna and Professor Pavel Kocovsky for their work in reviewing my dissertation and giving valuable comments. I would also like to thank all the co-workers and staff at Department of Chemistry for your assistance and support over the years.

Pihko group members both past and present that I worked with deserves a special mention. Thank you for all the help making me settle in, get used to the lab routines, and with the language. You people thought me more about Finland, and Finnish culture than I could have ever imagined. Everyday group coffee breaks require a special shout out for being the necessary stress busters. Lunch outings, sauna evenings, group dinners, and late-night parties; four years seemed like a very short time with you all. Thank you.

Moving to Finland during winter from one of the hottest parts of India might be a crazy thing to do. Rahul & Lasya, thank you for the help during the initial days. I will be forever grateful for treating me as family and making me feel at home.

I want to give my sincerest acknowledgements to my family for believing in me and supporting me all the time. Thank you to all the friends and mentors who helped me on my journey up to this point. My heartfelt gratitude to all the kameeni's & haraami's who were always by my side during the fun times and through the tough times. I am fortunate to have you people in my life.

Jyväskylä 27.1.2023

Rajanish Reddy Pallerla

## ABBREVIATIONS

|   |  |
|---|--|
| [O]   | oxidation  |
| °   | degree   |
| AChE  | acetylcholinesterase   |
| Ac  | acetyl   |
| AcOH  | acetic acid  |
| Ar  | aryl   |
| atm   | atmosphere   |
| AIBN  | 2,2'-azobis(2-methylpropionitrile)   |
| (S)-BINAP   | (S)-(-)-2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl  |
| Bn  | benzyl   |
| Bu  | butyl  |
| <i>t</i> -Bu                                      | <i>tert</i> -butyl   |
| <i>i</i> -Bu                                      | <i>iso</i> -butyl  |
| Bz  | benzoyl  |
| C   | centigrade/celsius   |
| CDI   | 1,1'-carbonyldiimidazole   |
| d   | doublet  |
| dba   | dibenzylideneacetone   |
| DCC   | N,N'-dicyclohexylcarbodiimide  |
| DCE   | 1,2-dichloroethane   |
| DCM   | dichloromethane  |
| DEE   | diethyl ether  |
| DEAD  | diethyl azodicarboxylate   |
| DIAD  | diisopropyl azodicarboxylate   |
| DIBAL-H   | diisobutylaluminium hydride  |
| DIPEA   | N,N-diisopropylethylamine  |
| DMAP  | 4-dimethylaminopyridine  |
| DMEA  | dimethylethylamine   |
| DMF   | N,N-dimethylformamide  |
| DMSO  | dimethyl sulfoxide   |
| DOWEX   | ion exchange resin   |
| Dppf  | 1,1'-ferrocenediyl-bis(diphenylphosphine)  |
| dr  | diastereomeric ratio   |
| E   | electrophile   |
| equiv.  | molar equivalent   |
| Et  | ethyl  |
| EtOAc   | ethyl acetate  |
| EtOH  | ethanol  |
| Grubbs' 2 <sup>nd</sup><br>generation<br>catalyst | (1,3-Bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene)dichloro(phenylmethylene)<br>(tricyclohexylphosphine)ruthenium |
| HGPRT   | hypoxanthine-guanine phosphoribosyltransferase   |
| HMPA  | hexamethylphosphoramide  |



|                      |   |
|----------------------|---|
| HOMO                 | highly occupied molecular orbital                               |
| <i>J</i>             | coupling constant   |
| Jones reagent        | oxidant, solution of chromium trioxide in aqueous sulfuric acid |
| LAH                  | lithium aluminium hydride                                       |
| LDA                  | lithium diisopropylamide  |
| LiTMP                | lithium 2,2,6,6-tetramethylpiperidide                           |
| LUMO                 | lowest unoccupied molecular orbital                             |
| <i>m</i>             | multiplet   |
| <i>M</i>             | molarity, mol . l <sup>-1</sup>                                 |
| Me                   | methyl  |
| MeOH                 | methanol  |
| <i>n</i>             | linear chain  |
| NaH                  | sodium hydride  |
| NBS                  | <i>N</i> -bromosuccinimide                                      |
| NCS                  | <i>N</i> -chlorosuccinimide                                     |
| NHPI                 | <i>N</i> -hydroxyphthalimide                                    |
| NMM                  | <i>N</i> -methylmorpholine                                      |
| NMR                  | nuclear magnetic resonance spectroscopy                         |
| OAc                  | acetate   |
| OEt                  | ethoxy  |
| OMe                  | methoxy   |
| Pd                   | palladium   |
| Ph                   | phenyl  |
| PhCl                 | chlorobenzene   |
| PhMe                 | toluene   |
| PIDA                 | (diacetoxyiodo)benzene  |
| PIFA                 | (bis(trifluoroacetoxy)iodo)benzene                              |
| PPh <sub>3</sub>     | triphenylphosphine  |
| ppm                  | parts per million   |
| PPTS                 | pyridinium <i>p</i> -toluenesulfonate                           |
| Pr                   | propyl  |
| <i>i</i> -Pr         | <i>iso</i> -propyl  |
| <i>p</i> TSA         | <i>para</i> -toluenesulfonic acid                               |
| Pyr                  | pyridine  |
| R                    | a general abbreviation for an atom or a group of atoms          |
| Rb                   | round-bottomed flask  |
| RCM                  | ring closing metathesis   |
| <i>R<sub>f</sub></i> | retardation factor  |
| RNA                  | ribosenucleic acid  |
| rt                   | room temperature  |
| <i>s</i>             | singlet   |
| SOMO                 | singly occupied molecular orbital                               |
| SPS                  | solvent purification system                                     |

|       |                                 |
|-------|---------------------------------|
| TBAB  | tetrabutylammonium bromide      |
| TBDPS | <i>tert</i> -butyldiphenylsilyl |
| TBS   | <i>tert</i> -butyldimethylsilyl |
| TEA   | Triethylamine                   |
| Tf    | triflate                        |
| TFA   | Trifluoroacetic acid            |
| TfOH  | triflic acid                    |
| THF   | tetrahydrofuran                 |
| TLC   | thin-layer chromatography       |
| TMSBr | bromotrimethylsilane            |
| TMSCl | trimethylsilyl chloride         |
| TMSI  | trimethylsilyl iodide           |
| T3P   | propylphosphonic anhydride      |
| UV    | ultraviolet                     |

# CONTENTS

ABSTRACT  
TIIVISTELMÄ  
ACKNOWLEDGEMENTS  
ABBREVIATIONS  
CONTENTS

|           |  |    |
|-----------|--|----|
| 1         | FAVIPIRAVIR.....   | 13 |
| 1.1       | Introduction.....  | 14 |
| 1.2       | Reported syntheses of favipiravir .....                                  | 16 |
| 1.2.1     | Methods developed by Toyama Chemical Company .....                       | 16 |
| 1.2.2     | Methods developed by academic laboratories and generic<br>companies..... | 22 |
| 1.3       | Modifications to favipiravir .....                                       | 25 |
| 1.4       | Our retrosynthesis .....   | 28 |
| 1.5       | Studies towards synthesis of favipiravir .....                           | 29 |
| 1.5.1     | Synthesis of 2,5-dichloropyrazine.....                                   | 29 |
| 1.5.1.1   | Literature survey of synthesis of 2,5-dichloropyrazine ...               | 30 |
| 1.5.1.1.1 | Chloropyrazines from pyrazinones.....                                    | 31 |
| 1.5.1.1.2 | Chloropyrazines from pyrazine- <i>N</i> -oxides.....                     | 32 |
| 1.5.1.2   | Experimental results and discussion.....                                 | 36 |
| 1.5.2     | Ortho-lithiation strategy .....  | 37 |
| 1.5.2.1   | Functionalization of pyrazines: a brief survey of the<br>literature..... | 37 |
| 1.5.2.1.1 | Synthesis of the pyrazine ring .....                                     | 38 |
| 1.5.2.1.2 | Nucleophilic aromatic substitution .....                                 | 38 |
| 1.5.2.1.3 | Transition metal catalyzed cross-coupling.....                           | 39 |
| 1.5.2.1.4 | Metalation.....  | 40 |
| 1.5.2.2   | Dehydrometalation or directed metalation .....                           | 41 |
| 1.5.2.2.1 | Lithiation.....  | 42 |
| 1.5.2.2.2 | Alkali metal mediated metalation.....                                    | 43 |
| 1.5.2.3   | Experimental results of the ortho-lithiation strategy .....              | 45 |
| 1.5.3     | Minisci reaction strategy .....  | 48 |
| 1.5.3.1   | The Minisci reaction.....  | 49 |
| 1.5.3.1.1 | Alkylation.....  | 50 |
| 1.5.3.1.2 | Acylation.....   | 52 |
| 1.5.3.1.3 | Versatility of Minisci reaction.....                                     | 53 |
| 1.5.3.2   | Scope and limitations.....   | 56 |
| 1.5.3.3   | Experimental results of Minisci reaction strategy .....                  | 57 |
| 1.6       | Conclusion and outlook.....  | 59 |
| 2         | HUMILISIN E .....  | 60 |
| 2.1       | Isolation and structure .....  | 60 |

|         |   |     |
|---------|---|-----|
| 2.2     | Retrosynthesis and synthesis target.....                                | 61  |
| 2.3     | Bicyclo[3.2.0]heptane motif .....                                       | 62  |
| 2.3.1   | Natural products with bicyclo[3.2.0]heptane skeleton.....               | 63  |
| 2.3.2   | Synthetic methodologies to generate bicyclo[3.2.0]heptane skeleton..... | 65  |
| 2.3.2.1 | Intermolecular photochemical [2+2] cycloaddition .....                  | 65  |
| 2.3.2.2 | Lewis acid-catalyzed [2+2] cycloaddition.....                           | 67  |
| 2.3.2.3 | Intramolecular photochemical [2+2] cycloaddition .....                  | 68  |
| 2.3.2.4 | CuOTf-catalyzed [2+2] cycloaddition .....                               | 71  |
| 2.3.2.5 | Other methodologies .....   | 74  |
| 2.4     | Synthesis of the bicyclic core of humilisin E.....                      | 76  |
| 2.4.1   | Intramolecular [2+2] cycloaddition strategy .....                       | 76  |
| 2.4.1.1 | Strategy involving an ester tether .....                                | 77  |
| 2.4.1.2 | Strategy involving a silicon tether .....                               | 79  |
| 2.4.2   | Intramolecular Michael addition strategy .....                          | 83  |
| 2.4.3   | Epoxy nitrile cyclization strategy .....                                | 85  |
| 2.5     | Conclusion and outlook.....   | 96  |
| 3       | SUMMARY OF THE THESIS .....   | 97  |
| 4       | EXPERIMENTAL SECTION.....   | 99  |
| 4.1     | General Information .....   | 99  |
| 4.2     | Favipiravir synthesis .....   | 100 |
| 4.2.1   | 2,5-dichloropyrazine (1.68) .....                                       | 100 |
| 4.2.2   | Lithiation of 2,5-dichloropyrazine .....                                | 100 |
| 4.2.3   | Minisci reaction of 2,5-dichloropyrazine .....                          | 101 |
| 4.3     | Humilisin E synthesis .....   | 102 |
| 4.3.1   | 6-methylheptane-2,5-diol (2.56) .....                                   | 102 |
| 4.3.2   | 6-methylheptane-2,5-dione (2.57) .....                                  | 102 |
| 4.3.3   | 3-isopropylcyclopent-2-en-1-one (2.54).....                             | 103 |
| 4.3.4   | 3-ethoxycyclopent-2-en-1-one (2.59).....                                | 104 |
| 4.3.5   | 3- isopropylcyclopent-2-en-1-ol (2.60).....                             | 105 |
| 4.3.6   | Phosphonate 2.61.....   | 105 |
| 4.3.7   | 3- methylcyclopent-2-en-1-ol (2.63) .....                               | 106 |
| 4.3.8   | 1,3- dimethylcyclopent-2-en-1-ol (2.65).....                            | 107 |
| 4.3.9   | Acetal 2.68 .....   | 107 |
| 4.3.10  | Triflate 2.72.....  | 108 |
| 4.3.11  | Protected allyl alcohol 2.75 .....                                      | 108 |
| 4.3.12  | 2- bromo-3-methylcyclopent-2-en-1-one (2.76).....                       | 109 |
| 4.3.13  | 2-iodo-3-methylcyclopent-2-en-1-one (2.80) .....                        | 109 |
| 4.3.14  | Protected propargyl alcohol 2.81 .....                                  | 110 |
| 4.3.15  | Enynone 2.82.....   | 110 |
| 4.3.16  | Alcohol 2.83.....   | 111 |
| 4.3.17  | Enolsilane 2.88 .....   | 111 |
| 4.3.18  | Nitrile 2.87 .....  | 112 |
| 4.3.19  | Alcohol 2.89.....   | 113 |

|        |                            |     |
|--------|----------------------------|-----|
| 4.3.20 | Epoxides 2.90 & 2.91 ..... | 114 |
| 4.3.21 | Ketodiol 2.96 .....        | 115 |
| 4.3.22 | Humilisin E core 2.85..... | 118 |
| 4.4    | X-ray data.....            | 122 |
| 4.4.1  | Epoxide 2.90.....          | 122 |
| 5      | REFERENCES .....           | 124 |

# 1 FAVIPIRAVIR

COVID-19 pandemic is the worst health crisis the modern world has experienced and brought the entire global community to an impasse. Corona virus disease 2019 (COVID-19) is caused by an unidentified strain of corona virus, which is named severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) by WHO<sup>1</sup>. Rapid increase in number of infections overwhelmed the health services around the world. The inability to fully treat COVID-19 led to an increase in death toll and inspired a global collaborative effort in finding new drugs and effective treatments. Development of vaccine for COVID-19 and repurposing existing antivirals for emergency usage was carried out simultaneously. Multiple approved antivirals used for treating SARS, MERS, HIV/ AIDS and malaria were repurposed to treat initial stages of COVID-19. Remdesivir, favipiravir, hydroxychloroquine, pirfenidone, baricitinib, camostat and lopinavir/ritonavir were among the small molecule antivirals that went to clinical trials for treating COVID-19<sup>2</sup>.

The situation in Finland during COVID-19 pandemic was concerning both in the number of rising infections and death rate. Protocols were put in place to curb the rising infections which led to the shut down of research labs in the university, including our laboratories. The time off from laboratory work coincided with the commencement of clinical studies for repurposing existing antiviral drugs. Favipiravir, with its simple structure and highly functionalized pyrazine core, appeared to us as an interesting target to synthesize and to assist the global community in case molecules of this type were needed in large quantities. A thorough literature survey revealed that several complex synthetic routes were developed for the synthesis of favipiravir. These routes developed by both academia and industry often included harsh conditions, multiple steps, low yields and allergenic or toxic intermediates. Our motive was to reduce the number of steps and access favipiravir in a shorter time in an atom economical fashion.


The core pyrazine ring of favipiravir was our initial starting point. The inherent acidity of the hydrogen atoms on a pyrazine ring is favourable for ortho-lithiation and subsequent substitution reactions. With methodologies available

to install a wide variety of functional groups, ortho-lithiation is an efficient way to functionalize electron deficient heteroaromatics like pyrazine<sup>3,4</sup>. Applying this methodology to access favipiravir seemed to be a promising way to reduce the number of steps in the synthetic route.

In the following discussion, the existing synthetic routes to faviripavir are presented. This is followed by a discussion of our synthesis designs and attempts to access favipiravir are described along with relevant literature. This chapter concludes with a summary and future prospects to be addressed.

## 1.1 Introduction

Favipiravir (**1.1**) (6-fluoro-3-hydroxypyrazine-2-carboxamide), sold under the trade name Avigan is a novel broad-spectrum, low molecular weight antiviral developed by Toyama Chemical Company (Figure 1). This modified pyrazine analogue was approved in Japan as an anti-influenza medicine<sup>5</sup>, and is known to inhibit replication of influenza A and B. Favipiravir has shown activity against avian influenza and for many other RNA type viruses<sup>6</sup>.



Favipiravir (**1.1**)

Figure 1: Small-molecule antiviral favipiravir.

Favipiravir can exist in several different tautomeric forms. Mirzaei and co-workers reported the structural analysis of favipiravir and examined the tautomeric structures of favipiravir (Figure 2) using DFT calculations<sup>7</sup>. Further studies involved calculation of molecular properties and subsequent docking studies on COVID-19 related enzymes. Structural analysis revealed tautomer T3 (-380891 kcal/mol) to be energetically favourable over tautomer T1 (-380886 kcal/mol) by 5 kcal/mol. The other two tautomers were less stable with energy values of -380871 kcal/mol for tautomer T2 and -380876 kcal/mol for tautomer T4. Although T3 was the most stable tautomer, tautomer T1 was the most active against protease and polymerase macromolecules.




Figure 2: Tautomeric structures of favipiravir based on DFT calculations<sup>7</sup>.

In spite of lower energy, synthesis routes reported tautomer T1 instead of tautomer T3 as the final isolated product. The X-ray crystallographic studies (CCDC deposition number 969968) revealed the planar structure of favipiravir (tautomer T1) with the presence of an intramolecular O–H···O hydrogen bonding making a 6-membered ring as illustrated in Figure 3<sup>8</sup>. The presence of favipiravir in enol form (T1) and not the energetically favourable keto form (T3) can be attributed to the presence of intramolecular hydrogen bonding. Li and co-workers reported the <sup>1</sup>H NMR of tautomer T1 in DMSO-*d*<sub>6</sub> with the singlet at 13.41 ppm representing the hydrogen atom of hydroxyl group<sup>9</sup>.




Figure 3: X-ray crystal structure of favipiravir<sup>8</sup>.

The active form of favipiravir, the corresponding ribofuranosyl-5'-triphosphate (**1.3**) (Favipiravir-RTP), is generated intracellularly via phosphoribosylation of the prodrug favipiravir (Figure 4) and is known to inhibit RNA-dependent RNA polymerase (RdRp)<sup>10</sup>. Favipiravir-RTP potently binds to RdRp and inhibits RNA polymerase activity, resulting in disruption of viral transcription and replication. The unique structure of favipiravir offers various advantages in inhibiting the viral RdRp. The fluoro group improves the binding affinity with the RNA polymerase<sup>11</sup>, and the purine nucleoside analogue replaces the purine nucleotide resulting in prevention of RNA chain elongation and subsequently causing chain termination.







Figure 4: Metabolism of favipiravir to the active ingredient, favipiravir-RTP<sup>10</sup>.

## 1.2 Reported syntheses of favipiravir

Favipiravir (**1.1**), with a molecular weight of 157, has been a complicated target to synthesize in spite of its structural simplicity. Favipiravir was first synthesized in 2000, and since then a variety of approaches have been disclosed. Reported synthesis routes to favipiravir can be divided into two categories, with one group being the routes developed by the innovator Toyama Chemical Company and the other group being routes developed by academia and generic companies.

### 1.2.1 Methods developed by Toyama Chemical Company

The first-generation medicinal chemistry route to favipiravir by Toyama Chemical Co. (Scheme 1) comprised six steps with an overall yield of 2%<sup>12-14</sup> starting from methyl 3-amino-6-bromopyrazine-2-carboxylate (**1.4**). The synthesis begins with diazotization of **1.4** using conc. sulfuric acid and sodium nitrite followed by addition of MeOH to generate methoxy compound **1.5** in 35% yield. Subsequent cross-coupling of **1.5** with benzophenone imine was carried out using (*S*)-BINAP generating adduct **1.6**, which was then hydrolysed using 2M HCl to provide **1.7** in 43% yield over two steps. Treating methyl ester **1.7** with methanolic ammonia furnished primary amide **1.8** in 88% yield. Fluorination of **1.8** was accomplished by highly corrosive Olah reagent (sodium nitrite in 70% pyridinium hydrofluoride) with a yield of 86%, furnishing **1.9**. The final step involved *O*-demethylation using *in situ* generated TMSI to obtain favipiravir in 15% yield.




Scheme 1: First generation route to favipiravir by Toyama Chemical Co.<sup>12-14</sup>. Reagents and conditions: a)  $\text{H}_2\text{SO}_4$ ,  $\text{NaNO}_2$ , MeOH, reflux, 35%; b) diphenylmethanimine, (*S*)-BINAP, *t*-BuONa,  $\text{Pd}_2(\text{dba})_3$ , PhMe, 80 °C; c) 2 M HCl, THF, 43% (2-steps); d)  $\text{NH}_3$ , MeOH, 88%; e)  $\text{NaNO}_2$ , Pyr-HF, 86%; f) NaI, TMSCl, MeCN, 15%.


The second-generation route developed by Toyama Chemical Co. in 2001 was carried out on a multigram scale (section I of Scheme 2)<sup>15</sup>. The first step involved nitration of 3-hydroxypyrazine-2-carboxamide (**1.10**) using sodium nitrate in concentrated sulfuric acid, followed by neutralization with aq. NaOH to furnish product **1.11** in 65% yield. Subjecting the nitro compound **1.11** to phosphorus oxychloride and pyridine resulted in the formation of 3,6-dichloropyrazine-2-carbonitrile (**1.12**) by displacing both the nitro and hydroxyl groups with chlorine atoms along with the dehydration of amide group to nitrile in overall 77% isolated yield. Conversion of compound **1.12** to 3,6-difluoro-2-carbonitrile (**1.13**) was achieved in 79% yield using potassium fluoride and tetrabutylammonium bromide in DMSO. The nitrile group of **1.13** was hydrolyzed to amide using 12 M HCl to furnish 3,6-difluoropyrazine-2-carboxamide (**1.15**) in 82% yield. The final step included the selective 3-F group hydrolysis. This was accomplished using sodium bicarbonate in dioxane/water resulting in crystalline favipiravir with 52% yield. The synthesis of favipiravir was achieved in 5 steps with an overall yield of 17%, including chromatographic purifications and an allergenic intermediate **1.12**.

In 2009, Toyama Chemical Co. came up with an alternative route to favipiravir from 3,6-difluoropyrazine-2-carbonitrile (section II of Scheme 2)<sup>16</sup>. This approach involved the selective hydrolysis of the C3 fluoride using potassium acetate in aqueous DMF as the first step. The hydrolysis product **1.14** was purified in 82% yield in the form of a dicyclohexylammonium salt, which proved to be the best approach due to the high-water solubility of **1.14**. Further hydrolysis of **1.14** with aqueous hydrogen peroxide provided favipiravir in 89% yield after crystallization.

### I) Second generation route by Toyama Chemical Co.




### II) Alternative route to favipiravir from intermediate 1.13



Scheme 2: Second generation route to favipiravir by Toyama Chemical Co.<sup>15,16</sup>. Reagents and conditions: a)  $\text{NaNO}_3$ , Conc.  $\text{H}_2\text{SO}_4$ , 40 °C; b) aq.  $\text{NaOH}$ , 65%; c)  $\text{POCl}_3$ , pyridine, 100 °C, 77%; d)  $\text{KF}$ , TBAB, DMSO, 100 °C, 6 h, 79%; e) 12 M  $\text{HCl}$ , THF, 35 °C, 84%; f)  $\text{NaHCO}_3$ , dioxane,  $\text{H}_2\text{O}$ , 50 °C, 52%; g)  $\text{KOAc}$ , DMF,  $\text{H}_2\text{O}$ , 82%; h)  $\text{H}_2\text{O}_2$ ,  $\text{H}_2\text{O}$ , 89%.


Realizing the importance of compound 3,6-dichloropyridazine-2-carbonitrile (**1.12**) in the synthesis of favipiravir, Nippon soda developed an improved route starting from 2-aminomalonamide (**1.16**) (Scheme 3)<sup>17</sup>. Treating compound **1.16** with glyoxal in aqueous sodium hydroxide solution resulted in the sodium salt of **1.17** in 92% yield, which was crystallized directly from the reaction mixture. Brominating sodium salt of **1.17** with molecular bromine resulted in **1.18** which was crystallized from water in 76% yield. Displacement of bromine and hydroxyl group of **1.18** with chlorine atoms was accomplished using phosphorus oxychloride and DIPEA in chlorobenzene furnishing 3,6-dichloropyridazine-2-carbonitrile (**1.12**) in 83% yield. The dichloro compound **1.12** was converted to difluoro compound **1.13** using  $\text{KF}$  and TBAB in DMSO with 92% yield. Further selective 3-F hydrolysis and nitrile hydrolysis to amide were accomplished using sodium acetate and concentrated sulfuric acid in two steps. This approach establishes a three-step route to 3,6-dichloropyridazine-2-carbonitrile (**1.12**), and utilizes the conditions outlined in Scheme 3 to complete the synthesis of favipiravir. Overall yield of the scalable six-step second-generation route to favipiravir from compound **1.16** was 33%.



Scheme 3: Improved route to favipiravir by Nippon Soda<sup>17</sup>. Reagents and conditions: a) glyoxal, aq. NaOH, 92%; b) Br<sub>2</sub>, MeOH/MeCN, 76%; c) POCl<sub>3</sub>, DIPEA, PhCl, 100 °C, 83%; d) KF, TBAB, DMSO, 100 °C, 6 h, 79%; e) KOAc, DMF, H<sub>2</sub>O, 82%; f) H<sub>2</sub>O<sub>2</sub>, H<sub>2</sub>O, 89%.


The third-generation route by Toyama Chemical Co. in 2013<sup>18-20</sup> was longer but made use of simple and inexpensive starting materials to make the core pyrazine ring system (Scheme 4). The strategy was to mask the ortho amide and hydroxyl functional groups as an isoxazole. The patent reports the first steps in kilogram scale while final steps were reported in gram scale.

Synthesis started by saponification of diethoxyacetate **1.19** to give diethoxyacetic acid (**1.20**) in 95% yield. The next step involved a CDI mediated acid amine coupling with amino-acetonitrile obtaining product **1.21** in 60% yield. Reaction of **1.21** with dimethyl oxalate with potassium *tert*-butoxide resulted in intermediate **1.22**, which was further treated with hydroxylamine hydrochloride and trifluoroacetic acid to furnish the oxazole **1.23** in 48% yield over two steps. Pyrazine ring was established by hydrolysis of acetal group using *p*-TSA to generate **1.24** in 58% yield. Replacing the hydroxyl group of **1.24** with a chloride using phosphorus oxychloride and triethyl amine hydrochloride resulted in compound **1.25** in 89% yield. At this stage various esters were synthesized, which gave differing yields in further steps and resulting in ease of operation. The fluorination of **1.25** was carried out with KF in DMSO to yield **1.26** in 84% yield. Addition of 1-chloro-2,4-dinitrobenzene resulted in cleaner reactions by acting as sink for excess fluorides. An alternate route where **1.24** was directly converted to the fluorinated compound **1.26** was reported with an isolated yield of 44% by using 2,2-difluoro-1,3-dimethylimidazolidine. The final steps include oxazole ring opening with aqueous sodium hydroxide resulting in nitrile **1.14**, after purification by an ion-exchange resin. Final hydrolysis of nitrile group was carried out with basic hydrogen peroxide to obtain favipiravir. The authors were able to crystallize favipiravir as its dicyclohexylamine salt resulting in 99.0% pure favipiravir.



Scheme 4: Third generation route to favipiravir by Toyama Chemical Co.<sup>18-20</sup>. Reagents and conditions: a) aq. NaOH, 70 °C, 95%; b) amino-acetonitrile, CDI, Et<sub>3</sub>N, MeCN, 60 %; c) dimethyl oxalate, *t*-BuOK, THF; d) NH<sub>2</sub>OH.HCl, TFA, MeOH, reflux, 48% (2-steps); e) *p*-TSA-H<sub>2</sub>O, AcOH, 77 °C, 58%; f) POCl<sub>3</sub>, Et<sub>3</sub>N-HCl, 85 °C, 89%; g) KF, DMSO, 80 °C, 84%; h) 2,2-difluoro-1,3-dimethylimidazolidine, MeCN, 44%; i) NaOH, THF/H<sub>2</sub>O, 90%; j) NaOH, H<sub>2</sub>O<sub>2</sub>, 84%.

Toyama Chemical Co. also reported a four-step synthetic route to intermediate **1.31** using maleic amide-ester **1.27** as the starting material (Scheme 5)<sup>18-20</sup>. Ester-amide **1.28** was obtained by Michael addition of hydroxylamine to **1.27** in aqueous isopropanol with an isolated yield of 59% after crystallization. Condensation of **1.28** using aqueous glyoxal solution along with sodium carbonate solution resulted in pyrazine *N*-oxide **1.29** in 62% yield after crystallization. The *N*-oxide **1.29** was further converted to oxime **1.30** using isoamyl nitrite and acetyl chloride with an 88% yield after crystallization from reaction mixture. Final step involving the ring closure and chlorination was accomplished on treatment of **1.30** with phosphorus oxychloride affording isopropyl ester **1.31** in 49% yield. Although the yields have been moderate in most of the steps, the advantage is in the isolation of products. All the products are crystalline, and several products were directly crystallized from the reaction mixture.



Scheme 5: Alternate route to intermediate **1.31** by Toyama Chemical Co.<sup>18-20</sup>. Reagents and conditions: a) aq.  $\text{NH}_2\text{OH}$ , *i*-PrOH, 59%; b) glyoxal, aq.  $\text{Na}_2\text{CO}_3$ , *i*-PrOH, 41 °C, 62%; c) isoamyl nitrite,  $\text{CH}_3\text{COCl}$ , *i*-PrOH, 88%; d)  $\text{POCl}_3$ , PhMe/DMF, 70 °C, 49%.

In summary the innovative routes developed by Toyama Chemical Company included significant developments from first-generation synthesis route to the third-generation synthesis route in terms of yields, separation, and scalability.

The first-generation route focused mainly on obtaining small quantities of compound for various screening studies and initial testing. Unfortunately, this was not appropriate for scaling up due to the use of highly corrosive reagents, expensive catalysts, and purification hurdles.

The second-generation route provided a six-step scalable route to favipiravir owing to the contributions from both Toyama Chemical Co.<sup>15,16</sup> and Nippon Soda<sup>17</sup>. The overall yield of favipiravir has been increased to 33% on a scale as compared to the first-generation route. The Nippon Soda route provides a short and scalable route to 3,6-dichloropyrazine-2-carbonitrile (**1.12**) (Scheme 3)<sup>17</sup> from inexpensive and commercially available diamide **1.16** in three-steps. This was followed by Toyama Chemical Co. route (**1.12** → **1.13** → **1.14** → **1.1**, Scheme 2) which involves purification of intermediate **1.14** as a dicyclohexylamine salt<sup>16</sup>. The only drawback of this route was the late-stage intermediate 3,6-difluoropyrazine-2-carbonitrile (**1.13**), which was reported to be volatile and have high skin irritancy requiring special equipment and handling techniques.


The third-generation route has an overall yield of 9% with nine-steps (Scheme 4) or 10% (Scheme 4 & Scheme 5). Due to modest yields and length of the synthesis, this has not been an attractive route to synthesize favipiravir. Most of the compounds reported were liquids and required vacuum distillation. This

approach has an advantage from the safety point of view. It skips the difluoro intermediate **1.13** reported to be volatile and a skin irritant, thereby eliminating the need for special equipment.

## 1.2.2 Methods developed by academic laboratories and generic companies


A variety of synthetic routes have been developed by generic companies and academic laboratories all over the world. Some of these focus on making key intermediates, but a range of syntheses have been developed for the full synthesis of favipiravir using a wide range of commercially available starting materials.

In 2012, Zhang and co-workers from Shandong Qidu Pharmaceutical company patented a short route to favipiravir starting from 3-aminopyrazine-2-carboxylic acid (**1.32**) (Scheme 6)<sup>21</sup>. Nitration of **1.10** as described in Scheme 6 gave the nitro compound **1.11** in 76% yield. Hydrogenation of **1.11** over Pd/C gave the corresponding amine **1.35** in 65% yield after crystallization. Treatment of amine **1.35** with 70% pyridinium hydrofluoride and sodium nitrite furnished favipiravir in 70% yield after an aqueous workup. No information regarding the purity of favipiravir was mentioned and the three-step route from **1.10** to favipiravir had an overall yield of 34%.




Scheme 6: Synthesis route to favipiravir by Zhang and co-workers<sup>21</sup>. Reagents and conditions: a) 1 M HCl, NaNO<sub>2</sub>, 0 °C, 90%; b) H<sub>2</sub>SO<sub>4</sub>, MeOH, 40 °C, 92%; NH<sub>3</sub>·H<sub>2</sub>O, MeOH, rt, 95%; d) H<sub>2</sub>SO<sub>4</sub>, HNO<sub>3</sub>, -5 °C, 76%; e) H<sub>2</sub>, 5% Pd/C, AcOH, 10 °C, 65%; f) NaNO<sub>2</sub>, 70% Pyr-HF, -20 °C, 70%.

A route from Zhang and co-workers in year 2013 (Scheme 7)<sup>22</sup> arrives at the intermediate **1.18** of Nippon Soda synthesis (Scheme 3) starting from 3-amino-2-pyrazinecarboxylic acid (**1.32**). Esterification of **1.32** was followed by bromination using NBS, diazotization, hydrolysis and amide formation resulted in the required intermediate **1.18**.



Scheme 7: Route to intermediate **1.18** by Zhang and co-workers<sup>22</sup>. Reagents and conditions: a)  $\text{H}_2\text{SO}_4$ , MeOH,  $0^\circ$ , 8 h, 70%; b) NBS, MeCN, rt, 24 h, 87%; c)  $\text{H}_2\text{SO}_4$ ,  $\text{NaNO}_2$ ,  $\text{H}_2\text{O}$ , rt, 2 h, 93%; d)  $\text{NH}_3 \cdot \text{H}_2\text{O}$ , rt, 3 h, 94%.


A key method involving one-pot conversion of 3,6-dichloro-2-pyrazinecarbonitrile (**1.12**) to favipiravir has been developed by Liu and co-workers. This procedure avoids the isolation of volatile 3,6-difluoro-2-pyrazinecarbonitrile (**1.13**) which is a known skin irritant (Scheme 8)<sup>9</sup>. The optimized yield turned out to be 60% over three steps.



Scheme 8: One-pot conversion of 3,6-dichloro-2-pyrazinecarbonitrile to favipiravir<sup>9</sup>. Reagents and conditions: a) KF, TBAB, DMSO,  $50^\circ\text{C}$ ; b)  $\text{K}_2\text{CO}_3$ ,  $\text{H}_2\text{O}_2$ , DMSO,  $25^\circ\text{C}$ ; c)  $\text{NaHCO}_3$ ,  $\text{H}_2\text{O}$ ,  $50^\circ\text{C}$ , 60% (3-steps).


A report by Li revealed the synthesis of 3,6-dichloro-2-pyrazinecarbonitrile (**1.12**) in 2 steps starting from Pyrazine-2-carbonitrile (**1.38**) (Scheme 9)<sup>23</sup>. The scheme involves the generation of bis-*N*-oxide **1.39** followed by subsequent chlorination to generate **1.12**.





Scheme 9: Two-step route to 3,6-dichloro-2-pyrazinecarbonitrile<sup>23</sup>. Reagents and conditions: a) 30% H<sub>2</sub>O<sub>2</sub>, AcOH, reflux, 57%; b) POCl<sub>3</sub>, Et<sub>3</sub>N, reflux, 45%; c) i. KF, TBAB, DMSO, 50 °C; ii. K<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O<sub>2</sub>, DMSO, 25 °C; iii. NaHCO<sub>3</sub>, H<sub>2</sub>O, 50 °C, 60% (3-steps).

Xie and co-workers developed a four-step synthesis of **1.12** starting from 2-aminopyrazine (**1.40**) (Scheme 10)<sup>24</sup>. Chlorination of 2-aminopyrazine using TSA followed by bromination via NBS gave compound **1.42**. Palladium catalyzed cyanation mediated by CuI followed by conversion of amine to chloride using *t*-butyl nitrite and titanium tetrachloride resulted **1.12** in 48% yield over four steps. The intermediate **1.12** was then converted to favipiravir over 3 steps to complete the synthesis.




Scheme 10: Four-step route to 3,6-dichloro-2-pyrazinecarbonitrile by Xie and co-workers<sup>24</sup>. Reagents and conditions: a) TSA (*N*-chloro-*N*-methoxy-4-toluenesulfonamide), MeCN, 80%; b) NBS, DCM, 87%; c) NaCN, CuI, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 85%; d) *t*-butyl nitrite, DCM, TiCl<sub>4</sub>, 81%; e) KF, TBAB, DMSO, 60%; f) Conc. HCl, THF, 75%; g) NaHCO<sub>3</sub>, 1,4-dioxane, H<sub>2</sub>O, 82%.

In summary, these reports present the synthesis of favipiravir from a variety of starting materials such as pyrazine-2-carbonitrile (**1.38**), 3-aminopyrazine-2-carboxylic acid (**1.32**), 2-aminopyrazine (**1.40**), and 3-hydroxypyrazine-2-carboxamide (**1.10**). Though many of these academic routes involve issues with scaling up and product purity, two of these methods stand out for the significant advances they reported in the synthesis of key intermediates and favipiravir. One of them is the three-step favipiravir synthesis starting from 3-hydroxypyrazine-2-carboxamide (**1.10**) (Scheme 6) and the other being one-pot conversion of 3,6-dichloropyrazine-2-carbonitrile to favipiravir avoiding the isolation of volatile intermediate **1.13** (Scheme 8).


### 1.3 Modifications to favipiravir

A report in 2013 by Naesens and co-workers describes the transformation of favipiravir to its active metabolite favipiravir-RTP to be the key limiting step in the antiviral action mechanism<sup>25</sup>. This discovery paved way for various modifications to be applied to favipiravir. One such attempt was at the preparation of favipiravir derivatives based on monosaccharides. Successful synthesis of favipiravir ribonucleoside and its 5'-monophosphate **1.44** (Scheme 11) followed by various chemical stability studies revealed the remarkable labile nature of the derivatives<sup>26</sup>. It was observed that even under very mild conditions the nucleoside bond was prone to cleavage along with the decomposition of the heterocyclic fragment.<sup>26</sup>



Scheme 11: Monosaccharide based favipiravir derivatives<sup>26</sup>. Reagents and conditions: a)  $\text{O}(\text{SiMe}_3)_2$ ,  $(\text{NH}_4)_2\text{SO}_4$ ,  $140^\circ\text{C}$ , 1 h; b) 1,2,3,5-tetra-*O*-acetyl- $\beta$ -D-ribofuranose  $\text{SnCl}_4$ , MeCN, rt, 7 h; c)  $\text{Bu}_2\text{SnO}$ , MeOH,  $80^\circ\text{C}$ , 24 h, 40%; d)  $\text{POCl}_3$ , pyridine,  $\text{H}_2\text{O}$ -MeCN,  $0^\circ\text{C}$ , 20 min; e)  $\text{NH}_4\text{HCO}_3$ ,  $\text{H}_2\text{O}$ ,  $0^\circ\text{C}$ , 30 min, 50%.


Alkylation of phosphate moiety resulted in more stable derivatives of favipiravir ribosides with comparable antiviral activity (Scheme 12)<sup>27</sup>.



Scheme 12: Alkylated derivatives of favipiravir ribonucleosides<sup>27</sup>. Reagents and conditions: a)  $\text{Et}_3\text{N}$ ,  $\text{N}_2$  atm, DMF, rt, 13-27%.

Mimicking the glucosidic bond formation in the riboside triphosphate, modifications were attempted to the pyrazine ring nitrogen of favipiravir by treatment with various esters (Scheme 13). Synthesized compounds had better


pharmacokinetic characteristics and strong antiviral activity against H1N1 influenza virus in comparison to favipiravir<sup>28</sup>. Substitution of amide group in the reaction resulted in unwanted byproducts. (Competing side reaction of amide group substitution resulted in undesired byproducts **1.49**, **1.51**.)



X = Cl, Br; R<sup>1</sup> = H, Me; R<sup>2</sup> = Me, Pr, *i*-Pr, *t*-Bu


Scheme 13: Modification to favipiravir by Li and co-workers<sup>28</sup>. Reagents and conditions: a) PPTS, THF, rt, 72 h; b) Et<sub>3</sub>N, N<sub>2</sub> atm, DMF, rt, 24 h.

An interesting discovery has been made when favipiravir was modified using oxathiolane derivative **1.52** (Scheme 14). The *cis* and *trans* isomers of 2-(hydroxymethyl)oxathiolane-containing derivative formed exhibited activity against H1N1 influenza virus and HIV respectively<sup>29</sup>.




Scheme 14: Oxathiolane based derivatives of favipiravir<sup>29</sup>. Reagents and conditions: a) SnCl<sub>4</sub>, N<sub>2</sub> atm, MeCN, rt, 20 min; b) NH<sub>4</sub>F, MeOH, rt, 8h.

Combining favipiravir and another antiviral drug oseltamivir **1.55** in one molecule (Scheme 15) manufactured a synergistic effect. The resulting compound **1.57** had enhanced antiviral activity against H5N2 influenza virus<sup>30</sup>.




Scheme 15: Derivatizing favipiravir using oseltamivir<sup>30</sup>. Reagents and conditions: a) DMEA, MeCN, rt, 3 h; b) **1.1**, K<sub>2</sub>CO<sub>3</sub>, MeCN, reflux, 5 h, 69%.

Alkylation of favipiravir with nitrogen-containing acyclic phosphonates **1.58** under Mitsunobu conditions led to the generation of *N*- and *O*-regioisomers **1.59** and **1.60**. Obtained *N*-isomers were unstable under the deprotection conditions (Scheme 16). However, few of the *O*-regioisomers **1.60** exhibited selective inhibition of human enzymes HGPRT and PfHGXPT. When the nitrogen-containing acyclic phosphonates were replaced by oxygen-containing acyclic phosphonates as alkylating agents, *O*-alkylation products of favipiravir were obtained exclusively<sup>31</sup>.




Scheme 16: Alkylation of favipiravir with acyclic phosphonates<sup>31</sup>. Reagents and conditions: a) PPh<sub>3</sub>, DIAD, PhMe, 60 °C, 10 min, 73-94%; b) i. TMSBr, pyridine, rt, 48 h; ii. DOWEX; c) i. TMSBr, pyridine, rt, 48 h; ii. DOWEX, 26-92%.

Wu and co-workers reported the synthesis of favipiravir phosphate **1.63** (Scheme 17), with enhanced solubility and pharmacokinetic properties<sup>32</sup>.



Scheme 17: Synthesis of favipiravir phosphate **1.63**<sup>32</sup>. Reagents and conditions: a) 60% NaH, DMF, rt, 3 h, 36%; b) TMSBr, DCM, rt, 4 h; c) NaOH, H<sub>2</sub>O, 80%.

Further trials towards derivatization of favipiravir involved substituted cyclobutanes. A series of such cyclobutane-containing favipiravir derivatives **1.65** (Scheme 18) were active against various influenza virus strains<sup>33</sup>.



Scheme 18: Substituted cyclobutane based favipiravir derivatives<sup>33</sup>. Reagents and conditions: a) SO<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, DCM, 0 °C, 5 h; b) NaH, DMF, 130 °C, 25 h; c) NH<sub>4</sub>Cl or NH<sub>2</sub>OH.HCl, NaOH, MeOH, rt.

## 1.4 Our retrosynthesis

Our retrosynthetic analysis presented in Figure 5 focused on minimizing the number of steps required to make **1.1**. Our short synthesis plan involved making the intermediate cores **1.66** and **1.67** from commercially available starting materials. Using 2,5-dichloropyrazine (**1.68**), the first approach involved installation of an ester functionality at the ortho position using an ortho-lithiation strategy to arrive at intermediate **1.66**. While the second approach involved carbamylation of **1.68** using Minisci reaction to obtain the required intermediate **1.67**. Our plan also included exploring the synthesis of 2,5-dichloropyrazine (**1.68**) from 2,5-diketopiperazine (**1.69**), which was cheap and abundant for industrial scale synthesis.




Figure 5: Retrosynthetic analysis for favipiravir.

## 1.5 Studies towards synthesis of favipiravir

With definite target molecule and defined synthetic plan in hand, the synthesis of **1.1** was divided in three phases. The plan to arrive at favipiravir was based on selectively functionalizing 2,5-dichloropyrazine (**1.68**) using either ortho-lithiation or Minisci reaction (Figure 6). Thus, the emphasis was on synthesizing 2,5-dichloropyrazine (**1.68**) in a reliable and efficient way and constituted the first phase of our synthesis plan. The second and third phases concentrated on ortho-lithiation and Minisci strategies to get to the planned intermediates **1.66** & **1.67** respectively. This section follows a similar sequence explaining the relevant literature and work done in all three phases.




Figure 6: Synthesis plan illustrating functionalization of 2,5-dichloropyrazine (**1.68**).


### 1.5.1 Synthesis of 2,5-dichloropyrazine

The following section describes the procedures reported in literature to synthesize monochloro- and dichloropyrazine compounds. The literature survey is then succeeded by details of our attempts at synthesizing 2,5-dichloropyrazine (**1.68**).

### 1.5.1.1 Literature survey of synthesis of 2,5-dichloropyrazine


Pyrazine and substituted pyrazines comprise the core of several natural products and pharmaceuticals used in our day-to-day life<sup>34</sup>. Halopyrazines make up a key class of intermediates due to their relative ease of displacing the halogen atoms to incorporate various functionalities. Chloropyrazines with high availability and better reactivity are preferred over other halopyrazines as ideal starting materials.

Although the mono- and dihalopyrazines are structurally relatively simple heterocycles, their synthesis is surprisingly challenging. Direct nuclear halogenation of pyrazine ring required elevated temperatures and harsh conditions to install multiple halogen atoms onto the pyrazine ring. The earliest published protocols to make chloropyrazine involved vapor phase chlorination of pyrazine at 400 °C in a steel tube. The presence of activated carbon or copper chloride allowed the chlorination to take place at lower temperatures. However, employing a higher chlorine to pyrazine ratio at 580 °C resulted in the formation of tetrachloropyrazine<sup>35</sup>. Other routes involving elemental chlorine<sup>36</sup> and *N*-chlorosuccinimide<sup>37</sup> as chlorine source are illustrated in Scheme 19.



Scheme 19: Examples of chlorination of substituted pyrazines from the literature using elemental chlorine and NCS<sup>35-37</sup>.

A traditional approach to prepare chloropyrazine involved treating hydroxypyrazine (1.74) with phosphorus oxychloride as shown in Scheme 20<sup>38</sup>.




Scheme 20: Preparation of chloropyrazine<sup>38</sup>.

Alternative methods to make chloropyrazines involved treatment of tautomeric pyrazinones or pyrazine *N*-oxides with phosphorus oxychloride, while other halopyrazines required either a direct halogenation procedure or transhalogenation of chloropyrazines.

### 1.5.1.1.1 Chloropyrazines from pyrazinones


Chloropyrazines from pyrazinones can be made by using various chlorinating reagents like phosphorus oxychloride<sup>39-41</sup>, phenylphosphonic dichloride<sup>42</sup> and phosgene<sup>43</sup> as shown in Scheme 21.



Scheme 21: Examples of chlorination of pyrazinones from the literature using a) phosphorus oxychloride<sup>39-41</sup>, b) phenylphosphonic dichloride<sup>42</sup> and c) phosgene<sup>43</sup>.

Although phosphorus oxychloride with pyrazinone results in the formation of the desired chloropyrazine, it is also used in combination with phosphorus pentachloride<sup>44</sup> or sulfur monochloride<sup>45</sup> or with a tertiary amine base<sup>46</sup> (Scheme 22). A mixture of reagents is typically used, if the reaction with neat phosphorus oxychloride is either too slow or additional chlorination of pyrazine ring is needed.






Scheme 22: Examples of chlorination of pyrazinones from literature using a mixture of chlorinating reagents<sup>44-46</sup>.


### 1.5.1.1.2 Chloropyrazines from pyrazine-*N*-oxides

Generating chloropyridine by treating pyridine *N*-oxide with  $\text{POCl}_3$  is a well-known reaction<sup>47</sup>. Likewise, the procedure has been applied to pyrazine *N*-oxides to generate chloropyrazines<sup>48-51</sup>. Scheme 23 illustrates few reactions involving preparation of chloropyrazines from pyrazine *N*-oxides.




Scheme 23: Examples of chlorination of pyrazine *N*-oxides<sup>48-51</sup>.

A literature survey suggested numerous procedures to synthesize chloropyrazine in presence of various substituents and functionalities<sup>35</sup>. Further focus on synthesis of dichloropyrazines revealed the necessity of extremely harsh conditions starting from pyrazine. A simple Reaxys search for 2,5-dichloropyrazine resulted in a multitude of patents and reports utilizing very high temperatures furnishing all possible regioisomers as shown in Scheme 24.




Scheme 24: Dichlorination of pyrazine using elemental chlorine.

Klein and co-workers<sup>52</sup> reported a four-step synthesis to **1.68** starting from pyrazine. As shown in Scheme 25, the route included sequential formation of *N*-oxide using peracids followed by chlorination using phosphorus oxychloride.




Scheme 25: Four-step route to 2,5-dichloropyrazine<sup>52</sup> reported by Klein and co-workers. Reagents and conditions: a) AcOH, 30% H<sub>2</sub>O<sub>2</sub>, 95 °C, 8 h, 60%; b) POCl<sub>3</sub>, reflux, 0.5 h, 25%; c) AcOH, 30% H<sub>2</sub>O<sub>2</sub>, 75 °C, 17 h, 49%; d) POCl<sub>3</sub>, reflux, 1 h, 64.2%.

Bernardi and co-workers repeated the procedure reported by Klein and co-workers to find out that the final chlorination step did not result in 2,5-dichloropyrazine rather gave rise to 2,3-dichloro and 2,6-dichloropyrazine compounds (**1.83** & **1.110**)<sup>53</sup>. The Bernardi group confirmed this result by preparing an authentic sample of 2,5-dichloropyrazine by treating 2-hydroxy-5-chloropyrazine (**1.112**) with phosphorus oxychloride as shown in Scheme 26 to compare the spectroscopic data.




Scheme 26: Synthesis of 2,5-dichloropyrazine from 2-hydroxy-5-chloropyrazine<sup>53</sup>.

Sato and co-workers reported on the regioselective synthesis of chloropyrazines from 3-substituted pyrazine-1-oxides<sup>54</sup>. Attempts to synthesize **1.68** starting from 3-chloropyrazine-1-oxides (Scheme 27) has been mentioned under various reaction conditions. On treating 3-chloropyrazine-1-oxides with phosphorus oxychloride in presence of base resulted in 2,3-dichloropyrazine (**1.83**) as the major product, whereas substituting phosphorus oxychloride with chloroacetyl chloride produced 2,6-dichloropyrazine (**1.110**) as the major product. In both the cases 2,5-dichloropyrazine (**1.68**) was obtained in negligible amounts.




Scheme 27: Chlorination of 3-chloropyrazine-1-oxide<sup>54</sup> reported by Sato and co-workers

Synthesis of **1.68** from 5-chloro-1,2-dihydro-2-oxopyrazine<sup>55</sup> (**1.113**) using phosphorus oxychloride gave 9% yield, whereas the same experiment in a sealed tube at high temperatures gave a much-improved yield of 69% (Scheme 28).




Scheme 28: Synthesis of 2,5-dichloropyrazine reported by Tuntiwachwuttikal and co-workers<sup>55</sup>.

Alternative approaches to halopyrazines have become a necessity due to the harsh reaction conditions. One such approach was to use 2,5-diketopiperazines along with phosphorus oxychloride. Treatment of compound **1.114** with phosphorus oxychloride resulted in mono and dichlorinated pyrazines **1.115** & **1.116** as shown in Scheme 29<sup>35</sup>.



Scheme 29: Conversion of substituted diketopiperazines to substituted dihalopyrazines<sup>35</sup>.

Yudin and co-workers<sup>56</sup> reported a detailed study on the reaction of 2,5-diketopiperazine (**1.69**) with various chlorinating and brominating agents as shown in Scheme 30. In each case the resulting products were either tri- or tetra-halogenated pyrazines.




Scheme 30: Reagents and conditions: a)  $\text{POCl}_3$ ,  $\text{PCl}_5$ ,  $\text{Cl}_2$ , rt; b)  $\text{POCl}_3$ ,  $\text{PCl}_5$ ,  $\text{Cl}_2$ , 20 °C to 104 °C; c)  $\text{POCl}_3$ ,  $\text{PCl}_5$ ,  $\text{Br}_2$ , 40 °C to 104 °C; d)  $\text{POCl}_3$ ,  $\text{PCl}_5$ ,  $\text{Br}_2$ , rt; e)  $\text{PBr}_5$ ,  $\text{Br}_2$ , DMSO, 40 °C to 80 °C.

### 1.5.1.2 Experimental results and discussion

With limited literature precedents, we started by trying to find a reasonable method to synthesize **1.68** from 2,5-diketopiperazine (**1.69**). Our initial attempts included the treatment of **1.69** with phosphorus oxychloride and phosphorus pentachloride. Reactions at elevated temperatures always resulted in a black sticky tar, whereas reaction at room temperature yielded the required product in 20% yield.

Optimizing the reaction conditions with respect to equivalents of phosphorus oxychloride, phosphorus pentachloride, solvent, temperature, and their subsequent yields have been mentioned in Table 1.

Table 1: Optimization of reaction conditions for 2,5-dichloropyrazine synthesis.



| Entry | POCl <sub>3</sub><br>(eq.) | PCl <sub>5</sub><br>(eq.) | Solvent   | Temperature<br>(°C) | Yield<br>(%) | Observation |
|-------|----------------------------|---------------------------|-----------|---------------------|--------------|-------------|
| 1     | 5                          | 0                         | neat      | Reflux              | -            | Black tar   |
| 2     | 5                          | 0                         | neat      | 60                  | -            | Black tar   |
| 3     | 5                          | 0                         | neat      | rt                  | -            | No reaction |
| 4     | 13                         | 2.5                       | neat      | rt                  | 20%          | -           |
| 5     | 5                          | 2.5                       | Sulfolane | rt                  | 15%          | -           |
| 6     | 5                          | 2.5                       | MeCN      | rt                  | -            | No reaction |
| 7     | 5                          | 2.5                       | DCM       | rt                  | -            | No reaction |

Despite our elaborate optimization attempts, the yield did not improve and stayed at around 20%. Unsuccessful optimization efforts can be attributed to differences in solubility of starting material and product coupled with corrosive chlorinating agents made it difficult to monitor the reaction effectively. Yet, this was a milder one step procedure compared to the reported protocols to synthesize 2,5-dichloropyrazine (**1.68**).

Failed attempts at synthesizing 2,5-dichloropyrazine (**1.68**) using multiple chlorination methods led us to focus on functionalization of pyrazine core. The first strategy to be utilized was the ortho-lithiation strategy.

## 1.5.2 Ortho-lithiation strategy

A brief description of various methodologies reported in literature to functionalize pyrazine core is mentioned, followed by a detailed literature study on directed metalation (ortho-lithiation) of pyrazines. Our attempts at functionalizing the pyrazine core by utilizing ortho-lithiation methodology are described below, after the survey of the literature.


### 1.5.2.1 Functionalization of pyrazines: a brief survey of the literature

Substituted pyrazines make up the core of a plethora of important natural products and pharmaceutical agents<sup>57,58</sup>. Methodologies to synthesize polyfunctionalized pyrazines have always been limited increasing the need to develop new and efficient procedures to make substituted pyrazines. With growing importance of substituted pyrazines in synthesis, numerous protocols were developed targeting each position on the pyrazine ring for functionalization. Key methodologies to access functionalized pyrazines include construction of the pyrazine ring, nucleophilic aromatic substitution, transition-metal catalyzed

cross-coupling and direct metalation. Forthcoming sections will concentrate on directed metalation of pyrazines, while the other methodologies are briefly discussed.

#### 1.5.2.1.1 Synthesis of the pyrazine ring

Self-condensation of amino ketones has been the general protocol to synthesize pyrazines with the limitation of being able to synthesize symmetrically substituted pyrazines. Reported in 1876, the Staedel-Rugheimer pyrazine synthesis<sup>35</sup> is the oldest procedure to make pyrazine ring (Scheme 31). This method involves self-condensation of  $\alpha$ -amino ketones to form a dihydropyrazine intermediate which was subsequently oxidized to pyrazine ring. Various methods to generate  $\alpha$ -amino carbonyl compounds with wide range of substituents make them desired for self-condensation reactions to form pyrazine rings.




Scheme 31: The Staedel-Rugheimer pyrazine synthesis<sup>35</sup>.

Several methodologies developed over time rely on condensation chemistry with an expansion in the scope of starting materials. The reaction of  $\alpha,\beta$ -dicarbonyl compounds with  $\alpha,\beta$ -diamines has been largely used owing to its ability to generate unsymmetrically substituted pyrazines<sup>59,60</sup>. Development of other methodologies has become a necessity due to the limited substituent scope.


#### 1.5.2.1.2 Nucleophilic aromatic substitution

Pyrazines and halogenated pyrazines are prone to undergo nucleophilic aromatic substitution reactions due to their high electron-deficient nature<sup>61,62</sup>. The nature of nucleophile and type of substituents present on the pyrazine ring have a pronounced effect on the reactivity, while the position or type of halogen atom has little to no effect. Amines, alcohols, and thiols are common heteroatom nucleophiles to take part in the nucleophilic aromatic substitution of halogenated pyrazines. The most common reaction includes halopyrazines with different amines to generate amine substituted products. As mentioned above, the electronic nature of substituents on the pyrazine ring has a pronounced effect, with electron withdrawing substituents accelerating the reaction whereas electron donating substituents slowing the reaction or needing forcing conditions as shown in Scheme 32<sup>63,64</sup>. This observation justifies the facile nature of reaction and the necessity of an electron deficient system.

### Electron withdrawing substituent



### Electron donating substituent




Scheme 32: Nucleophilic aromatic substitution of halopyrazines bearing electron donating and electron withdrawing substituents<sup>63,64</sup>.

### 1.5.2.1.3 Transition metal catalyzed cross-coupling

Transition metal catalyzed cross-couplings are one of the most frequently utilized reactions in organic chemistry. Though these reactions are very useful to generate diverse and complex entities required in organic synthesis, the scope with respect to pyrazine motifs has been limited. This situation has been steadily improving with the development of better catalytic systems and easy access to halopyrazines from commercial sources.

The first report involving a halopyrazine as a coupling partner in Suzuki reaction was reported by Thompson and co-workers in 1988<sup>65</sup>. Optimization of catalysts and reaction conditions led to the coupling of bromopyrazines with a wide range of arylboronic acids (electron poor, electron rich, heteroaryl) in very good yields (Scheme 33)<sup>65</sup>.



Scheme 33: Suzuki reaction of a pyrazine substrate<sup>65</sup> reported by Thompson and co-workers.

Further studies reported the compatibility of various arylboronic acids with the Suzuki reaction and the role of electronic nature of arylboronic acids in determining the reactivity of coupling partner<sup>66</sup>. The availability of




halopyrazines, large scope of coupling partners and high functional group tolerance has made Suzuki reaction an important pathway to generate functionalized pyrazine scaffolds. Over time, the pyrazine core has been successfully used in various coupling reactions such as the Buchwald-Hartwig, Kumada, Negishi, Heck, Sonogashira, and Stille couplings<sup>67</sup>.


#### 1.5.2.1.4 Metalation

Synthetic methodologies to functionalize pyrazine ring with electrophiles are nonexistent due to the highly electron-deficient nature of the pyrazine core. In other words, regioselective functionalization of pyrazine ring can be achieved by reacting the electrophile with a specifically metalated pyrazine. With the focus on generating metalated pyrazines, various synthetic protocols have been developed over the decades. The developed methodologies include dehydrometalation (directed metalation), dehalometalation, transmetalation and oxidative addition. Scheme 34 illustrates the different types of metalations developed.


##### a) Dehalometalation




##### b) Transmetalation



##### c) Oxidative Addition



##### d) Dehydrometalation



Scheme 34: Methodologies for generating organometallic intermediates of pyrazine.

Dehalometalation is a non-deprotonative halogen-metal exchange developed extensively using bromo and iodo derivatives of pyridine. In spite of having a wide scope with halopyridines, this method lacks the applicability in case of halopyrazines due to the difficulty in the synthesis of heavy halogenated pyrazine compounds.

Transmetalation reaction occurs when a more electropositive metal M2 replaces a less electropositive metal M1. Bases involving a highly electropositive metal like lithium are commonly used to make lithiated derivatives via deprotonation of substrate, which are further used to access various organometallic species by utilizing transmetalation reactions.

Achieving metalated species by oxidative addition is a well-known procedure and is possible by reaction of a metal like magnesium with haloderivatives. The requirement of active metals due to the presence of basic nitrogen ring atoms in heteroaromatics makes this procedure difficult to use.

A labile carbon-metal bond is widely used to establish a variety of functionalities and generate substituted moieties. Dehydrometalation or direct metalation is one such useful method to generate the highly reactive carbon-metal bond. Conventional metalation is a method in which highly reactive electropositive metal such as lithium is commonly used to generate highly polar and labile carbon-lithium bonds. Extremely high reactivity of lithio-derivatives generated requires the use of low reaction temperature and is incompatible with a large variety of functional groups. Recent research has led to the development of alternative metalating reagents involving a mixture of compounds with alkali metal as a key component and is termed as alkali-metal-mediated metalations. The following section discusses about the direct metalation of pyrazines and substituted pyrazines in detail.

### 1.5.2.2 Dehydrometalation or directed metalation


Dehydrometalation or directed metalation of pyrazine followed by quenching with electrophiles is a well-established methodology to install a wide range of electrophiles onto the pyrazine ring. Higher acidity of ring hydrogens and the symmetrical structure of pyrazine makes metalation at  $\alpha$  position of nitrogen atom very favorable. The presence of lone pair of electrons on the ring nitrogen atoms has an added advantage of coordinating with the metal of the base and assisting in disaggregation of the base used thereby enhancing the reactivity of the base. Despite the ring nitrogen atoms of pyrazine being less chelating, the ring hydrogens are acidic enough to facilitate deprotonation using non-nucleophilic bases.

With pyrazines, the metalated species generated is stabilized by the electron-withdrawing nature of the ring nitrogen. The presence of electron-withdrawing nitrogen atoms in the ring makes the pyrazine ring highly electron deficient and prone to nucleophilic addition reactions. Hence the use of

nucleophilic bases (alkyl lithiums) is ignored and non-nucleophilic bases (LDA, LiTMP, etc) are preferred for the metalation of pyrazine substrates.


#### 1.5.2.2.1 Lithiation

The metalation of pyrazine has been noticed and reported as a side reaction taking place during nucleophilic substitution reactions of pyrazine with alkyllithium reagents. Similar instances have also been noted during the metalation of alkylpyrazine substrates<sup>68</sup>. With reports mentioning similar metalations in case of electron-deficient heterocycles like pyridine and diazines<sup>69</sup>, Queguiner and co-workers worked on developing a methodology for direct metalation of pyrazine ring. Synthesis of 2,3-disubstituted pyrazines by ortho-lithiation of chloropyrazine (**1.131**)<sup>70</sup> was first reported by Queguiner and co-workers in 1988. Initial attempts to metalate chloropyrazine have been carried out using an “equilibrium shift” protocol. This protocol requires the presence of quenching electrophile in the reaction medium from the start of the reaction, generating the metalated products in low yields (Scheme 35). Equilibrium shift procedure suffers with the scope of electrophiles, limiting to those that are immune to react with lithium alkylamides.



Scheme 35: Ortho-lithiation of chloropyrazine using the “equilibrium shift” procedure reported by Queguiner and co-workers<sup>70</sup>.

Transitioning from the equilibrium shift protocol to a stepwise protocol resulted in higher yields with a broader scope of electrophiles as illustrated in Scheme 36<sup>70</sup>. Further studies by Queguiner and co-workers led to the advancement of methodologies compatible with a wide range of diazines and highly substituted pyrazines<sup>4,71-76</sup>.




Scheme 36: Ortho-lithiation of chloropyrazine using “stepwise” procedure reported by Queguiner and co-workers<sup>70</sup>.

Although hindered non-nucleophilic bases, such as LDA or LiTMP allow reliable deprotonation of a variety of pyrazines and substituted pyrazines, the high reactivity of the lithiated species generated renders them prone to side reactions. Regioselectivity issues can also arise as lithiation may take place at multiple sites, and under both kinetic and thermodynamic control<sup>77</sup>.


#### 1.5.2.2.2 Alkali metal mediated metalation

To evade the restrictions imposed by lithium alkylamides, a new class of metalating agents have been discovered and reported by several groups<sup>78–80</sup>. Methodologies utilizing magnesium amides (Scheme 37) to achieve directed metalation of heterocyclic compounds have been reported. But low solubility of magnesium amides coupled with the necessity to use a large excess of base for higher conversions led to decline in its synthetic utility. Marked increase in reactivity of alkylmagnesium chlorides on addition of lithium chloride in magnesium-bromine exchange reaction<sup>81,82</sup> led Knochel and co-workers towards implementing the methodology to magnesium amides and generate a better metalating reagent. With reports mentioning LiTMP to be an effective metalating reagent with pyrazines, Knochel and co-workers reported a mixed Mg/Li amide by reaction of TMP with *i*PrMgCl·LiCl (Scheme 37)<sup>83</sup>. The generated reagent turned out to be better soluble, with a shelf life of up to 6 months in solution. Various aromatic and heteroaromatic compounds have been functionalized under mild conditions and illustrated in Scheme 37<sup>83</sup>.



Scheme 37: a) Magnesium amides and Knochel's route to the mixed Mg/Li amide metalating reagent. b) Examples utilizing **1.134** to functionalize halopyrimidines<sup>83</sup>.


Further studies in the development of alkali metal mediated metalating reagents led to the development of the mixed Zn/Li amide  $\text{TMPZnCl}\cdot\text{LiCl}$  (**1.135**) (Scheme 38)<sup>84</sup>. These zinc-based reagents, developed in-house in the Knochel group, were utilized in functionalizing a variety of heteroaromatic compounds<sup>84-88</sup> and there by generating their corresponding zincated species, which were used in cross coupling reactions or quenched with electrophiles respectively<sup>84</sup> (Scheme 38). Directed metalation remains as the prominent methodology to functionalize pyrazines, halopyrazines and other various mono and di-substituted pyrazines.



Scheme 38: a) Synthesis of Knochel's mixed Zn/Li amide metalating reagent. b) Examples of functionalization of 2,6-dichloropyrazine using reagent **1.135**<sup>84</sup>.

### 1.5.2.3 Experimental results of the ortho-lithiation strategy


Following the reports available on ortho-lithiation of monohalo and dihalopyrazines, we have set our goals to functionalize 2,5-dichloropyrazine and establish an ester moiety. As shown in Scheme 39, the plan consisted of generating a metalated 2,5-dichloropyrazine species using a non-nucleophilic lithiated base (LiTMP), followed by quenching it with an electrophile to generate a 3-substituted-2,5-dichloropyrazine.



Scheme 39: Ortho-lithiation approach to functionalize 2,5-dichloropyrazine.


The stepwise protocol by Queguiner and co-workers<sup>70</sup> involved the generation of the lithiated species of substituted pyrazine and then quenching it with an electrophile. Following this methodology, lithiation of 2,5-dichloropyrazine was carried out using LiTMP as base at very low temperatures (-40 °C to -100 °C) followed by slow addition of an electrophile. The reaction mixture turned dark brown immediately on addition of 2,5-dichloropyrazine to a solution containing LiTMP. Further addition of electrophile did not change the appearance of the

reaction mixture. Workup of the reaction followed by purification by column chromatography resulted in the recovery of starting material. Optimization with respect to temperature ranging from -40 °C to -100 °C and with a variety of electrophiles did not give the desired product (Scheme 40).



Scheme 40: Functionalization of 2,5-dichloropyrazine using “stepwise” protocol.

The immediate color change of the reaction mixture to dark brown on addition of 2,5-dichloropyrazine to a solution of LiTMP, prompted us to try out the equilibrium shift protocol also reported by Queguiner group<sup>70</sup>. In this procedure, electrophile is present in the reaction mixture before the addition of starting material. Lithiation of 2,5-dichloropyrazine using LiTMP, also resulted in a dark brown reaction mixture almost immediately. Purification of the reaction mixture by column chromatography resulted in the recovery of starting material. The presence of an electrophile in the reaction medium from the start did not have any impact on the reaction (Scheme 41). We were unable to replicate the reported results of functionalizing 2,5-dichloropyrazine using Knochel’s mixed Zn/Li amide metalating reagent **1.135**<sup>89</sup>. Hence further functionalization attempts with the mixed Zn/Li amide reagent **1.135** were abandoned.




Scheme 41: Functionalization of 2,5-dichloropyrazine using “equilibrium shift” protocol.

Comparing the NMR data of starting material to that of the recovered one after reaction showed a slight peak shift in <sup>1</sup>H NMR. Literature revealed that the <sup>1</sup>H NMR peaks of 2,3-dichloro (<sup>1</sup>H NMR in CDCl<sub>3</sub>: δ 8.33 ppm (s, 2H))<sup>54</sup>, 2,5-dichloro (<sup>1</sup>H NMR in CDCl<sub>3</sub>: δ 8.40 ppm (s, 2H))<sup>54</sup>, and 2,6-dichloropyrazine (<sup>1</sup>H NMR in CDCl<sub>3</sub>: δ 8.53 ppm (s, 2H))<sup>54</sup> being very close to each other.

With a suspicion on the stability of the generated lithiated species and with the possibility of a halogen rearrangement, we decided to study and determine the possibility of a rearrangement as shown in Scheme 42. With the hypothesis in hand, we embarked on finding a valid proof to support the hypothesis. We generated a lithiated species of 2,5-dichloropyrazine following equilibrium shift procedure with the highly reactive electrophile cyanogen bromide in the system to quench the hypothesized intermediate. Numerous attempts and several

purifications by column chromatography resulted in mixtures with a complex  $^1\text{H}$  NMR spectra, thus resulting in inconclusive data to support the hypothesis.




Scheme 42: Possible rearrangements and reactions of lithiated 2,5-dichloropyrazine.

As a final attempt, we repeated the ortho-lithiation experiment of 2,5-dichloropyrazine with methylchloroformate ( $\text{ClCO}_2\text{Me}$ ) as an electrophile using equilibrium shift protocol (Scheme 41).  $^1\text{H}$  NMR of the purified crude in  $\text{CD}_2\text{Cl}_2$  had a singlet peak at 8.39 ppm. We then spiked the same NMR sample with commercially available 2,3-dichloropyrazine & 2,6-dichloropyrazine and measured the  $^1\text{H}$  NMR. 2,3-dichloropyrazine and 2,6-dichloropyrazine displayed singlet peaks at 8.32 ppm and 8.52 ppm respectively. This affirms the absence of halogen rearrangement as hypothesized.

With considerable amount of time spent on optimizing the lithiation of 2,5-dichloropyrazine and with concerns over the stability of the lithiated species generated, we changed our starting material from 2,5-dichloropyrazine to 2,5-difluoropyrazine for implementing the same strategy.

With the aim of scaling up the reaction and avoiding highly corrosive reagents, we opted for fluorination procedures that utilize sodium fluoride and potassium fluoride. With ample literature procedures for the use of NaF and KF as fluorinating reagents, we started to convert 2,5-dichloropyrazine to 2,5-difluoropyrazine. A wide range of conditions using KF, NaF along with TBAB, 18-Crown-6 at various temperatures were attempted (Scheme 43). Multiple attempts with various reaction conditions resulted in the recovery of 2,5-dichloropyrazine and did not yield 2,5-difluoropyrazine as expected.





Scheme 43: Synthesis attempts towards 2,5-difluoropyrazine.

Functionalization of 2,5-dichloropyrazine using ortho-lithiation strategy was a key step in our planned synthesis of Favipiravir. Substitution in the pyrazine ring with an electrophile using this strategy never returned reliable results, which made us change the starting material from 2,5-dichloropyrazine to 2,5-difluoropyrazine, but unfortunately the synthesis of 2,5-dichloropyrazine was not successful either. Despite the negative results, this approach has highlighted our lack of knowledge and understanding about the metalation of 2,5-dichloropyrazine and subsequent substitution reactions. In contrast, metalation of 2,3-dichloropyrazine and 2,6-dichloropyrazine are well documented resulting in literature gap related to the stability and reactivity of metalated 2,5-dichloropyrazine species.

Failure in functionalizing 2,5-dichloropyrazine core using ortho-lithiation strategy led us to pursue alternative methods. The second strategy we came up to functionalize pyrazine core is by utilizing Minisci reaction.

### 1.5.3 Minisci reaction strategy

The following section describes the Minisci reaction in general and examples of Minisci reactions using pyrazines. The literature survey is then followed by the results of experimental attempts at functionalizing pyrazine core using Minisci reaction.

Free radicals represent an unusual odd-electron species which possess a distinct feature of combining electrophilicity and nucleophilicity at the same reaction center. The single electron is in a common molecular orbital termed as SOMO (Singly Occupied Molecular Orbital). Thus, the reactivity of free radicals is governed by orbital interactions instead of coulombic interactions as in the case of polar reactions<sup>90</sup>. Being located in between the HOMO and the LUMO energetically, overlap of SOMO with either frontier orbitals is favorable. A dominant SOMO-HOMO interaction attributes the radical an electrophilic character, and a dominant SOMO-LUMO interaction ascribes the nucleophilic character to the radicals<sup>90</sup>.


Free radicals and their reactions were infamous for their regioselectivity issues in organic chemistry for a long time<sup>91</sup>. Free radicals attracted interest from theoretical chemists due to their peculiar properties followed by industrial chemists due to their importance in basic chemical industries for vinyl

polymerization, chlorination of methane, etc. The use of structurally simple molecules did not give rise to selectivity issues in the case of industrial applications. Rather the complexity of structures in organic chemistry combined with the unreliable selectivity made free radical reactions less appealing to organic chemists.

With a growing number of small molecule drugs containing an aromatic heterocycle core, the need for developing a library of molecules for clinical and pharmacological testing intensified. However, derivatization of electron-deficient heteroaromatic bases like pyrazines, pyrimidines, and pyridazines has not always been straightforward with direct functionalization methods<sup>92</sup>. A comprehensive, but underrated methodology often ignored is the tendency of heteroaromatic bases to react with radicals. Methodologies that include radical addition are expected to be suitable to expand the required heteroarenes, yet this reactivity is rarely employed in synthesis<sup>93</sup>. Usually this has been justified by citing unpredictable regioselectivity, frequent low yields, and complex mixture of products. Although this reasoning is suitable in some cases, the main issue arises from the improper and incomplete understanding of the factors controlling the selectivity and reactivity of radicals and heteroarenes.

#### 1.5.3.1 The Minisci reaction


The Gomberg-Bachmann reaction<sup>94</sup> developed in the 1920s is an example of homolytic aromatic substitution, where an aryl radical is added to an aromatic system to generate biaryls (Scheme 44). Reactions dating to early 1890's involved addition of aryl radicals to heteroaromatic systems such as pyridine<sup>95-98</sup>. Very little progress has been achieved over the next 50 years to develop the methodology required to successfully integrate it with mainstream synthesis for organic chemists. Even though the methodology to generate phenyl radicals has been expanded significantly, the efficiency and regioselectivity of reaction with pyridine was not optimized resulting in multiple regioisomers with low yields (Scheme 44)<sup>93</sup>. With studies aimed at understanding and controlling the regioselectivity of radical addition reactions, it was found that the regioselectivity of addition of phenyl radical to pyridine can be controlled by using pyridine-*N*-oxide instead of pyridine<sup>99</sup>(Scheme 44). Lynch, Chang, and Dou<sup>100-102</sup> reported the role of acidity of the reaction medium on the regioselectivity and rate of radical addition to heteroarenes. This study established that the *N*-protonation of the heteroaromatic base amplifies the rate of the reaction and tilts the regioselectivity compared to that of neutral bases (pyridine, pyrazine, thiazole, quinoline, isoquinoline, *N*-methylimidazole, quinoxaline, benzothiazole, pyrimidine, *N*-methylbenzimidazole)<sup>103</sup> (Scheme 44).



Scheme 44: a) Gomberg-Bachmann biaryl synthesis<sup>94</sup>; Radical phenylation of b) pyridine<sup>93</sup>; c) pyridine-*N*-oxide<sup>99</sup>; d) protonated pyridine<sup>103</sup>.


### 1.5.3.1.1 Alkylation

In 1971, Minisci reported a silver catalyzed decarboxylation of carboxylic acids with peroxydisulfate to generate alkyl radicals. This methodology involves homolytic alkylation of heteroarenes and illustrates the effect of acidic conditions on the reaction (Scheme 45)<sup>104</sup>. Henceforth the reaction scope has seen a staggering growth and the methodology evolved to be the most useful method to functionalize electron-deficient heteroaromatic bases. Thus, all kinds of homolytic substitution reactions of protonated heteroaromatics are known as “Minisci Reactions”. The Minisci reactions constitute a versatile method of heteroarene CH-functionalization. The reaction mechanism (Scheme 45)<sup>104</sup> involves the addition of alkyl radical to the protonated heteroarene to give an aminyl radical cation which is then oxidized to form the corresponding alkylated heteroarene under reaction conditions.



Scheme 45: Mechanism illustrating alkylation of protonated pyridine (molecules 2014).

The Minisci reaction shows parallel reactivity patterns with Friedel-Crafts-alkylation with inverted reactivity and selectivity as more electron-deficient heteroarene reacts faster<sup>103</sup>. Due to the electron donating effect of the alkyl group, radical alkylation of heteroarene results in a slight increase of LUMO energy. Despite the increase in LUMO energy, it is not enough to warrant polyalkylation of heteroarenes as the energy increase is not sufficient to hinder consecutive reactions. Punta et al., also reported the conditions favoring monoalkylation over polyalkylation<sup>103</sup>. The use of a two-phase system as reaction medium favors monoalkylation, as the more lipophilic alkylated compound is extracted into the aqueous phase (Scheme 46) thereby arresting polyalkylation of heteroarene.




Scheme 46: Alkylation of 4-substituted pyridine a) in aqueous medium; b) in two-phase system.


### 1.5.3.1.2 Acylation

In an electrophilic process such as the Friedel-Crafts reaction, acylation is much more selective than alkylation, as the incoming acyl group deactivates the aromatic ring for further acylation whereas the incoming alkyl group activates the aromatic ring for further alkylation resulting in polyalkylated products. Importantly, in a radical process such as the Minisci reaction, the reactivity and selectivity patterns are inverted compared to Friedel-Crafts reaction<sup>89</sup>. Addition of acyl radical to a protonated heteroarene increases the electron-deficient nature of heteroarene and activates the ring for further radical additions by lowering the LUMO energy. Hence, arresting monosubstitution by carbonyl radicals in the presence of multiple reactive centers has been a major limitation unless the reaction centers are blocked by various substituents/groups. With monosubstitution of heteroarenes by carbonyl radicals being a synthetic interest, developing a methodology to overcome polysubstitution has become a necessity. Apparent change in the basic character of starting heteroarene on acylation led to the development of a two-phase reaction medium to overcome polysubstitution<sup>105-110</sup>. In a two-phase system, monoacylation of heteroarene decreases the basicity and increases the amount of unprotonated species resulting in *in situ* extraction to the organic layer, whereas the protonated heteroarene is in the aqueous phase reacting with the radicals generated. Section I of Scheme 47 illustrates the principle mentioned using a general acylation mechanism of pyridine. Section II of Scheme 47 is an example of acylation of methyl isonicotinate in both aqueous phase and a two-phase system<sup>103</sup>.

### I) Acylation of pyridine in a two-phase system




### II) Acylation of methyl isonicotinate in a) aqueous medium and b) two-phase medium



Scheme 47: I) A mechanism showing radical acylation of pyridine in a two-phase system. II) acylation of methyl isonicotinate<sup>103</sup> in a) aqueous medium; b) two-phase system.


#### 1.5.3.1.3 Versatility of Minisci reaction

Apart from alkylation and acylation, a variety of functionalizations of heteroarenes via the Minisci reaction have been developed. Hydroxyalkylated heteroarenes are generated by using alcohols as carbon centered radicals. Oxalic acid monoesters result in hydroxycarbonylation, and carbamoylation can be achieved by generating a carbon centered radical from formamide (Scheme 48)<sup>103</sup>.



Scheme 48: Functionalization of heteroarenes a) hydroxycarbonylation; b) hydroxyalkylation; c) carbamoylation.

Utilization of aryl radicals has been limited by the fact that their generation from aromatic carboxylic acids by oxidative decarboxylation is often impractical<sup>103</sup>. Several alternative sources were designed and developed to generate aryl radicals. Methodologies involving generation of aryl radicals from arylboronic acids<sup>111</sup> and aryldiazonium salts<sup>112</sup> were developed with tolerance towards a wide range of functional groups. Overtime huge progress has been made in expanding the scope of the reaction with development of various radical generating protocols, and systems to enhance regioselectivity. Understanding the rate constants for radical addition, and mechanistic investigations of Minisci reaction have been accomplished<sup>91,93,95,96,113,114</sup> along with computational studies predicting the regioselectivity<sup>92</sup>. The versatility of the Minisci reaction is illustrated in Scheme 49.



Scheme 49: Versatility of Minisci reaction and variety of methods for radical generation.



### 1.5.3.2 Scope and limitations

The Minisci reactions include a variety of transformations resulting in a diverse set of functionalizations of corresponding heteroaromatic bases. The potential scope of Minisci reactions is based on heterocyclic base and the radical partner, along with apparent limitations.

Heterocyclic cores have become a key component in drug development and thus methodologies focusing on selective CH-functionalization of heterocycles are of extreme importance. The compatibility of a broad range of heteroaromatic bases (5-membered, 6-membered, 6,5-bicyclic, 6,6-bicyclic heteroaromatics) along with a few non-basic heteroaromatics makes a compelling case for using Minisci reaction. The ability of late-stage functionalization using radical intermediates makes Minisci reaction an attractive option for medicinal and industrial chemists<sup>93,115</sup>. The availability of various radical precursors with efficient radical generating protocols opened new avenues to reach late-stage transformations of heteroaromatic bases. Both these factors combined render the Minisci reaction a versatile tool to functionalize and transform all chemical substrates containing a heteroaromatic core. Figure 7 illustrates examples involving late-stage functionalization by Minisci reaction<sup>116-118</sup>.





Figure 7: Synthesis examples utilizing Minisci reaction<sup>116-118</sup>.

The Minisci reaction has three main limitations. The first one involves regioselectivity of the reaction when more than once positions are available to react. Even though it is handy for medicinal chemists, it is a roadblock for other chemists working with the reaction. The second one involves the modest yields (<50%) in most of the cases. The third one is a combination of both the issues

mentioned before. Low yields with multiple regioisomeric products require a purification step which can be tedious and challenging.


### 1.5.3.3 Experimental results of Minisci reaction strategy

The availability of methodologies aimed at tuning the regioselectivity of Minisci reaction assisted in sorting out the procedures to attempt functionalization of 2,5-dichloropyrazine. Easy access to large amounts of pyruvic acid made it an attractive choice to try out and optimize the reaction conditions. Reaction of 2,5-dichloropyrazine with pyruvic acid under Minisci reaction conditions (Scheme 50) did not yield the expected product. Instead, the starting material was recovered. Tweaking the reaction conditions (with respect to equivalents of reagents used, reaction temperature, solvent ratio) to find an optimal set of control parameters to arrive at the expected product were not successful.



Scheme 50: Functionalization of 2,5-dichloropyrazine using Minisci reaction conditions.


Exploring the literature revealed a solvent free procedure for carbamoylation of pyrazine and several other substituted pyrazines<sup>119</sup>. The protocol consisted of heating the heteroaromatic compound with Potassium persulfate with formamide resulting in installing an amide group onto the heteroaromatic ring. Replicating the same procedure with 2,5-dichloropyrazine resulted in the expected product **1.136** along with a disubstituted byproduct **1.137** (Scheme 51). Repeating the experiment produced the required monosubstituted product **1.136** as the minor one (<20% yield) and the disubstituted product **1.137** as the major one (80% Yield).



Scheme 51: Carbamoylation of 2,5-dichloropyrazine.

Replicating the same procedure in the presence of a solvent (chlorobenzene, DMSO, 1,4-dioxane, DCE, hexane, 1:1 mixture of DCM:Hexane) resulted either in the disubstituted product **1.137** or in the recovery of unreacted starting material.

In contrast to the results obtained with 2,5-dichloropyrazine, the desired monosubstitution was the major reaction pathway in a competition experiment with pyrazine in 70% yield (Scheme 52). Minisci reaction proceeds with the protonation of the heteroaromatic base followed by nucleophilic radical addition. Hence the observed result can be justified based on the ease of protonation of both the pyrazine and 2,5-dichloropyrazine. Pyrazine with a higher  $pK_a$  value is expected to be protonated faster than 2,5-dichloropyrazine in the same medium, giving rise to carbamoylation of pyrazine and recovery of 2,5-dichloropyrazine. Monosubstitution in case of pyrazine can be attributed to weak electron withdrawing nature of the amide group. Incoming amide group does not affect the electron deficient nature of pyrazine significantly to undergo additional substitution resulting in monosubstituted pyrazine. In contrast, in case of 2,5-dichloropyrazine, the incoming amide group coupled with two additional chloro substituents makes the pyrazine ring electron deficient to undergo additional substitution resulting in disubstituted compound.



Scheme 52: Competition experiment for carbamoylation under Minisci conditions.

The Minisci reaction is a versatile way to establish wide range of functionalities over electron deficient heterocycles. 2,5-dichloropyrazine turned out to be either too reactive or too unreactive under the Minisci reaction conditions, giving either a disubstituted product, or no product at all. Attempts to further functionalize 2,5-dichloropyrazine have been ineffective. The observed disubstitution during the carbamoylation reaction can be attributed to the higher susceptibility of monosubstituted product to additional nucleophilic attack due to the increased electron deficiency of the heteroaromatic ring.

## 1.6 Conclusion and outlook

Repurposing approved antivirals for treatment of early stage COVID-19 infections increased the demand for favipiravir. With an aim to reduce the number of steps in the synthesis and make the synthesis more efficient, we have designed multiple approaches to assemble the functionalities on to the pyrazine ring in minimal number of steps. Unfortunately, the strategies employed in generating the intermediates required for making favipiravir were unsuccessful. Initial attempts at functionalization of 2,5-dichloropyrazine by ortho-lithiation resulted in recovery of starting material. Optimization of reaction conditions and using various lithiated bases did not yield any favourable results either. Lack of literature utilizing 2,5-dichloropyrazine to generate metalated species contributed to our lack of understanding the mechanistic aspects involved. Although the Minisci reaction is highly utilized and reported in functionalization of electron deficient heteroaromatics, its application to functionalize 2,5-dichloropyrazine was not fruitful initially. While the carbamoylation of 2,5-dichloropyrazine was successful, poor regioselectivity resulted in an undesired disubstituted compound as the major product. This observed selectivity favouring disubstituted product can be attributed to the highly electron deficient nature of monosubstituted 2,5-dichloropyrazine over 2,5-dichloropyrazine. In summary, these strategies were unsuccessful with 2,5-dichloropyrazine but are reported to work well with chloropyrazines making it an interesting path to pursue. Improving the regioselectivity of the Minisci addition to 2,5-dichloropyrazine and investigating the stability and reactivity of metalated 2,5-dichloropyrazine species will make an interesting puzzle to solve in future.

## 2 HUMILISIN E

### 2.1 Isolation and structure

In 2021, Li group reported the isolation, structure, and absolute configuration of humilisin E (Figure 8)<sup>120</sup>. A library of four new cembranoids (humilisins A-D), two unique diterpenoids (humilisins E and F), and eight other related compounds were isolated from soft coral species *Sinularia humilis* found in South China sea.




Figure 8: Structure of humilisin E<sup>120</sup>.

Humilisin E consists of a tricyclic ring system with cyclobutane ring sandwiched between a cyclopentane and a cyclononane moiety. There are seven stereogenic centers of which five are contiguous stereocenters. All the four carbons of the cyclobutane ring are stereogenic centers with one being a hindered quaternary stereocenter bearing an isopropyl group. The nine-membered ring system bears an epoxide along with a trisubstituted olefin. These distinct structural features of humilisin E make it an appealing target for synthetic organic chemists. The absence of information about biosynthetic pathway of humilisin E along with the prospect of developing a methodology needed to assemble the unprecedented, fused ring structure provides justification for a total synthesis attempt.

## 2.2 Retrosynthesis and synthesis target

Natural products are an integral part of medicinal & industrial chemistry owing to their frequent utility in our everyday life. The natural products targeted for total synthesis are usually based on their biological activity and industrial utility. Although these reasons are compelling enough, often the structural complexity and chemical diversity drives the discovery process. The rationale behind undertaking a total synthesis of a molecule can be attributed to understanding the reaction pathways along with discovering novel methodologies to access unique and complex structural moieties.

Humilisin E was introduced as an assignment for an advanced level synthetic organic chemistry course, and I never imagined that it would be a part of my dissertation. The distinct structural features, in particular the complex assembly of the three fused rings, along with the inherent complexity of the the entire molecule was enough to draw our attention despite having no reported biological activity or industrial use. The absence of similar skeletal structures in literature motivated us to attempt the total synthesis of humilisin E and develop novel methodologies to synthesize highly constrained and sterically hindered systems.

Retrosynthesis is a process of breaking down a complex molecule into individual components which are easily accessible from commercially available compounds. At first glance it is quite evident that the complex stereogenic centers and sterically bulky groups of humilisin E are part of A & B rings, while the nine-membered C ring is simpler in comparison. A minimal risk synthesis design involves the installation of complex bits in earlier stages followed by simple straight forward steps in later stages. Following this minimum risk strategy, we have decided to install the five contiguous stereocenters of A & B rings in earlier stages and then continue with the construction of C ring.

Retrosynthetic design of humilisin E as shown in Figure 9 involved disconnecting the trisubstituted olefin on C ring (C3-C4 disconnection) based on ring closing metathesis reaction leading to intermediate **2.2**. Functional group transformations to **2.2** guides us to compound **2.3**, which can be further disconnected by olefination step (C7-C8 disconnection) to the bicyclo[3.2.0]heptane skeleton **2.4**. The bicyclic fragment **2.4** consists of fused A & B rings with all the complex stereocenters we envisioned to install in early stages. Hence our primary target for the total synthesis of humilisin E was to assemble the bicyclo[3.2.0]heptane skeleton with suitable handles necessary to install the nine-membered C ring. The next section includes a literature survey of natural products containing bicyclo[3.2.0]heptane skeleton and various methods reported to generate the fused skeleton. The subsequent sections describe our strategies at generating the bicyclic core, conclusions, and future prospects.





Figure 9: Retrosynthetic design to bicyclo[3.2.0]heptane skeleton.

### 2.3 Bicyclo[3.2.0]heptane motif

The bicyclo[3.2.0]heptane skeleton (Figure 10) is an uncommon molecular architecture that intrigues synthetic organic chemists. Although there are a range of natural products<sup>121</sup> and therapeutic agents<sup>122,123</sup> with the bicyclo[3.2.0]heptane skeleton, these systems are not so prevalent in nature. Some of the analogues with this structural skeleton are found to have cytotoxic, antimicrobial, anticancer and AChE inhibition activities<sup>124</sup>. The ring strain of the system provides an impetus for a wide range of skeletal isomerizations<sup>123,125</sup> or ring expansions<sup>123</sup>, which has extensive utility in organic synthesis. The structural versatility along with the ability to access a wide range of cyclic & bicyclic systems makes the bicyclo[3.2.0]heptane fascinating for organic chemists.



Bicyclo[3.2.0]Heptane




Figure 10: Natural products containing bicyclo[3.2.0]heptane skeleton.

### 2.3.1 Natural products with bicyclo[3.2.0]heptane skeleton

Natural products comprising of bicyclo[3.2.0]heptane skeleton can be subdivided into categories based on further ring fusions at different positions. Figure 11 illustrates naked and various fused skeletons along with the isolated and reported examples of natural products.







Figure 11: Natural products with naked and fused bicyclo[3.2.0]heptane skeleton.

## 2.3.2 Synthetic methodologies to generate bicyclo[3.2.0]heptane skeleton

The typical procedure to construct bicyclo[3.2.0]heptane skeleton is to utilize the photochemical [2+2] cycloaddition. Various intermolecular and intramolecular versions of photochemical [2+2] cycloadditions have been reported and utilized in organic synthesis. Apart from the photochemical methodologies, thermal and metal catalyzed [2+2] cycloadditions have also been developed to access a wide range of highly functionalized & substituted bicyclo[3.2.0]heptane skeletons<sup>121</sup>. The mechanistic aspects of photochemical [2+2] cycloadditions and Lewis acid/transition metal-catalyzed [2+2] cycloadditions have been subjected to extensive studies and have been discussed in several reviews<sup>126-128</sup>. Hence, this section does not focus on the mechanistic aspects of [2+2] cycloaddition, but instead describes the various methodologies employed to construct the bicyclic skeleton along with their usage in total synthesis of natural products.


### 2.3.2.1 Intermolecular photochemical [2+2] cycloaddition

Intermolecular photochemical [2+2] cycloaddition is one of the most utilized methods to synthesize all kinds of molecular architectures containing a four-membered ring. In the synthesis of  $\alpha$  and  $\beta$ -bourbonene, this methodology has been used to generate the precursors of the target molecules. Photochemical [2+2] cycloaddition of 1-methyl-3-isopropylcyclopentene with cyclopentenone resulted in the cycloadduct **2.5** along with its regioisomer **2.6** in 1:1 ratio (Scheme 53). Further transformations of **2.5** led to the target molecules  $\alpha$ - and  $\beta$ -bourbonene<sup>129,130</sup>.




Scheme 53: Synthesis of  $\alpha$ - and  $\beta$ -bourbonene via intermolecular [2+2] photocycloaddition<sup>129,130</sup>.

Wickberg and co-workers<sup>131</sup> employed similar procedure to synthesize (-)-norbourbonone from (*R*)-limonene and cyclopentanone (Scheme 54). Later, the asymmetric total synthesis of (-)- $\beta$ -bourbonene was accomplished by Koga and co-workers by photochemical [2+2] cycloaddition<sup>132</sup>.




Scheme 54: Synthesis of (-)-norbourbonone by Wickberg and co-workers<sup>131</sup>.

In the synthesis of (+) and (-)-kelsoene, the key step to generate the tricyclic skeleton was an intermolecular [2+2] photocycloaddition. Mehta and co-workers reported the total synthesis of racemic kelsoene<sup>133</sup> along with the total syntheses of (+) and (-)-kelsoene<sup>134</sup>. The synthetic approach to the tricyclic precursor of kelsoene was based on a [2+2] photochemical cycloaddition of *trans*-1,2-dichloroethylene with optically pure diquinanes **2.7** and **2.8** (Scheme 55.). Further transformations of the tricyclic intermediates resulted in (+)-kelsoene and (-)-kelsoene respectively. Reports by Orellana<sup>135</sup> and Jones<sup>136</sup> on the total synthesis of kelsoene involved [2+2] photocycloaddition of ethylene with diquinanes to access the tricyclic intermediate.




Scheme 55: Synthesis of (+)-kelsoene and (-)-kelsoene via intermolecular [2+2] photocycloaddition.<sup>134</sup>

Total synthesis of tricyclic sesquiterpene (-)-sulcatine G has been accomplished by [2+2] photocycloaddition of *trans*-1,2-dichloroethylene with functionalized optically active diquinane **2.9** (Scheme 56)<sup>137,138</sup>.



Scheme 56: Synthesis route to (-)-sulcatine G via intermolecular [2+2] photocycloaddition.<sup>137,138</sup>

Total synthesis of spatol and spatane derivatives involved [2+2] cycloaddition as the key step to construct the tricyclic core. Salomon and co-workers built the tricyclic core by [2+2] photocycloaddition of cyclopentenone with norbornene derivative **2.10** (Scheme 57)<sup>139</sup>.




Scheme 57: Salomon and co-workers' approach towards spatol and spatane derivatives<sup>139</sup>.

Syntheses of hippolachnin A by Carrier<sup>140</sup>, spatadiene by Dauben and Kowalczyk<sup>141,142</sup>, along with spatol and stoechospermol<sup>143,144</sup> all include intermolecular photochemical [2+2] cycloaddition as the key step to assemble the core.

### 2.3.2.2 Lewis acid-catalyzed [2+2] cycloaddition


Total synthesis of (+)-tricycloclavulone<sup>145,146</sup> was achieved by Iguchi and co-workers, based on an enantioselective intermolecular [2+2] cycloaddition of 2-methoxycarbonyl-2-cyclopenten-1-one and phenylthioacetylene catalysed by a chiral copper catalyst **2.11** (Scheme 58). Lewis acid-catalyzed [2+2] cycloaddition has also been implemented in accessing the skeleton **2.12** of stoechospermol as shown in Scheme 58 using zirconium tetrachloride<sup>147,148</sup>.



Scheme 58: Intermolecular Lewis Acid catalyzed [2+2] cycloaddition approach towards synthesis of a) tricycloclavulone<sup>145,146</sup> b) stoechospermol<sup>147,148</sup>.


### 2.3.2.3 Intramolecular photochemical [2+2] cycloaddition

Intramolecular reactions are preferred over intermolecular [2+2] cycloadditions owing to reliable and better regio- & stereoselectivity. Intramolecular photochemical [2+2] cycloaddition of 1,6-dienes is a common and simple method to generate bicyclo[3.2.0]heptane systems. In the synthesis of  $\alpha$ -bourbonone by Brown and co-workers, photolysis of 1,6-diene **2.13** resulted in the bicyclo[3.2.0]heptane precursor **2.14**, which was then transformed to  $\alpha$ -bourbonone<sup>149</sup> (Scheme 59).




Scheme 59: Intramolecular [2+2] photocycloaddition towards the synthesis of  $\alpha$ -bourbonone<sup>149</sup>.

The same methodology has been applied to the synthesis of  $\alpha$ - and  $\beta$ -panasinsene<sup>150,151</sup>. Intramolecular [2+2] cycloaddition of enone **2.15** resulted in intermediate **2.16**, which was subsequently converted to  $\alpha$ - and  $\beta$ -panasinsene (Scheme 60).




Scheme 60: Synthesis of  $\alpha$ - and  $\beta$ -panasinsene via intramolecular [2+2] photocycloaddition.<sup>150,151</sup>

Optically pure compound **2.17**, underwent a highly regio- and diastereoselective intramolecular [2+2] photocycloaddition resulting in a 97:3 ratio of cycloadducts **2.18** and **2.19** (Scheme 61). The cycloadduct **2.18** has been further modified to complete the synthesis of (-)-italicene<sup>152</sup>.



Scheme 61: Synthesis of (-)-italicene<sup>152</sup>.


Polycyclic ring system of precursor **2.21** to artocarpol A<sup>153</sup> has been built using a [2+2] cycloaddition reaction of compound **2.20** (Scheme 62). Koga and co-workers reported an asymmetric total synthesis of (+)-stoechospermol with an intramolecular [2+2] photocycloaddition of compound **2.22** (Scheme 62) as the key step to establish the tricyclic ring system **2.23**<sup>154,155</sup>. Utilizing the same methodology, Koga and co-workers also reported the synthesis of (+)-spatol<sup>156</sup>.




Scheme 62: Synthesis of artocarpol A<sup>153</sup> and stoechospermol<sup>154,155</sup>.

Wang and co-workers<sup>157</sup> synthesized rhododaurichromanic acids A and B by intramolecular [2+2] photocycloaddition of ester **2.24** (Scheme 63). Jin and co-workers utilized daurichromenic acid **2.25** as the starting material (Scheme 63) and synthesized rhododaurichromanic acids A and B by using same strategy<sup>158</sup>.

**Synthesis by Wang and Co-workers**




**Synthesis by Jin and Co-workers**




Scheme 63: Synthetic approaches towards rhododaurichromanic acids A and B<sup>157,158</sup>.

Synthesizing the core of hippolachnin A using intramolecular [2+2] photocycloaddition has been reported by multiple groups. Ghosh and co-workers reported the synthesis of enantiomerically pure form of tricyclic lactone **2.27** from butenolide **2.26** (Scheme 64) which forms the core structure of hippolachnin A<sup>159</sup>. Wu et al. and Tang et al. arrived at the tricyclic lactone **2.29** from butenolide **2.28**<sup>160</sup> (Scheme 64). Tricyclic lactone **2.29** is an advanced intermediate in synthesis of hippolachnin A by Wood & Brown<sup>149</sup>. Tang and co-workers accomplished the biomimetic total synthesis of hippolachnin A by intramolecular [2+2] photocycloaddition of furan derivative **2.30** (Scheme 64)<sup>161</sup>.


#### Ghosh and co-workers' approach towards hippolachnin A



#### Wu's group & Tang's group approach towards hippolachnin A



#### Tang and co-workers approach towards hippolachnin A



Scheme 64: Different approaches towards synthesis of hippolachnin A<sup>149,159-161</sup>.

Further examples of intramolecular [2+2] photocycloaddition as the key step in total synthesis of natural products include the total syntheses bielschowskysin<sup>162-166</sup>, isocomene<sup>167</sup> and ginkgolide B<sup>168,169</sup>. In all cases, the [2+2] cycloaddition was highly regio- and stereoselective.


#### 2.3.2.4 CuOTf-catalyzed [2+2] cycloaddition

Simple alkenes lack the ability to reach the excited state and undergo photocycloaddition through direct irradiation. To enable the use of alkenes and allylic alcohols in photocycloadditions, addition of transition metal salts as catalysts has been successfully applied. Copper (I) trifluoromethanesulfonate (CuOTf) has been the most suitable catalyst among a wide range of transition metal salts investigated<sup>170</sup> and this catalyst applied in the total synthesis of various natural products.

CuOTf-catalyzed intramolecular [2+2] photocycloaddition of 1,6-heptadienols has been a reliable methodology to construct bicyclo[3.2.0]heptane




skeletons and used accordingly in the total synthesis of  $\alpha$ - and  $\beta$ -panasinsene<sup>150</sup>. The key step in the synthesis involved CuOTf catalysed cycloaddition of dienol **2.31** to construct the tricyclic ring skeleton **2.32**, which was then converted to  $\alpha$ - and  $\beta$ -panasinsene (Scheme 65).




Scheme 65: CuOTf-catalyzed [2+2] cycloaddition approach towards  $\alpha$ - and  $\beta$ -panasinsene<sup>150</sup>.

Formal total synthesis of hippolachnin A was accomplished by Wu and co-workers<sup>160</sup> by generating the tricyclic intermediate **2.34** by CuOTf-catalysed [2+2] cycloaddition of dihydrofuran derivative **2.33** (Scheme 66). The tricyclic intermediate **2.34** was transformed to hippolachnin A by Carreira and co-workers.<sup>140</sup>



Scheme 66: Synthesis of intermediate **2.34** used in formal total synthesis of hippolachnin A by Wu and co-workers<sup>160</sup>.


Bach and co-workers utilized the same methodology to achieve the total synthesis of sesquiterpene kelsoene. Irradiating cyclopentane derivative **2.35** in presence of CuOTf resulted in a [2+2] cycloaddition product **2.36** (Scheme 67). Further manipulations of tricyclic intermediate **2.36** has resulted in total synthesis of ( $\pm$ )-kelsoene<sup>171</sup>.



Scheme 67: CuOTf-catalyzed [2+2] cycloaddition approach towards ( $\pm$ )-kelsoene<sup>171</sup>.



Intramolecular CuOTf-catalyzed [2+2] photocycloaddition methodology has been employed in the total synthesis of diterpene beilschowskyisin to generate the desired [3.2.0]heptane system with full stereochemical control. Ghosh and co-workers reported two different routes employing CuOTf-catalyzed

photocycloaddition as the key step to arrive at the bicyclo[3.2.0]heptane intermediates **2.38**<sup>172</sup> and **2.40**<sup>173</sup> (Scheme 68).



Scheme 68: Synthesis of bicyclo[3.2.0]heptane intermediates towards total synthesis of beilschowskysin by Ghosh and co-workers<sup>172,173</sup>.


Grandisol (Scheme 69) has been a subject to multiple synthetic approaches using the CuOTf-catalysed cycloaddition methodology. Rosini and co-workers achieved the total synthesis by CuOTf-catalyzed photocycloaddition of 1,6-heptadienols **2.41** and **2.43** generating bicyclo[3.2.0]heptane intermediates **2.42** and **2.44** respectively (Scheme 69). Cleavage of five membered ring of intermediates **2.42** and **2.44** resulted in ( $\pm$ )-grandisol<sup>174,175</sup>. Rosini group also reported the synthesis of both the enantiomers of grandisol by resolution of bicyclo intermediate **2.42**<sup>176,177</sup>. Racemic synthesis of grandisol by Mattay and co-workers involved intramolecular CuOTf-catalyzed [2+2] photocycloaddition of 1,6-heptadienol **2.45** to generate the bicyclic skeleton **2.46** and then proceeding to complete the synthesis<sup>178</sup> (Scheme 69). By using enantiomerically pure dienol, Mattay and co-workers also accomplished enantioselective total synthesis of (+)- and (-)-grandisol.



Scheme 69: (±)-Grandisol and different intermediates involved in racemic and enantioselective total syntheses of grandisol<sup>174-178</sup> by using CuOTf-catalyzed cycloaddition method.

### 2.3.2.5 Other methodologies

Other methodologies to construct the bicyclo[3.2.0]heptane core include [2+2] cycloaddition of a ketene and an alkene. This has been achieved by generating a ketene *in situ* followed by thermal cycloaddition with an alkene. This protocol has been successfully applied in the total synthesis of raikovenal and filifolone<sup>179-183</sup>. Rosini and co-workers reported the synthesis of both raikovenal and filifolone starting from 3-hydroxy-3-methyl-6-heptenoic acid (**2.47**) (Scheme 70). Treating **2.47** with potassium acetate and acetic anhydride generates a ketene *in situ* which undergoes [2+2] cycloaddition with the alkene generating 4-methylbicyclo[3.2.0]hept-3-en-6-one (**2.48**). Further manipulations of **2.48** resulted in the successful syntheses of raikovenal and filifolone. Dreiding's group<sup>184</sup> reported the synthesis of filifolone by [2+2] cycloaddition of olefin **2.49** to dimethylketene followed by further manipulations (Scheme 70). Treating isobutyryl chloride with triethylamine yielded the required dimethylketene *in situ*.



Scheme 70: Synthesis approaches towards filifolone and raikovenal<sup>179-184</sup>.

Apart from these approaches, a variety of other methodologies have been developed to construct the bicyclo[3.2.0]heptane framework. Lewis acid-catalyzed thermal cycloaddition<sup>185</sup>, gold(I)-catalyzed cycloaddition of allene-alkenes<sup>186</sup>, thermal cyclization of keteneiminium-alkenes<sup>187,188</sup> and ketene-allenes<sup>189</sup> are a few reported methodologies. Apart from these, cobalt-catalyzed intramolecular cycloadditions of bis(enones)<sup>190</sup>, gold(I)-catalyzed enyne cycloisomerizations<sup>125</sup>, photochemical<sup>191,192</sup> and electrochemical<sup>193-195</sup> methodologies have also been reported. Although these new methodologies can construct the bicyclic framework, they are yet to be used in a total synthesis of natural products containing a bicyclo[3.2.0]heptane framework.

## 2.4 Synthesis of the bicyclic core of humilisin E

The bicyclo[3.2.0]heptane system of humilisin E is highlighted in Figure 12, along with the ideal and alternative bicyclic intermediates that can be utilized in the construction of 9-membered ring.




Figure 12: Illustration of bicyclo[3.2.0]heptane skeleton of humilisin E along with ideal and alternative bicyclic intermediates.

### 2.4.1 Intramolecular [2+2] cycloaddition strategy

The bicyclic AB ring fragment consists of a bicyclo[3.2.0]heptane skeleton. With [2+2] photocycloaddition being a straightforward method to assemble this skeleton, our thought was instantly directed towards a [2+2] cycloaddition strategy involving a cyclopentenone moiety with an olefinic counterpart. The chemical literature reveals several successful total syntheses attempts utilizing intermolecular [2+2] photocycloaddition strategy to assemble the bicyclo[3.2.0]heptane skeleton. The structural complexity of humilisin E along with sterically demanding groups rendered this approach very risky, as the intermolecular [2+2] cycloaddition might be very challenging to control in terms of regio- and stereoselectivity. This made us focus on a more controlled intramolecular approach which was expected to guide the regioselectivity as desired. An intramolecular [2+2] cycloaddition strategy basically involves having both the olefinic fragments in a single molecule. The next step was to design an intermediate that can execute two different roles. The first role includes holding both the olefinic parts together for [2+2] cycloaddition and the second one is the ability to modify into a suitable handle for further transformations. Figure 13 illustrates a general representation of an intermediate that would realize the mentioned criteria.





Figure 13: Representation of intramolecular [2+2] cycloaddition strategy. The final [2+2] cycloaddition could take place via either a photochemical or an iminium-catalyzed<sup>196</sup> route.

#### 2.4.1.1 Strategy involving an ester tether


The first design was based on utilizing an ester group as a tether holding the olefinic components together. It was a simple and efficient design to access the intermediate **2.4**. The retrosynthesis plan to make the intermediate with an ester tether is depicted in Scheme 71. We arrived at an ester tethered intermediate **2.51** which can undergo intramolecular [2+2] cycloaddition to assemble the skeleton and then generate the required handle by simple hydrolysis of ester. Compound **2.51** can be accessed by HWE olefination (C9-C10 disconnection) of **2.53** and functionalized 3-alkylcyclopent-2-en-1-one.



Scheme 71: Retrosynthetic plan of intramolecular [2+2] cycloaddition using an ester tether.


Experimental work started with the synthesis of 3-isopropylcyclopent-2-en-1-one (**2.54**) due to its commercial unavailability. Hydroboration of 2-methyl-2-hepten-6-one (**2.55**) with borane in THF followed by oxidation using alkaline hydrogen peroxide furnished diol **2.56** in quantitative yields. Further oxidation of diol **2.56** to diketone **2.57** using Jones reagent was low yielding due to incomplete oxidation of diol **2.56**. Aldol condensation of diketone **2.57** to generate **2.54** was sluggish with 45% yield. Low yields coupled with the unacceptably high

quantities of chromium waste generated made this an impractical route to synthesize 3-isopropylcyclopent-2-en-1-one (**2.54**) (Scheme 72), and an alternative route was developed later on (Scheme 73). However, accessing the required aldehyde **2.53** was straightforward involving a DIBAL-H reduction of commercially available ethyl 3,3-diethoxypropanoate<sup>197</sup>.




Scheme 72: Preparation of enone **2.54** by aldol reaction. Reagents and conditions: a) i.  $\text{BH}_3$ -THF complex,  $0\text{ }^\circ\text{C}$  to rt, 4h, ii. 3N aq. NaOH, 30%  $\text{H}_2\text{O}_2$ ,  $0\text{ }^\circ\text{C}$  to rt, 17h, 99%; b) Jones oxidation, 18%; c) 2% aq. NaOH, EtOH, reflux, 6h, 45%.

Scheme 73 shows an alternative approach to synthesize **2.53** from cyclopentane-1,3-dione (**2.58**). Refluxing diketone **2.58** with *p*-TSA in ethanol resulted in 3-ethoxycyclopent-2-en-1-one (**2.59**) in 91% yield<sup>198</sup>. We opted for a Cu-catalyzed 1,4-addition of *i*PrMgCl to **2.59** to arrive at the required enone **2.54** in 83% yield.




Scheme 73: Preparation of enone **2.54** by Cu-catalyzed 1,4-addition. Reagents and conditions: a) *p*-TSA, EtOH, reflux, 17h, 91%; b) CuBr·Me<sub>2</sub>S, *i*PrMgCl, HMPA, TMSCl, THF,  $-78\text{ }^\circ\text{C}$ , 3h, 83%.

With enone **2.54** at our disposal, our focus was on the precursor for HWE olefination. Reduction of enone **2.54** using LAH furnished the secondary alcohol **2.60** (volatile and acid sensitive) in 62% yield. Esterification of **2.60** with 2-(diethoxyphosphoryl)acetic acid in presence of T3P was slow with 20% yield of **2.61** after 3 days. Further optimization efforts failed in enhancing the yield (Scheme 74).



Scheme 74: Preparation of ester **2.61**. Reagents and conditions: a) LAH, DEE,  $0\text{ }^\circ\text{C}$  to rt, 2 h, 62%; b) 2-(diethoxyphosphoryl)acetic acid, T3P, DIPEA, PhMe, rt, 72 h, 20%.

To try and optimize the esterification reaction further, we temporarily switched from 3-isopropylcyclopent-2-en-1-one (**2.54**) to 3-methylcyclopent-2-en-1-one (**2.62**), which was inexpensive and commercially available. Scheme 75 illustrates our efforts towards generating a HWE olefination precursor using enone **2.62**. Luche reduction of 3-methylcyclopent-2-en-1-one (**2.62**) resulted in a highly volatile and extremely unstable secondary alcohol **2.63**. Crude alcohol **2.63** was subjected to a wide range of coupling conditions to generate **2.64**. Unfortunately, all our trials resulted in the recovery of starting alcohol **2.63**. The next attempt involved methylating enone **2.62** using MeLi producing tertiary alcohol **2.65** in 85% yield. Tertiary alcohol **2.65** was less volatile, and somewhat surprisingly, more stable compared to the secondary alcohol **2.63**. Unfortunately, the tertiary alcohol **2.65** was unreactive, and esterification using T3P and 2-(diethoxyphosphoryl)acetic acid never progressed to furnish the desired product **2.66**. Unreactivity, instability and low yields of various intermediates in the synthesis plan led us to abandon this approach and search for new possibilities.




Scheme 75: Synthetic attempts to prepare esters **2.64** & **2.66**. Reagents and conditions: a)  $\text{NaBH}_4$ ,  $\text{CeCl}_3 \cdot 7\text{H}_2\text{O}$ , MeOH,  $0^\circ\text{C}$ , 1 h, >99%; b) 2-(diethoxyphosphoryl)acetic acid and i. DCC, DMAP, DCM, rt, 19 h or ii. T3P, DIPEA, PhMe, rt, 48 h or iii.  $\text{PPh}_3$ , DIAD, THF, rt, 12 h or iv.  $\text{PPh}_3$ , DEAD, THF, rt, 18 h; c) MeLi, DEE,  $-78^\circ\text{C}$ , 2 h, 85%; d) 2-(diethoxyphosphoryl)acetic acid, T3P, DIPEA, PhMe, rt, 24 h.

#### 2.4.1.2 Strategy involving a silicon tether

Intramolecular reactions possess superior rates as well as generally better regio- and stereoselectivities over intermolecular reactions, and these properties render them important in complex molecule synthesis. Transforming an intermolecular reaction to an intramolecular variant has added advantages and is preferred in organic synthesis. The use of temporary tethers facilitates this transformation and aid in numerous cycloaddition reactions. Easy availability and inert nature of




silicon derivatives in reactions along with selective and mild removal procedures made silicon-based tethers attractive. Use of silicon tethers in cycloaddition reactions along with other reactions has been compiled elegantly in several reviews<sup>199,200</sup> and this acted as a solid reference for our silicon tethered strategy. Retrosynthetic plan involves generation of bicyclo[3.2.0]heptane fragment by [2+2] cycloaddition reaction of silicon tethered intermediate **2.67** as shown in Scheme 76. Intermediate **2.67** can be assembled from smaller and easily available components as required.




Scheme 76: Retrosynthetic plan of intramolecular [2+2] cycloaddition using a silicon tether.

Synthesizing the required components to assemble the intermediate **2.67** was straightforward. Tertiary alcohol **2.65** was prepared as shown in Scheme 75. Cross-metathesis of 3,3-diethoxyprop-1-ene with but-3-en-1-ol using Grubbs' second-generation catalyst furnished the required primary alcohol **2.68** in 98% yield. Dichlorodiphenylsilane (**2.69**) and di-tert-butylchlorosilane (**2.70**) were commercially available and are used without any further purifications. Di-tert-butylchlorosilane (**2.71**) was treated with trifluoromethanesulfonic acid to generate di-tert-butylchlorosilyl trifluoromethanesulfonate (**2.72**) in 72% yield after vacuum distillation (Scheme 77).



Scheme 77: Synthesis of intermediates **2.68** & **2.72**.


Trials to silylate the tertiary alcohol **2.65** with the available silanes was not fruitful. Treatment of alcohol **2.65** with a base and silane resulted in either dark sticky tar (decomposition) or the recovery of starting material on numerous attempts. Excess of additional base has also been added to avoid degradation of alcohol by acid generated in the reaction medium. The results of trials using various bases and silanes has been depicted in Scheme 78. With tertiary alcohol **2.65** being not reactive enough, we have switched to secondary alcohol **2.63** and tried to optimize the reaction conditions. Unfortunately, reactions of secondary alcohol **2.63** with diphenylsilane **2.69** resulted in black tar (decomposition), while reactions with di-*tert*-butylsilane **2.70** led to the recovery of starting material (Scheme 78).



Scheme 78: Attempts to prepare silyl protected alcohols from **2.63** & **2.65**.

With little success in previous attempts, we now moved to a one-pot procedure to assemble the silicon tether. Tertiary alcohol **2.65** and primary alcohol **2.68** were treated with a base in presence of various silanes to generate a silicon tethered intermediate. Exhaustive experimental trials using different protocols, additional

bases were futile. Repeating the protocols by replacing tertiary alcohol **2.65** with secondary alcohol **2.63** was of no use. Under several different conditions, either the starting alcohol was recovered, or decomposition was observed leaving a dark brown tar which was very difficult to characterize. Scheme 79 illustrates the results of the experiments undertaken to generate a silicon tethered intermediate.




Scheme 79: Attempts to prepare silyl tethers from alcohols **2.63** & **2.65**.

Inability to generate an intermediate holding both the olefinic components together for an intramolecular reaction pathway prompted us to abandon intramolecular [2+2] cycloaddition strategy and opt for alternative strategies.

## 2.4.2 Intramolecular Michael addition strategy

Bicyclo[3.2.0]heptane skeleton of humilisin E is structurally unique owing to the presence of a quaternary carbon (C1) bearing a sterically demanding isopropyl group. The complexity is further enhanced by a tertiary carbon center (C11) adjacent to the quaternary center. Attempts to establish both quaternary and tertiary carbon centers with high steric density in a single step is always a gamble. Realizing this, we have opted for a stepwise approach to establish the sterically demanding centers one by one. As illustrated in Figure 14, we have opted for a stepwise pathway to establish the tertiary carbon center first, followed by the quaternary carbon center.

### Concerted pathway



### Stepwise pathway






Figure 14: Illustration of concerted and stepwise pathways to establish consecutive stereo-centers of the humilisin E core.

The new retrosynthetic design as depicted in Scheme 80 utilizes intramolecular Michael addition as the key step to assemble the skeleton. The core assembly was to be accomplished from compound **2.73** by Michael addition. A Heck coupling of an allylic alcohol and a vinyl bromide would result in the required intermediate **2.73**.



Scheme 80: Retrosynthetic plan based on intramolecular Michael addition reaction.

As shown in Scheme 81, monoprotection of diol **2.74** with NaH and TBSCl produced monosilylated allylic alcohol **2.75** in 90% yield. Bromination of 3-methylcyclopent-2-en-1-one (**2.62**) in presence of triethylamine resulted in the required vinyl bromide species **2.76**. Preliminary Heck cross coupling attempts to generate intermediate **2.73** were unsuccessful. We were unable to isolate even trace amounts of intermediate **2.73** for characterization following exhaustive chromatographic purifications. Considering the issues encountered with generating intermediate **2.73** and unaware of its stability, we decided to abandon this approach and go forward with a much safer epoxynitrile cyclization strategy.




**Heck reaction conditions:**

- 1) K<sub>2</sub>CO<sub>3</sub>, PPh<sub>3</sub>, Pd(OAc)<sub>2</sub>, MeCN, reflux, 24h
- 2) Et<sub>3</sub>N, Pd(PPh<sub>3</sub>)<sub>4</sub>, MeCN, reflux, 22h
- 3) TBAB, K<sub>2</sub>CO<sub>3</sub>, Pd(OAc)<sub>2</sub>, DMF, 60 °C, 24h
- 4) Bu<sub>4</sub>NHSO<sub>4</sub>, Pd(OAc)<sub>2</sub>, Ag<sub>2</sub>CO<sub>3</sub>, MeCN, rt, 24h

Scheme 81: Synthetic attempts towards realizing intramolecular Michael addition strategy.


### 2.4.3 Epoxynitrile cyclization strategy

After the failure of all the previous strategies, we therefore turned to cyclobutane syntheses that were known to be exceptionally reliable in view of literature precedents. Stork *et al.* reported in 1974 a selective transformation, called the epoxynitrile cyclization, to construct functionally substituted cycloalkanes, including cyclobutanes<sup>201,202</sup>. The transformation involves the intramolecular attack of a highly nucleophilic nitrile anion to an epoxide, generating a new C-C bond and a ring of various sizes. Interestingly, the epoxynitrile cyclization always prefers formation of cyclobutane over cyclopentane even when both sides of the oxirane ring are equally substituted and is applied in the synthesis of ( $\pm$ )-grandisol<sup>202</sup> (Scheme 82).



Scheme 82: Synthesis of ( $\pm$ )-grandisol by Stork *et al.* utilizing epoxynitrile cyclization<sup>202</sup>.


Based on this transformation, we came up with a plan to install the epoxide component and the nitrile component on the adjacent carbons of the cyclopentanone ring, thereby facilitating the cyclization to generate the four-membered ring. Scheme 83 illustrates the required intermediate **2.78** for epoxynitrile cyclization and the retrosynthetic plan to arrive at the intermediate **2.78**. In this model study, the isopropyl group at C1 was replaced by a methyl group as the starting materials were more readily available. The basic idea was that the C12 OH group could be used to direct both the cyclopropanation as well as the epoxidation reactions, thereby controlling the stereochemistry.



Scheme 83: Retrosynthetic plan to generate intermediate **2.78** for epoxy-nitrile cyclization.

The design involved a cyclopropane ring opening, reduction of the alkyne, and an epoxidation step to establish the epoxy nitrile intermediate **2.78** starting from **2.79**. Access to compound **2.79** can be achieved starting from 2-iodo-3-methylcyclopent-2-en-1-one **2.80**.

The synthesis towards the intermediate **2.78** started by iodination of commercially available 3-methylcyclopent-2-en-1-one **2.62** to generate compound **2.80** in 54% yield. Sonogashira coupling of iodide **2.80** and TBS protected propargyl alcohol **2.81** proceeded well with 98% isolated yield resulting in compound **2.82**. Methylation of compound **2.82** using MeMgBr produced the intermediate **2.83** required for cyclopropanation (Scheme 84).




Scheme 84: Attempts towards preparation of intermediate **2.84**. Reagents and conditions: a)  $I_2$ , pyridine/DCM (1:4), rt, 60 h, 54%; b) **2.81**,  $PdCl_2(PPh_3)_2$ , CuI,  $iPr_2NH$ , THF, rt, 5 h, 98%; c) MeMgBr, DEE,  $-50\text{ }^\circ\text{C}$  to rt, 16 h, 83%; d)  $Pd(OAc)_2$ , ethyl diazoacetate, DCM, rt, 20 h.

Metal-catalyzed decomposition of ethyl diazoacetate generated the required carbene *in situ* for insertion to compound **2.83**. Multiple attempts at establishing the cyclopropane ring by carbene insertion turned out to be futile and did not result in the required intermediate **2.84**. A quick literature survey revealed that the cyclopropanation of allylic alcohols using diazo compounds suffers with competing O-H insertion, leading us to survey alternative intermediates<sup>203</sup>.

Following the minimal risk approach, we decided to establish the sterically demanding quaternary carbon (C1) and then move on to other stereocenters (C11, C12, C2, C10) in a step-wise manner. A new approach utilizing the inherent reactivity of the cyclopentenone **2.54** was designed (Scheme 85). Specifically, the Cu-catalyzed 1,4-addition to the enone **2.54** should generate an intermediate enolate, which would then be alkylated by bromoacetonitrile. The latter alkylation was expected to take place from the vinyl-substituted side as it is less hindered. In addition, the cuprate addition could also be catalyzed by chiral ligands, opening the possibility of enantioselective synthesis<sup>204-206</sup>.


Addition of MeLi or MeMgX was then expected to provide the tertiary alcohol with the required stereochemistry at C12, as the C11 substituent would disfavor attack syn to the cyanomethyl group. Finally, epoxidation of the vinyl group should lead us to the precursor **2.86** that is now primed for epoxy-nitrile cyclization to generate the desired core **2.85**.



Scheme 85: Retrosynthetic plan to synthesize bicyclic intermediate **2.85** using epoxy-nitrile cyclization.

Efforts to synthesize the bicyclic intermediate **2.85** started with synthesizing 3-isopropylcyclopent-2-en-1-one (**2.54**) from cyclopentane-1,3-dione (**2.58**) as shown in Scheme 73. Cu-catalyzed 1,4-addition of vinyl magnesium bromide to enone **2.54** followed by isolation of enolate as silyl enol ether **2.88** (Scheme 86). The generated silyl enol ether **2.88** is remarkably stable and can be purified by silica gel column chromatography.

Several attempts were made to alkylate **2.88**. In the end, the most reliable method involved treatment of silyl enol ether **2.88** with MeLi in presence of TEA to generate the lithium enolate, followed by addition of bromoacetonitrile. This protocol furnished nitrile **2.87** (9:1 mixture of diastereomers) in 35% yield. Although low yielding, this step establishes the relative stereochemistry at C1 and C11. The sluggishness of the alkylation is certainly attributed to the steric hindrance at C11 due to its proximity to a crowded quaternary center, which may also explain the remarkable stability of the silyl enol ether **2.88**.



Scheme 86: Synthesis scheme for ketonitrile **2.87**.

Compound **2.87** was isolated as an inseparable mixture of diastereomers (9:1) with **2.87** being the major one. The relative stereochemistry of compound **2.87** was confirmed by 1D-NOE experiments by irradiating the highlighted protons at C10 and C2 as shown in Figure 15 and analyzing the NOE enhancements.







Figure 15: Illustration of 1D-NOE interactions in compound **2.87**.


Methylation of compound **2.87** using MeMgBr furnished the tertiary alcohol **2.89** in moderate yield but with excellent stereoselectivity (>20:1). The relative stereochemistry of the tertiary alcohol was determined by 1D-NOE experiments irradiating the highlighted protons at C20 and C11 as shown in Scheme 87.



Scheme 87: Synthesis scheme of tertiary alcohol **2.89** and corresponding 1D-NOE interactions observed in 1D  $^1\text{H}$  NMR NOE experiments.

We then turned to the critical epoxidation reaction. The commonly employed epoxidation procedures using *m*CPBA or TBHP were unsuccessful in epoxidation of the olefin **2.89**. Multiple attempts all resulted in the recovery of starting material. Anticipating the steric bulk around the olefin again to be the main culprit, we turned towards epoxidation reagents which are highly reactive but sterically small, such as dimethyl dioxirane (DMDO). Gratifyingly, epoxidation of the tertiary alcohol **2.89** using *in situ* generated DMDO resulted in a mixture of separable diastereomeric epoxides **2.90** and **2.91** (Scheme 88).

Although the epoxidation provided a mixture of diastereomers, these stereoisomers were readily separable. It turned out that the first eluting isomer **2.90** was the major diastereomer, with undesired stereochemistry at C2, and the second isomer **2.91** is the minor diastereomer with the desired relative stereochemistry at C2.



Scheme 88: Synthesis scheme of compound **2.90** & **2.91**.

Establishment of the relative stereochemistry of these epoxides was initially fraught with difficulties. The NMR spectroscopy data of both the diastereomers

was almost identical with minor differences. 1D-NOE data also clearly identified very similar contacts in both isomers (Figure 16), making it difficult to assign the relative stereochemistry of the epoxide in compounds **2.90** and **2.91**. The key difference between both the diastereomers included the presence of a singlet at 3.05 ppm in  $^1\text{H}$  NMR of compound **2.90**. This peak did not exhibit a cross-peak in HSQC spectrum, indicating it was likely resulting from a OH group. This peak was absent in compound **2.91**. Additionally, epoxide **2.90** was a white solid and non-polar compared to compound **2.91**, which was a colorless oil. These differences made us speculate that diastereomer **2.90** possesses an intramolecular hydrogen bond.




Figure 16: Illustration of 1D-NOE interactions in compounds **2.90** & **2.91**.

Based on this speculation, a conformational analysis was carried out by Monte Carlo conformational search using initially force field (OPLS4) method on both the expected diastereomers. Further optimization and energy calculations for selected conformations was carried out by DFT (M06-2X/6-311G++\*\*) method. The optimized structures of both the diastereomers are illustrated in Figure 17. These calculations confirmed that only in **2.90** an intramolecular hydrogen bonding pattern is feasible for geometric reasons, and also confirmed the relative stereochemistry. Thus, from these conformational studies, the relative stereochemistry at C2 in epoxide diastereomers **2.90** and **2.91** has been established, and the compound **2.91** would then be the desired isomer for the cyclization step. Final confirmation of the stereochemistry was obtained by single-crystal X-ray characterization of epoxide **2.90** (Figure 17). The details of the X-ray characterization are included in the experimental section (Figure 21).





Figure 17: a) Lowest-energy optimized conformations of compounds **2.90** & **2.91** calculated using DFT method M06-2X and basis set 6-311G++\*\*. b) X-ray structure of compound **2.90**.

These computations, however, revealed a potential risk in the synthesis plan which we did not anticipate. In compound **2.91**, the tertiary hydroxyl group

at C12 stands at striking distance to the terminal epoxide carbon (C3). Indeed, the computed distances between the potentially nucleophilic oxygen at C12 and the desired C10 carbon to their respective epoxide carbons are nearly equal (2.93 & 2.95 Å, see Figure 17a). The preceding epoxy nitrile cyclizations reported by Stork<sup>201,202</sup> utilized bases such as KHMDS, NaHMDS or LiHMDS to generate the nitrile anion. We were concerned that subjecting compound **2.91** to similar reaction conditions might result in rapid deprotonation of the tertiary alcohol and undesired cyclization to generate a bicyclic ether as shown in Scheme 89.




Scheme 89: Possible cyclization reactions of epoxy nitrile **2.91** on treating with KHMDS.

Protection of tertiary alcohol to prevent the competing alkoxide attack on epoxide seemed like a safe way to move forward. However, all attempts to silylate the tertiary alcohol (TMSOTf, 2,6-lutidine) were unsuccessful, resulting in recovery of the starting material. The observed reluctance of tertiary alcohol towards protection can be attributed to the steric crowding around the alcohol as evidenced by the computational structures.


A literature survey revealed that the Fleming group has carried out extensive studies on generation of C-metalated nitriles using alkyl magnesium chlorides and subsequent alkylation, acylation, and cyclization reactions with suitable electrophiles<sup>207-213</sup>. A report on generation of C-metalated nitriles using alkyl magnesium halides followed by cyclization<sup>213</sup> caught our attention due to its similarity to the  $\gamma$ -hydroxynitrile system in compound **2.91**. As shown in Scheme 90, treatment of  $\gamma$ -hydroxynitrile with excess isopropyl magnesium chloride resulted in generation of a C-metalated nitrile followed by cyclization.

Addition of  $i\text{PrMgCl}$  to  $\gamma$ -hydroxynitrile **2.92** generates a chloromagnesium alkoxide **2.93**<sup>212</sup>. The alkoxide **2.93**, in the presence of excess  $i\text{PrMgCl}$ , undergoes a halogen-alkyl exchange generating an alkylmagnesium alkoxide **2.94**. Internally directed deprotonation of **2.94** generates a C-metalated nitrile followed by cyclization to give compound **2.95**.



Scheme 90: Mechanism of C-metalation and subsequent cyclization of  $\gamma$ -hydroxynitriles reported by Fleming and co-workers<sup>213</sup>.

We thus followed the same procedure<sup>213</sup>. To our delight, treating epoxide **2.91** with excess  $i\text{PrMgCl}$  (6 equiv.) resulted in the desired bicyclo[3.2.0] skeleton **2.96** (Scheme 91). The connectivity and relative stereochemistry was revealed by 1D and 2D-NMR spectroscopic methods (COSY, HSQC, HMBC) which established the formation of the desired bicyclo[3.2.0]heptane skeleton along with an additional isopropyl group. The formation of the isopropyl ketone at C9 can be attributed to the nucleophilic addition of isopropylmagnesium reagent to nitrile and subsequent hydrolysis, resulting in a ketone.



Scheme 91: Synthesis scheme of bicyclo compound **2.96**.

Spin-spin coupling constants of the synthesized bicyclo[3.2.0]heptane intermediate **2.96** were calculated from  $^1\text{H}$  NMR spectrum and compared to the reported values for humilisin E. Coupling constants corresponding to H11-H10 ( $J_{\text{H11-H10}}$ ) was found to be 5.9 Hz, while the reported H11-H10 coupling constant

( $J_{H11-H10}$ ) for humilisin E was 6.5 Hz (Figure 18). Similarly, H10-H2 coupling constant ( $J_{H10-H2}$ ) was 7.9 Hz in case of compound **2.96** and 9.0 Hz in case of humilisin E. The near similar coupling constants served as an additional confirmation for the formation of the desired bicyclic system.




Figure 18: Illustration of humilisin E and compound **2.96** highlighting spin interactions of H11-H10 and H10-H2.

Conformational analysis of compound **2.96** was carried out by Monte Carlo conformational search using initially force field (OPLS4) method. Four different conformations containing i) no hydrogen bonding (**C1**), ii) hydrogen bonding from primary alcohol to carbonyl group (**C2**), iii) hydrogen bonding from primary alcohol to tertiary alcohol (**C3**), and iv) hydrogen bonding from tertiary alcohol to primary alcohol (**C4**) were selected and subjected to further studies. Optimization and energy calculations for the four selected conformations was carried out by DFT (M06-2X/6-311G++\*\*) method. The optimized structures of the four different conformations **C1**, **C2**, **C3** and **C4** are illustrated in Figure 19. The calculated energies of all four optimized conformations are all very close to each other. The lowest energy conformation in solution is **C1** with no intramolecular hydrogen bonding, followed by conformations **C2**, **C3** and **C4** in increasing order. Although the calculations point towards confirmation **C1** to be the most stable one with no intramolecular hydrogen bonding, the  $^1\text{H}$  NMR of compound **2.96** in  $\text{CD}_2\text{Cl}_2$  contains a broad singlet corresponding to one of the hydroxyl hydrogens' indicating the presence of intramolecular hydrogen bonding and suggesting that **C2**, **C3** or **C4**, or an ensemble of these structures, is more likely to be present in solution.





Figure 19: Lowest-energy optimized conformations of compound **2.96** and their respective relative energy values calculated using DFT method M06-2X and basis set 6-311G++\*\*.

To eliminate the undesired nucleophilic addition of *i*PrMgCl to the C9 nitrile group, we repeated the cyclization with epoxide **2.91** and 3 equivalents of *i*PrMgCl resulting in the formation of desired bicyclo[3.2.0] skeleton **2.85** (Scheme 92). The connectivity and relative stereochemistry was revealed by 1D and 2D-NMR spectroscopic methods (COSY, HSQC, HMBC) which established the formation of the desired bicyclo[3.2.0]heptane skeleton with the nitrile group intact.



Scheme 92: Synthesis scheme of bicyclo compound **2.85**.

As with the intermediate **2.96**, spin-spin coupling constants of the synthesized bicyclo[3.2.0]heptane intermediate **2.85** were calculated from  $^1\text{H}$  NMR spectrum and compared to the reported values for humilisin E. Coupling constants corresponding to H11-H10 ( $J_{\text{H11-H10}}$ ) was found to be 5.8 Hz, while the reported H11-H10 coupling constant ( $J_{\text{H11-H10}}$ ) for humilisin E was 6.5 Hz (Figure 20). Similarly, H10-H2 coupling constant ( $J_{\text{H10-H2}}$ ) was 8.3 Hz in case of compound **2.85** and 9.0 Hz in case of humilisin E. The relative stereochemistry was determined by selective 1D  $^1\text{H}$  NMR NOE experiments. Selectively irradiating H3 hydrogens revealed interactions with hydrogens H10, H14 and H13 determining the relative stereochemistry of the cyclized product **2.85**.




Figure 20: a) Illustration of humilisin E and compound **2.85** highlighting spin interactions of H11-H10, H10-H2 and 1D-NOE interactions. b) Overlay of  $^1\text{H}$  spectrum of compound **2.85** with 1D-NOE interactions.

In conclusion, the epoxynitrile cyclization strategy designed to construct the bicyclo[3.2.0]heptane framework was fruitful. The intention of establishing the quaternary center at earlier stages proved to be important as the steric bulk



helped in directing the incoming groups to result in desired relative stereochemistry.

## 2.5 Conclusion and outlook

Nature is full of organic molecules with complex structures and diverse functionalities that are always a source of challenge for the synthetic organic chemist. Humilisin E belongs to a unique class of natural products that offer immense potential to discover and develop novel methodologies to access highly strained and densely functionalized systems<sup>214-217</sup>. With a target of generating the complex core of humilisin E, we started our journey with a short and efficient strategy to assemble the core. The first strategy to utilize intramolecular [2+2] cycloaddition via iminium catalysis to establish the required contiguous stereocenters and assemble the bicyclo[3.2.0]heptane skeleton was not successful. Highly unstable intermediates in ester-based tethers for [2+2] cycloaddition proved to be a major road-block prompting us to shift towards a silicon-based tethers holding the olefin moieties together. Generation of silicon tethers failed due to unreactivity and instability of intermediates involved. An intramolecular Michael addition strategy based on establishing the required stereocenters in a step-wise manner failed as well.

Among the methodologies reported to construct 4-membered rings, epoxy nitrile cyclizations were found to be reliable. Based on this methodology, a new synthesis plan was designed involving Sonogashira coupling and cyclopropanation. Although Sonogashira coupling worked, cyclopropanation in presence of a tertiary alcohol proved to be difficult prompting us to change the path. Back to the drawing board, we came up with a 7-step synthesis plan involving Cu-catalyzed 1,4-addition followed by 1,3-alkylation establishing the contiguous quaternary and tertiary stereocenters with required relative stereochemistry. Functionalization from this point on were straight forward resulting in required relative stereochemistry. Epoxidation by DMDO followed by cyclization using excess of *i*PrMgCl established the required bicyclo[3.2.0]heptane.

The target of assembling the required bicyclo[3.2.0]heptane skeleton with handles for construction of 9-membered ring of Humilisin E has been achieved. Despite the success, there are a few steps in the synthesis plan which are low yielding. Optimization of low-yielding steps to facilitate scaling up, followed by construction of 9-membered ring to complete the total synthesis of Humilisin E will be a key challenge in the future to work on.

### 3 SUMMARY OF THE THESIS

Irrespective of the field we consider, access to new materials has led to generational changes and made human life easier by leaps and bounds. The ability to synthesize new materials is an important skill. Speaking from an organic chemistry perspective, ability to synthesize complex molecules is an essential skill to master. This dissertation is an attempt to use the synthesis knowledge and make useful molecules.

Favipiravir is a simple looking yet synthetically complicated molecule used as an antiviral. Our approach was to simplify the synthesis route to favipiravir enabling faster production when required. Attempts to develop a reliable and efficient protocol to synthesize 2,5-dichloropyrazine has been met with limited success starting from cheaply available 2,5-diketopiperazine. Solubility of 2,5-diketopiperazine has proved to be an obstacle in optimizing the reaction with  $\text{POCl}_3$ . With our focus being the functionalization of 2,5-dichloropyrazine towards favipiravir, we attempted to establish a suitable substituent using ortho-lithiation strategy with no success. Whereas the Minisci strategy was partially successful and the formation of undesired disubstituted product can be justified by the electronic factors involved. In summary, developing an optimized protocol to synthesize 2,5-dichloropyrazine from 2,5-diketopiperazine followed by understanding the stability of metalated 2,5-dichloropyrazine species require an in-depth study. And our attempts at developing a short and efficient route to favipiravir has left us with numerous issues to address.

Humilisin E is a unique molecule with a highly strained fused ring system with sterically demanding groups. Our initial approaches to construct the bicyclo[3.2.0]heptane core was met with issues involving instability and unreactivity of several intermediates. Although the epoxynitrile cyclization approach was successful in generating the required core, this design plagues with low yields in multiple steps while establishing the required diastereoselectivity. Optimization of the low yielding steps should make this route reliable and efficient in our efforts to complete the total synthesis of humilisin E. In short, an efficient route towards total synthesis of humilisin E will

act as a precedent towards constructing highly strained and sterically demanding natural products.

Organic synthesis has seen tremendous growth with new and efficient methodologies being discovered over time. Yet, nature reminds us of our infancy by producing unique and complex molecules with ease. We may never be as efficient as nature in synthesizing molecules, but each result we produce takes us closer to achieving that efficiency and makes an infinitesimal change in the field of synthesis.

## 4 EXPERIMENTAL SECTION


### 4.1 General Information

All reactions were carried out under an argon atmosphere in oven-dried glassware. When required, nonaqueous reagents were transferred under argon *via* syringe or cannula and dried prior to use. Tetrahydrofuran, toluene, acetonitrile, dichloromethane, and diethyl ether were obtained by passing deoxygenated solvents through activated alumina columns (MBraun SPS-800 Series solvent purification system). Vinyl magnesium chloride, <sup>i</sup>PrMgCl, n-BuLi and MeLi were titrated before each use (CAUTION: n-BuLi and MeLi are pyrophoric, and its handling requires proper air and moisture sensitive techniques). Other solvents and reagents were used as obtained from supplier, unless otherwise noted. Analytical TLC was performed using Merck silica gel F254 (230-400 mesh) plates and analyzed by UV light or by staining upon heating with KMnO<sub>4</sub> solution (1 g KMnO<sub>4</sub>, 6.7 g K<sub>2</sub>CO<sub>3</sub>, 1.7 mL 1M NaOH, 100 mL H<sub>2</sub>O), vanillin solution (6 g vanillin, 5 mL conc. H<sub>2</sub>SO<sub>4</sub>, 3 mL glacial acetic acid, 250 mL EtOH), or ninhydrin solution (0.3 g of ninhydrin, 100 mL of EtOH, 2 mL of AcOH). For silica gel chromatography, the flash chromatography technique with Merck silica gel 60 (230-400 mesh) and CombiFlash R<sub>f</sub> 200 with Redisep Gold columns (20–40 μm spherical silica, 400–632 mesh) were used. All solvents were HPLC grade unless otherwise mentioned. Degassing of solvents was carried out by purging with argon gas for 30 minutes. The <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded in either CDCl<sub>3</sub>, CD<sub>2</sub>Cl<sub>2</sub>, CD<sub>3</sub>CN, (CD<sub>3</sub>)<sub>2</sub>CO, or (CD<sub>3</sub>)<sub>2</sub>SO on Bruker Avance 500, or 300 MHz spectrometers. The chemical shifts were reported in ppm relative to (organometallics 2010 29 9 2176-2179 ref) CHCl<sub>3</sub> (δ 7.26), CDHCl<sub>2</sub> (δ 5.32), CHD<sub>2</sub>CN (δ 1.94), CD<sub>3</sub>CD<sub>2</sub>HCO (δ 2.05), CD<sub>3</sub>CD<sub>2</sub>HSO (δ 2.50), C<sub>6</sub>HD<sub>5</sub> (δ 7.16) or CHD<sub>2</sub>OD (δ 3.31) for <sup>1</sup>H NMR. For the <sup>13</sup>C NMR spectra, CDCl<sub>3</sub> (δ 77.16), CD<sub>2</sub>Cl<sub>2</sub> (δ 53.84), CD<sub>3</sub>CN (δ 118.26), (CD<sub>3</sub>)<sub>2</sub>CO (δ 29.84), or (CD<sub>3</sub>)<sub>2</sub>SO (δ 39.52), C<sub>6</sub>D<sub>6</sub> (δ 128.06) were used as the internal standards. High resolution mass spectrometric data were measured using Agilent Technologies 6560 Ion Mobility ESI-Q-TOF

LC/MS. Melting points (mp) were determined in open capillaries using Stuart melting point apparatus. IR spectra were recorded on a Bruker Tensor 27 FT-IR spectrometer.

## 4.2 Favipiravir synthesis

### 4.2.1 2,5-dichloropyrazine (1.68)




2,5-diketopiperazine **1.69** (0.2 g, 1.75 mmol, 1.0 equiv) was added to an RB followed by the addition of POCl<sub>3</sub> (2.12 mL, 22.79 mmol, 13.0 equiv) & PCl<sub>5</sub> (0.92 g, 4.38 mmol, 2.5 equiv) and the reaction mixture was let to stir at rt. After 18 h, the reaction mixture was added dropwise to crushed ice with rapid stirring. Aqueous phase was extracted with DCM (3x10 mL). The combined organic phases were washed with brine (20 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated to give crude 2,5-dichloropyrazine **1.68** (0.052 g, 0.35 mmol, 20%) as yellow oil. The crude was pure and did not need any further purification. The spectral data of **1.68** matched with the commercially procured 2,5-dichloropyrazine.

$R_f$  (EtOAc-hexane 30:70) = 0.71

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  8.39 (s, 2H)

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  147.7, 143.9

### 4.2.2 Lithiation of 2,5-dichloropyrazine




*Equilibrium Shift Procedure:* A freshly prepared solution of LiTMP in THF (1.1 equiv), was added to an RB and cooled to -78 °C. To this solution electrophile (1.5 equiv) was added followed by addition of 2,5-dichloropyrazine **1.68** (1.0 equiv). The reaction mixture was let to stir at -78 °C for 2 to 5 hours, followed by stirring at rt for 2-12 hours. Sat. aq. NH<sub>4</sub>Cl (10 mL) was added, and the aqueous layer was extracted with DCM (3x10 mL). The combined organic layers were washed with brine (20 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated.

*Stepwise Procedure:* A freshly prepared solution of LiTMP in THF (1.1 equiv), was added to an RB and cooled to -78 °C. To this solution 2,5-dichloropyrazine **1.68** (1.0 equiv) was added and let to stir at -78 °C for 0.5 h. Electrophile (1.5 equiv) in THF was added dropwise. The reaction mixture was let to stir at -78 °C for 1 to 3 hours, followed by stirring at rt for 1-12 hours. Sat. aq. NH<sub>4</sub>Cl (10 mL) was added, and the aqueous layer was extracted with DCM (3x10 mL). The combined organic layers were washed with brine (20 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated.

*Note:* Lithiation of 2,5-dichloropyrazine **1.68** was performed using both the general procedures mentioned above. Irrespective of the temperature, time, and electrophile, the reaction always led to brown sticky mixture and unreacted starting material.

#### 4.2.3 Minisci reaction of 2,5-dichloropyrazine



To a mixture of K<sub>2</sub>S<sub>2</sub>O<sub>8</sub> (0.498 g, 1.85 mmol, 1.1 equiv) and HCONH<sub>2</sub> (1.33 mL, 33.56 mmol, 20 equiv) in a dry RB, 2,5-dichloropyrazine **1.68** (0.25 g, 1.68 mmol, 1.0 equiv) was added and the reaction mixture was heated to 70 °C and let to stir at 70 °C for 12 h. The mixture was then allowed to cool to rt. Water (20 mL) was added to the mixture and filtered through a sintered glass filter (yellow precipitate observed). Aqueous phase was extracted with DCM (3x15 mL). The combined organic phases were washed with brine (30 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated to give compound **1.136** (0.061 g, 0.31 mmol, 19%) as an off white solid. The yellow precipitate observed was dissolved in DMF, concentrated, and dried under vacuum to give **1.137** as an off-white solid.

*Note:* Compound **1.137** was not soluble in water and common organic solvents. It was soluble only in DMF and DMSO.

#### Compound **1.136**

R<sub>f</sub> (EtOAc-hexane 50:50) = 0.4; IR (film, cm<sup>-1</sup>): 3500, 2960, 1690, 1260, 1087; mp 145-146 °C

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.55 (s, 1H), 7.31 (bs, 1H), 5.86 (br s, 1H)

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 163.0, 146.6, 146.1, 145.3, 141.5

HRMS (ESI<sup>+</sup>): m/z calculated for [C<sub>5</sub>H<sub>4</sub>Cl<sub>2</sub>N<sub>3</sub>O]<sup>+</sup> = 191.9726, found 191.9717, Δ = -4.7 ppm

### Compound 1.137

IR (film,  $\text{cm}^{-1}$ ): 3418, 3287, 3218, 3153, 1667, 1584, 1284, 1095; mp 266-269 °C (sublimes)


Anal. Calcd (%) for  $\text{C}_6\text{H}_4\text{Cl}_2\text{N}_4\text{O}_2$ : C, 30.7; N, 23.8; H, 1.7. Found: C, 30.8, N, 23.3, H, 2.2

$^1\text{H}$  NMR (300 MHz, DMF-*d*7):  $\delta$  8.40 (s, 2H), 8.14 (s, 2H)

$^{13}\text{C}$  NMR (75 MHz, DMF-*d*7):  $\delta$  165.1, 148.8, 143.5

## 4.3 Humilisin E synthesis

### 4.3.1 6-methylheptane-2,5-diol (2.56)




A solution of **2.55** (1.17 mL, 7.92 mmol, 1 equiv) in dry THF (10 mL) was cooled to 0 °C using an ice bath, followed by dropwise addition of borane THF solution (7.92 mL of 1M solution, 7.92 mmol, 1 equiv). The mixture was stirred at 0 °C for 1 h and at rt for 3 h. The mixture was then cooled to 0 °C and 3 mL  $\text{H}_2\text{O}$ , 4 mL 3N aq. NaOH solution and 4 mL 30%  $\text{H}_2\text{O}_2$  solution were added dropwise. Let to stir at 0 °C for 1 h and at rt for 16 h. The layers were separated, and the aqueous layer was extracted with DEE (3x30 mL). The combined organic phases were washed with brine (40 mL), dried ( $\text{Na}_2\text{SO}_4$ ), filtered and concentrated to give crude diol **2.56** as colorless oil (1.1 g, 7.52 mmol, 95%). No purification required for subsequent oxidation step. The spectral data of **2.56** match those reported in the literature<sup>218</sup>.

$R_f$  (EtOAc-hexane 70:30) = 0.2; IR (film,  $\text{cm}^{-1}$ ): 3370, 1340, 1050

$^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  3.76-3.70 (m, 1H), 3.52 (br s, 1H), 3.31-3.26 (m, 1H), 2.7 (br s, 1H), 1.64-1.37 (m, 5H), 1.14 (d,  $J = 6.3$  Hz, 3H), 0.86 (d,  $J = 6.8$  Hz, 6H)

$^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ ):  $\delta$  76.7, 68.4, 36.5, 33.9, 30.9, 23.8, 18.8, 17.6

### 4.3.2 6-methylheptane-2,5-dione (2.57)



A solution of 2.83 g of  $\text{CrO}_3$  in water (10 mL) was cooled to 0 °C. 3 mL conc.  $\text{H}_2\text{SO}_4$  was added dropwise and stirred at 0 °C until deep orange-red colored solution was obtained. This prepared solution was added dropwise to a solution of diol

**2.56** (1.48 g, 10.12 mmol, 1.0 equiv) in acetone (20 mL) at 0 °C. After stirring at 0 °C for 2 h, 3 mL isopropyl alcohol was added and the mixture was filtered through celite. Diluted with water and extracted with DEE (3x40 mL). Combined organic layers were washed with brine (50 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated to give diketone **2.57** (0.26 g, 1.8 mmol, 18%) as a colorless oil after purification. The spectral data of **2.57** match those reported in the literature<sup>219</sup>.


*R*<sub>f</sub> (EtOAc-hexane 20:80) = 0.5; IR (film, cm<sup>-1</sup>): 2970, 1707, 1358

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.65 (s, 4H), 2.59-2.56 (m, 1H), 1.06 (s, 3H), 1.05 (d, *J* = 7.0 Hz, 6H)

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 213.3, 207.4, 40.7, 36.8, 33.7, 29.9, 18.1

### 4.3.3 3-isopropylcyclopent-2-en-1-one (**2.54**)

#### Method 01:




To a solution of diketone **2.57** (0.12 g, 0.86 mmol, 1 equiv) and 2% aq. NaOH solution (5 mL), ethanol (5 mL) was added and heated to reflux. The reaction mixture was cooled to rt after 6 h and diluted with water (10 mL). The phases were separated, and aqueous phase was extracted with DEE (3x10 mL). Combined organic phases were washed with brine (20 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated to give crude enone **2.54** (0.047 g, 0.38 mmol, 45%) as a yellow oil. The spectral data of **2.54** match those reported in the literature<sup>220</sup>.

*R*<sub>f</sub> (EtOAc-hexane 4:6) = 0.5; IR (film, cm<sup>-1</sup>): 2964, 2931, 1706, 1608, 1175

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 5.83 (d, *J* = 1.2 Hz, 1H), 2.56-2.51 (m, 3H), 2.32-2.29 (m, 2H), 1.10 (d, *J* = 7.0 Hz, 6H)

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 210.0, 188.3, 127.6, 35.2, 32.0, 29.3, 20.7

#### Method 02:




To vacuum dried CuBr.Me<sub>2</sub>S (0.26 g, 1.25 mmol, 0.05 equiv), dry THF (100 mL) was added and the resulting suspension was cooled to -78 °C. A solution of iPrMgCl in THF (2 M, 17.48 mL, 35.0 mmol, 1.4 equiv) and HMPA (10.4 mL, 60 mmol, 2.4 equiv) were added dropwise and the mixture was let to stir at -78 °C for 15 minutes. A solution containing **2.59** (3.15 g, 25 mmol, 1 equiv), and



TMSCl (6.4 mL, 50 mmol, 2 equiv) in dry THF (10 mL) was added dropwise using a dropping funnel. The mixture was let to stir at -78 °C and monitored by TLC. The reaction was quenched with 2N HCl solution (50 mL). Layers were separated and aqueous layer extracted with DEE (3x75 mL). Combined organic layers were washed with sat. aq. NaHCO<sub>3</sub> solution (100 mL) to remove the copper salts followed by sat. aq. NH<sub>4</sub>Cl solution (100 mL). Organic phase washed with brine (75 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated to give yellow oil. Purification by column chromatography (40:60 pentane-DEE) resulted in 3-isopropylcyclopent-2-en-1-one **2.54** (2.59 g, 20.85 mmol, 83.51%) as a colourless oil. The spectral data of **2.54** match those reported in the literature<sup>220</sup>.

$R_f$  (EtOAc-hexane 4:6) = 0.5; IR (film, cm<sup>-1</sup>): 2964, 2931, 1706, 1608, 1175  
<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 5.83 (d,  $J$  = 1.2 Hz, 1H), 2.56-2.51 (m, 3H), 2.32-2.29 (m, 2H), 1.10 (d,  $J$  = 7.0 Hz, 6H)  
<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 210.0, 188.3, 127.6, 35.2, 32.0, 29.3, 20.7


#### 4.3.4 3-ethoxycyclopent-2-en-1-one (2.59)



To a solution of diketone **2.58** (2.5 g, 25.48 mmol, 1 equiv) and EtOH (50 mL), was added PTSA (0.97 g, 5.1 mmol, 0.2 equiv) and heated to reflux. The mixture was cooled to rt after 17 h and diluted with 100 mL EtOAc. The combined organic layers were washed with sat. aq. Na<sub>2</sub>CO<sub>3</sub> solution (1x80 mL) and brine (1x80 mL). The solution was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated to give 3-ethoxycyclopent-2-en-1-one **2.59** (2.93 g, 23.2 mmol, 91%) as a colorless oil. No purification was required to continue for the next step. The spectral data of **2.59** match those reported in the literature<sup>221</sup>.

$R_f$  (EtOAc-DCM 2:6) = 0.27; IR (film, cm<sup>-1</sup>): 2978, 1670, 1560, 1440, 1160  
<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 5.20 (s, 1H), 3.98 (q,  $J$  = 6.9 Hz, 2H), 2.55-2.51 (m, 2H), 2.36-2.33 (m, 2H), 1.33 (t,  $J$  = 7.0 Hz, 3H)  
<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 205.2, 189.3, 103.8, 66.9, 33.8, 28.8, 14.2

#### 4.3.5 3-isopropylcyclopent-2-en-1-ol (2.60)



A slurry of  $\text{LiAlH}_4$  (0.017 g, 0.44 mmol, 0.5 equiv) and dry DEE (5 mL) was prepared and cooled to -5 °C. A solution of Enone **2.54** (0.11 g, 0.89 mmol, 1 equiv) in DEE (2 mL) was added dropwise to the reaction mixture. The mixture was let to stir at rt. The reaction was quenched after 2 hours using  $\text{H}_2\text{O}$  (2 mL) and 3N NaOH solution (2 mL). The phases were separated, and the aqueous layer was extracted with DEE (3x10 mL). The combined organic layers were washed with brine (25 mL), dried ( $\text{Na}_2\text{SO}_4$ ), filtered and concentrated to give the alcohol **2.60** (0.07 g, 0.55 mmol, 62%) as a colorless oil. The spectral data of **2.60** match those reported in the literature<sup>220</sup>.


*Note:* The alcohol **2.60** was unstable and degraded significantly over silica. As such, the alcohol was used without further purification. Also, the compound **2.60** was volatile and acid sensitive.

$R_f$  (EtOAc-hexane 40:60) = 0.5 ( $\text{KMnO}_4$  Stain); IR (film,  $\text{cm}^{-1}$ ): 3336, 2960, 2931, 1711, 1681, 1466, 1024

$^1\text{H}$  NMR (300 MHz,  $\text{C}_6\text{D}_6$ ):  $\delta$  5.45 (p,  $J = 1.7$  Hz, 1H), 4.79 (br s, 1H), 2.35-1.94 (m, 5H), 1.76-1.69 (m, 1H), 0.96 (dd,  $J_1 = 4.6$  Hz,  $J_2 = 6.8$  Hz, 6H)

$^{13}\text{C}$  NMR (75 MHz,  $\text{C}_6\text{D}_6$ ):  $\delta$  154.3, 125.8, 77.4, 34.3, 31.6, 30.1, 21.5, 21.4

#### 4.3.6 Phosphonate 2.61



To a mixture of alcohol **2.60** (0.07 g, 0.55 mmol, 1 equiv) in dry toluene (5 mL), DIPEA (0.25 mL, 1.44 mmol, 2.6 equiv), 2-(diethoxyphosphoryl)acetic acid (114 mg, 0.58 mmol, 1.05 equiv), and T3P (0.43 mL, 0.72 mmol, 1.3 equiv) were added. The mixture was stirred at rt for 72 h and was diluted with water (5 mL) after 72 h. The phases were separated, and aqueous layer was extracted with EtOAc (3x5 mL). Combined organic layers were washed with brine (10 mL), dried ( $\text{Na}_2\text{SO}_4$ ), filtered and concentrated. Purification by flash column chromatography (40:60

Hexane-EtOAc) resulted in compound **2.61** (0.032 g, 0.11 mmol, 20%) as a colorless oil.


$R_f$  (EtOAc-hexane 70:30) = 0.35; IR (film,  $\text{cm}^{-1}$ ): 2980, 2933, 1726, 1444, 1374, 1331, 1253, 1108, 1020, 824

$^1\text{H}$  NMR (300 MHz,  $\text{CD}_3\text{CN}$ ):  $\delta$  5.63 (s, 1H), 5.43 (s, 1H), 4.07 (q,  $J = 6.8$  Hz, 4H), 2.92 (s, 1H), 2.85 (s, 1H), 2.51-2.22 (m, 5H), 1.27 (t,  $J = 7.0$  Hz, 6H), 1.06 (dd,  $J_1 = 1.4$  Hz,  $J_2 = 6.8$  Hz, 6H)

$^{13}\text{C}$  NMR (75 MHz,  $\text{CD}_3\text{CN}$ ):  $\delta$  160.2, 120.8, 82.9, 63.3, 36.0, 34.2, 32.1, 30.9, 30.7, 21.5, 16.7

HRMS (ESI<sup>+</sup>):  $m/z$  calculated for  $[\text{C}_{14}\text{H}_{25}\text{O}_5\text{PNa}]^+$  = 327.1332, found 327.1340,  $\Delta = 2.4$  ppm

#### 4.3.7 3- methylcyclopent-2-en-1-ol (**2.63**)



To vacuum dried  $\text{CeCl}_3 \cdot 7\text{H}_2\text{O}$  (0.45 g, 1.21 mmol, 1.2 equiv), a solution of enone **2.62** (0.1 g, 1.01 mmol, 1 equiv) in methanol (15 mL) was added and the resulting suspension was cooled to  $-78\text{ }^\circ\text{C}$ . After stirring for 15 minutes at  $-78\text{ }^\circ\text{C}$ ,  $\text{NaBH}_4$  (0.046 g, 1.21 mmol, 1.2 equiv) was added in portions. The cold bath was removed and the reaction mixture was allowed to warm to  $0\text{ }^\circ\text{C}$ . The mixture was stirred at  $0\text{ }^\circ\text{C}$  for 1 h and then warmed to rt. Sat. aq.  $\text{NH}_4\text{Cl}$  solution (5 mL) was added. The phases were separated, and the aqueous layer was extracted with EtOAc (3x5 mL). Combined organic layers were washed with brine (20 mL), dried ( $\text{Na}_2\text{SO}_4$ ), filtered and concentrated to give the alcohol **2.63** as colorless oil (0.1 g, 1 mmol, >99%). Crude alcohol **2.63** was used without purification. The spectral data of **2.63** match those reported in the literature<sup>222</sup>.


*Note:* The alcohol **2.63** was highly volatile and acid sensitive. A highly nonpolar spot was visible on TLC indicating the degradation of alcohol **2.63** by elimination of water.

$R_f$  (EtOAc-hexane 40:60) = 0.42; IR (film,  $\text{cm}^{-1}$ ): 3325, 2965, 2928, 1709, 1644

$^1\text{H}$  NMR (300 MHz,  $\text{CD}_3\text{CN}$ ):  $\delta$  5.37 (s, 1H), 4.68 (bs, 1H), 2.62-2.58 (m, 1H), 2.40-2.30 (m, 1H), 2.26-2.17 (m, 2H), 1.74 (s, 3H)

$^{13}\text{C}$  NMR (75 MHz,  $\text{CD}_3\text{CN}$ ):  $\delta$  145.0, 129.1, 77.9, 35.7, 35.0, 16.8

#### 4.3.8 1,3- dimethylcyclopent-2-en-1-ol (2.65)



A solution of enone **2.62** (0.485 g, 5.05 mmol, 1 equiv) in dry DEE (30 mL) was cooled to -78 °C, followed by dropwise addition of MeLi (1.6 M in DEE, 4.73 mL, 7.6 mmol, 1.5 equiv). The resulting mixture was let to stir at -78 °C for 0.5 h. After warming the mixture to rt and stirring for 2 h, 10 mL sat. aq. NH<sub>4</sub>Cl (15 mL) was added. The phases were separated, and aqueous layer was extracted with DEE (3x15 mL). Combined organic layers were washed with brine (30 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated to give tertiary alcohol **2.65** (0.48 g, 4.28 mmol, 85%) as colorless oil. The crude can be used without any purification. The spectral data of **2.65** match those reported in the literature<sup>223</sup>.


*Note:* The crude was suitable to use without any purification. The alcohol was volatile and highly acid sensitive.

R<sub>f</sub> (EtOAc-hexane 20:80) = 0.5; IR (film, cm<sup>-1</sup>): 3398, 3049, 2966, 2916, 1967, 1674, 1264, 733

<sup>1</sup>H NMR (300 MHz, C<sub>6</sub>D<sub>6</sub>): δ 5.27 (s, 1H), 1.91-1.81 (m, 4H), 1.53 (s, 3H), 1.34 (s, 3H)

<sup>13</sup>C NMR (75 MHz, C<sub>6</sub>D<sub>6</sub>): δ 141.7. 133.3. 83.3. 41.1. 35.5. 28.1. 16.6

#### 4.3.9 Acetal 2.68



A solution of dry degassed DCM (50 mL), but-3-en-1-ol (0.84 mg, 11.6 mmol, 1 equiv) and 3,3-diethoxyprop-1-ene (5.31 mL, 34.8 mmol, 3 equiv) was degassed followed by addition of Grubbs' second-generation catalyst (0.197 g, 232 mmol, 0.02 equiv). The reaction vessel was flushed with argon and heated to reflux. The reaction mixture was cooled to rt and concentrated. The crude was then subjected to flash column chromatography (50:50 DEE-Hexane) to give compound **2.68** (2 g, 11.48 mmol, 99%) as a colorless oil.


R<sub>f</sub> (EtOAc-hexane 40:60) = 0.6; IR (film, cm<sup>-1</sup>): 3426, 3052, 2930, 1338, 1047, 733

$^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  5.81-5.71 (m, 1H), 5.56-5.49 (m, 1H), 4.78 (d,  $J = 5.2$  Hz, 1H), 3.62-3.52 (m, 4H), 3.49-3.38 (m, 2H), 2.30-2.23 (m, 2H), 1.14 (t,  $J = 7.0$  Hz, 6H)

$^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ ):  $\delta$  130.8, 129.7, 101.4, 61.3, 60.9, 35.3, 15.0

HRMS (ESI<sup>+</sup>):  $m/z$  calculated for  $[\text{C}_9\text{H}_{18}\text{O}_3\text{Na}]^+$  = 197.1148, found 197.1154,  $\Delta = 3.0$  ppm


#### 4.3.10 Triflate 2.72



To a precooled ( $-20$  °C) silane **2.71** (4.42 g, 24.72 mmol, 1 equiv), triflic acid (4.38 mL, 49.45 mmol, 2 equiv) was added dropwise using a dropping funnel and stirred at rt for 2 h. The crude was then subjected to vacuum distillation to get compound **2.72** (5.8 g, 17.75 mmol, 72%) as colorless liquid. The spectral data of **2.72** match those reported in the literature<sup>224</sup>.

$^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  1.19 (s, 18H)

#### 4.3.11 Protected allyl alcohol 2.75




A suspension of NaH (0.485 g, 12.14 mmol, 1 equiv) in dry THF (20 mL) was cooled to  $0$  °C, followed by dropwise addition of diol **2.74** (1.07 g, 12.14 mmol, 1 equiv). After stirring at rt for 1 h, TBSCl (1.83 g, 12.14 mmol, 1 equiv) in 10 mL dry THF was added dropwise. After stirring the mixture at rt for 4 h, sat. aq.  $\text{NH}_4\text{Cl}$  solution (20 mL) was added. The phases were separated, and aqueous layer was extracted with DEE (3x30 mL). Combined organic layers were washed with brine (50 mL), dried ( $\text{Na}_2\text{SO}_4$ ), filtered and concentrated. Purification by flash column chromatography (20:80 EtOAc-Hexane) gave compound **2.75** (2.2 g, 10.87 mmol, 89%) as a colorless oil. The spectral data of **2.75** match those reported in the literature<sup>225</sup>.

$R_f$  (EtOAc-hexane 40:60) = 0.5; IR (film,  $\text{cm}^{-1}$ ): 3740, 2930, 2865, 1456

$^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  5.70-5.58 (m, 2H), 4.23-4.21 (m, 2H), 4.16-4.14 (m, 2H), 2.53 (bs, 1H), 0.88 (s, 9H), 0.06 (s, 3H)

$^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ ):  $\delta$  131.2, 130.1, 59.6, 58.7, 25.9, 18.3, -5.1

#### 4.3.12 2-bromo-3-methylcyclopent-2-en-1-one (2.76)




A solution of enone **2.62** (0.971 g, 10.1 mmol, 1 equiv) in dry DCM (10 mL) was cooled to 0 °C, followed by dropwise addition of bromine (0.78 mL, 15.15 mmol, 1.5 equiv) using a dropping funnel and the mixture was stirred at 0 °C for 2 h. Triethylamine (1.55 mL, 11.11 mmol, 1.1 equiv) was added dropwise and stirred at rt for 2.5 h. 0.1N HCl solution (10 mL) was added, and the phases were separated. Organic layer was washed with sat. aq.  $\text{NaHCO}_3$  solution (20 mL), dried ( $\text{Na}_2\text{SO}_4$ ), filtered and concentrated. Purification by flash column chromatography followed by recrystallization using 1:2 EtOAc-Hexane gave compound **2.76** (0.82 g, 4.7 mmol, 47%) as white solid. The spectral data of **2.76** match those reported in the literature<sup>226</sup>.

$R_f$  (EtOAc-hexane 30:70) = 0.69; IR (film,  $\text{cm}^{-1}$ ): 1699, 1613, 951, 587

$^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  2.66-2.64 (m, 2H), 2.55-2.52 (m, 2H), 2.18 (s, 3H)

$^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ ):  $\delta$  201.4, 173.3, 123.3, 33.4, 32.3, 19.1

#### 4.3.13 2-iodo-3-methylcyclopent-2-en-1-one (2.80)




To a solution of enone **2.62** (1.46 g, 15.2 mmol, 1 equiv), dry DCM (120 mL), and pyridine (30 mL), iodine (8.5 g, 33.4 mmol, 2.2 equiv) was added and the dark mixture was stirred at rt for 48 h. Sat. aq.  $\text{Na}_2\text{S}_2\text{O}_3$  solution (100 mL) was added to the reaction mixture and the phases were separated. The organic layer was washed with 2N HCl solution (100 mL), brine (100 mL), dried ( $\text{Na}_2\text{SO}_4$ ), filtered and concentrated. Purification by flash column chromatography (25:75 EtOAc-Hexane) gave the compound **2.80** (1.8 g, 8.11 mmol, 54%) as a white solid. The spectral data of **2.80** match those reported in the literature<sup>227</sup>.

$R_f$  (EtOAc-hexane 30:70) = 0.68; IR (film,  $\text{cm}^{-1}$ ): 1682, 1594, 1371, 1137, 581

$^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  2.75-2.73 (m, 2H), 2.58-2.56 (m, 2H), 2.21 (s, 3H)

$^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ ):  $\delta$  203.6, 179.7, 102.8, 34.4, 33.3, 22.1

#### 4.3.14 Protected propargyl alcohol **2.81**




A solution of propargyl alcohol (1.93 g, 34.35 mmol, 1 equiv) in dry DCM (50 mL) was cooled to 0 °C. Imidazole (4.68 g, 68.71 mmol, 2 equiv) was added followed by TBSCl (5.18 g, 34.35 mmol, 1 equiv). The mixture was stirred at rt for 1.5 h, and diluted with water (50 mL). The phases were separated, and organic layer was washed with sat. aq. NH<sub>4</sub>Cl solution (50 mL), brine (50 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated to give compound **2.81** (5.65 g, 33.17 mmol, 97%) as colorless oil. Purification by flash column chromatography was not necessary. The spectral data of **2.81** match those reported in the literature<sup>228</sup>.

*R*<sub>f</sub> (EtOAc-hexane 20:80) = 0.9 (KMnO<sub>4</sub> stain); IR (film, cm<sup>-1</sup>): 3309, 2930, 2858, 1255, 1089, 833

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 4.30 (d, *J* = 2.4 Hz, 2H), 2.37 (t, *J* = 2.4 Hz, 1H), 0.90 (s, 9H), 0.12 (s, 3H)

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 82.3, 72.8, 51.5, 25.7, 18.2, -5.2

#### 4.3.15 Enynone **2.82**



A solution of degassed dry THF (25 mL), CuI (22 mg, 0.112 mmol, 0.05 equiv), Pd(PPh<sub>3</sub>)<sub>3</sub>Cl<sub>2</sub> (80 mg, 0.112 mmol, 0.05 equiv) and compound **2.80** (0.5 g, 2.25 mmol, 1.0 equiv) was degassed for 20 minutes. Alcohol **2.81** (0.575 mg, 3.38 mmol, 1.5 equiv) was added and the mixture was cooled to 0 °C. Diisopropyl amine (2.3 mL, 15.76 mmol, 7 equiv) in degassed THF was added dropwise. Reaction mixture was stirred at 0 °C for 0.5 h and then at rt for 5 h. The mixture was filtered through celite, washed with sat. aq. NH<sub>4</sub>Cl solution (20 mL), 2N HCl solution (20 mL), sat. aq. NaHCO<sub>3</sub> solution (20 mL) and brine (20 mL). It was then dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated. Purification by flash column chromatography (25:75 EtOAc-Hexane) gave compound **2.82** (0.583 g, 2.20 mmol, 98%) as colorless oil.


*R*<sub>f</sub> (EtOAc-hexane 40:60) = 0.54; IR (film, cm<sup>-1</sup>): 2943, 2920, 1690, 1350, 1079, 826

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 4.53 (s, 2H), 2.65-2.61 (m, 2H), 2.48-2.44 (m, 2H), 2.23 (s, 3H), 0.91 (s, 9H), 0.13 (s, 6H)

$^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ ):  $\delta$  205.5, 179.7, 125.9, 96.7, 75.3, 52.4, 34.8, 32.0, 25.9, 19.0, 18.4, -4.9

HRMS (ESI<sup>+</sup>):  $m/z$  calculated for  $[\text{C}_{15}\text{H}_{24}\text{O}_2\text{SiNa}]^+$  = 287.1438, found 287.1448,  $\Delta$  = 3.5 ppm

#### 4.3.16 Alcohol 2.83



A solution of compound **2.82** (0.1 g, 0.38 mmol, 1.0 equiv) in dry DEE (8 mL) was cooled to -50 °C. A solution of MeMgBr solution in DEE (3 M, 0.14 mL, 0.42 mmol, 1.1 equiv) was added dropwise to the reaction mixture and stirred from -50 °C to rt overnight. Sat. aq.  $\text{K}_2\text{CO}_3$  solution (5 mL) was added to the reaction mixture and the phases were separated. Aqueous layer was extracted with DEE (3x5 mL). The combined organic layers were washed with brine (15 mL), dried ( $\text{Na}_2\text{SO}_4$ ), filtered and concentrated. Purification by flash column chromatography (40:60 DEE:Pentane) resulted in compound **2.83** (0.09 g, 0.32 mmol, 83%) as a colorless oil.


$R_f$  (EtOAc-hexane 40:60) = 0.4; IR (film,  $\text{cm}^{-1}$ ): 3367, 2956, 2929, 2857, 1365, 1254, 1084, 836, 814

$^1\text{H}$  NMR (300 MHz,  $\text{THF}-d_8$ ):  $\delta$  4.49 (s, 2H), 3.65 (s, 1H), 2.46-2.14 (m, 2H), 1.90-1.88 (m, 2H), 1.80 (s, 3H), 1.27 (s, 3H), 0.91 (s, 9H), 0.13 (s, 6H)

$^{13}\text{C}$  NMR (75 MHz,  $\text{THF}-d_8$ ):  $\delta$  166.0, 158.9, 121.1, 82.0, 62.4, 35.3, 34.2, 31.8, 30.7, 30.5, 21.3, 16.4, -4.9

HRMS (ESI<sup>+</sup>):  $m/z$  calculated for  $[\text{C}_{16}\text{H}_{28}\text{O}_2\text{SiNa}]^+$  = 303.1751, found 303.1763,  $\Delta$  = 4.0 ppm

#### 4.3.17 Enolsilane 2.88



To a 3-neck Rb, CuBr.Me<sub>2</sub>S (0.033 g, 0.161 mmol, 0.1 equiv) was added and dried under vacuum. Subsequently, dry THF (15 mL) was added and cooled to -78 °C. Vinylmagnesium bromide in THF solution (1 M, 2.9 mL, 2.90 mmol, 1.8 equiv) and HMPA (1.0 mL, 5.80 mmol, 3.6 equiv) were added dropwise and the mixture




was stirred at  $-78\text{ }^{\circ}\text{C}$  for 15 minutes. A mixture of enone **2.54** (0.20 g, 1.61 mmol, 1.0 equiv) and TMSCl (0.61 mL, 4.83 mmol, 3.0 equiv) in dry THF (5 mL) was added dropwise to the reaction vessel. The mixture was stirred at  $-78\text{ }^{\circ}\text{C}$  for 2 h and then diluted with 10 mL of pentane followed by addition of *N,N*-dimethylethylamine (0.68 mL, 4.83 mmol, 3.0 equiv). Mixture was filtered through celite, washed with water (10 mL), brine (10 mL), dried ( $\text{Na}_2\text{SO}_4$ ), filtered and concentrated. Purification by flash column chromatography (1:99 DEE-Pentane) gave silyl enol ether **2.88** (0.36 g, 1.60 mmol, >99%) as a colorless oil. The silyl enol ether degraded during storage and was used immediately.

$R_f$  (EtOAc-hexane 10:90) = 0.9 ( $\text{KMnO}_4$  stain); IR (film,  $\text{cm}^{-1}$ ): 2957, 2926, 1249, 1091, 867, 839, 755

$^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  5.88 (dd,  $J_1 = 9.8\text{ Hz}$ ,  $J_2 = 17.8\text{ Hz}$ , 1H), 4.95 (dd,  $J_1 = 1.8\text{ Hz}$ ,  $J_2 = 6.0\text{ Hz}$ , 1H), 4.91 (s, 1H), 4.58 (t,  $J = 1.5\text{ Hz}$ , 1H), 2.34-2.13 (m, 2H), 1.85-1.57 (m, 3H), 0.83 (dd,  $J_1 = 2.7\text{ Hz}$ ,  $J_2 = 6.8\text{ Hz}$ , 6H), 0.23 (s, 9H)

$^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ ):  $\delta$  154.7, 145.4, 111.1, 106.9, 55.6, 36.8, 32.9, 31.7, 18.3, 18.1, 0.1

#### 4.3.18 Nitrile **2.87**



A solution of silyl enol ether **2.88** (0.33 g, 1.47 mmol, 1 equiv) in dry THF (3 mL) was cooled to  $0\text{ }^{\circ}\text{C}$ . A solution of MeLi in DEE (1.6 M, 1.10 mL, 1.76 mmol, 1.2 equiv) was added dropwise and the resulting mixture was stirred for 0.5 h. The reaction mixture was cooled to  $-20\text{ }^{\circ}\text{C}$  and a mixture of HMPA (0.25 mL, 1.47 mmol, 1 equiv), bromoacetonitrile (0.15 mL, 2.21 mmol, 1.5 equiv) in 2 mL dry THF was added dropwise. The reaction mixture was stirred from  $-20\text{ }^{\circ}\text{C}$  to rt over 16 h. Sat. aq.  $\text{NH}_4\text{Cl}$  solution (5 mL) was added to the reaction medium, and the phases were separated. The aqueous layer was extracted with DEE (3x5 mL). The combined organic layers were washed with brine (10 mL), dried ( $\text{Na}_2\text{SO}_4$ ), filtered and concentrated. Purification by flash column chromatography (30:70 DEE-Pentane) gave the compound **2.87** (0.1 g, 0.52 mmol, 35%) as colorless oil.

$R_f$  (EtOAc-hexane 30:70) = 0.5 ( $\text{KMnO}_4$  stain); IR (film,  $\text{cm}^{-1}$ ): 2305, 1743, 1420, 1264, 732, 703


$^1\text{H}$  NMR (500 MHz,  $\text{C}_6\text{D}_6$ ):  $\delta$  4.99 (dd,  $J_1 = 11.1\text{ Hz}$ ,  $J_2 = 17.5\text{ Hz}$ , 1H), 4.80 (d,  $J = 11.0\text{ Hz}$ , 1H), 4.52 (d,  $J = 17.5\text{ Hz}$ , 1H), 2.22 (dd,  $J_1 = 5.0\text{ Hz}$ ,  $J_2 = 17.4\text{ Hz}$ , 1H), 1.93 (dd,  $J_1 = 5.2\text{ Hz}$ ,  $J_2 = 8.8\text{ Hz}$ , 1H), 1.68 (m, 3H), 1.59 (dd,  $J_1 = 8.9\text{ Hz}$ ,  $J_2 = 17.6\text{ Hz}$ ,

1H), 1.31-1.27 (m, 1H), 1.09-1.02 (m, 1H), 0.66 (d,  $J = 6.8$  Hz, 3H), 0.59 (d,  $J = 6.8$  Hz, 3H)

$^{13}\text{C}$  NMR (125 MHz,  $\text{C}_6\text{D}_6$ ):  $\delta$  212.8, 138.5, 118.7, 116.4, 52.4, 51.7, 33.9, 32.0, 23.1, 17.9, 17.0, 12.6

HRMS (ESI<sup>+</sup>):  $m/z$  calculated for  $[\text{C}_{12}\text{H}_{17}\text{NONa}]^+ = 214.1202$ , found 214.1203,  $\Delta = 0.5$  ppm

#### 4.3.19 Alcohol 2.89



Compound **2.87** (0.10 g, 0.52 mmol, 1 equiv) was dissolved in dry THF (5 mL) and the reaction mixture was cooled to  $-10$  °C. 3M MeMgBr in DEE solution (0.2 mL, 0.63 mmol, 1.20 equiv) was added dropwise and the reaction was let to stir from  $-10$  °C to rt overnight. Sat. aq.  $\text{NH}_4\text{Cl}$  (5 mL) was added and the phases were separated. Aqueous layer was extracted with DEE (3x5 mL). Combined organic layers were washed with brine (10 mL), dried ( $\text{Na}_2\text{SO}_4$ ), filtered and concentrated to give crude compound **2.89** (0.07 g, 0.38 mmol, 65%) as colorless oil.


$R_f$  (EtOAc-hexane 30:70) = 0.4 ( $\text{KMnO}_4$  stain); IR (film,  $\text{cm}^{-1}$ ): 3054, 2967, 2306, 1764, 1381, 1264, 732

$^1\text{H}$  NMR (500 MHz,  $\text{C}_6\text{D}_6$ ):  $\delta$  5.47 (dd,  $J_1 = 11.1$  Hz,  $J_2 = 17.6$  Hz, 1H), 4.93 (d,  $J = 17.4$  Hz, 1H), 4.85 (d,  $J = 11.0$  Hz, 1H), 2.10 (dd,  $J_1 = 7.9$  Hz,  $J_2 = 17.1$  Hz, 1H), 1.86 (dd,  $J_1 = 6.5$  Hz,  $J_2 = 17.1$  Hz, 1H), 1.68 (t,  $J = 7.1$  Hz, 1H), 1.59-1.37 (m, 5H), 1.20-1.14 (m, 1H), 1.10 (s, 3H), 0.68 (d,  $J = 6.8$  Hz, 3H), 0.65 (d,  $J = 6.8$  Hz, 3H)

$^{13}\text{C}$  NMR (125 MHz,  $\text{C}_6\text{D}_6$ ):  $\delta$  141.7, 120.2, 114.9, 79.8, 54.0, 51.6, 40.7, 33.3, 28.0, 27.1, 18.4, 17.3, 13.1

HRMS (ESI<sup>+</sup>):  $m/z$  calculated for  $[\text{C}_{13}\text{H}_{22}\text{NO}]^+ = 208.1696$ , found 208.1690,  $\Delta = -2.9$  ppm

### 4.3.20 Epoxides 2.90 & 2.91



A solution of **2.89** (0.11 g, 0.53 mmol, 1.0 equiv) and  $\text{NaHCO}_3$  (0.215 g, 2.57 mmol, 4.8 equiv), in acetone/water (1:1, 3 mL) was cooled to  $0\text{ }^\circ\text{C}$ . Oxone (0.33 g, 0.53 mmol, 1.0 equiv) was added to the solution and the reaction mixture was stirred at  $0\text{ }^\circ\text{C}$  for 24 hours. Sat. aq.  $\text{Na}_2\text{S}_2\text{O}_3$  solution (3 mL) was added, and the phases were separated. The aqueous layer was extracted with DEE (3x5 mL). The combined organic layers were washed with brine (10 mL), dried ( $\text{Na}_2\text{SO}_4$ ), filtered and concentrated. Purification by column chromatography (40:60 DEE:Pentane) resulted in two diastereomers with the undesired epoxide **2.90** (0.048 g, 0.21 mmol, 40%) as an off-white solid and desired epoxide **2.91** (0.033 g, 0.15 mmol, 27%) as colorless oil.

#### Epoxide **2.90**:

$R_f$  (EtOAc-hexane 30:70) = 0.3 ( $\text{KMnO}_4$  stain); IR (film,  $\text{cm}^{-1}$ ): 2279, 1391, 1329, 1161, 811, 516, 490

$^1\text{H}$  NMR (500 MHz,  $\text{C}_6\text{D}_6$ ):  $\delta$  3.05 (br s, 1H), 2.59 (t,  $J = 3.5\text{ Hz}$ , 1H), 2.28 (dd,  $J_1 = 9.9\text{ Hz}$ ,  $J_2 = 17.4\text{ Hz}$ , 1H), 2.15 (dd,  $J_1 = 5.4\text{ Hz}$ ,  $J_2 = 17.4\text{ Hz}$ , 1H), 2.11 (t,  $J = 4.2\text{ Hz}$ , 1H), 2.00 (t,  $J = 3.5\text{ Hz}$ , 1H), 1.82-1.75 (m, 2H), 1.43 (dd,  $J_1 = 7.7\text{ Hz}$ ,  $J_2 = 12.8\text{ Hz}$ , 1H), 1.11 (s, 3H), 1.07 (dd,  $J_1 = 4.3\text{ Hz}$ ,  $J_2 = 12.8\text{ Hz}$ , 1H), 0.75 (dd,  $J_1 = 7.9\text{ Hz}$ ,  $J_2 = 13.3\text{ Hz}$ , 1H), 0.57 (d,  $J = 6.8\text{ Hz}$ , 3H), 0.53 (dd,  $J_1 = 7.6\text{ Hz}$ ,  $J_2 = 13.6\text{ Hz}$ , 1H), 0.49 (d,  $J = 6.8\text{ Hz}$ , 3H)

$^{13}\text{C}$  NMR (125 MHz,  $\text{C}_6\text{D}_6$ ):  $\delta$  120.1, 78.7, 54.1, 51.3, 50.0, 46.2, 39.9, 34.0, 24.2, 20.4, 18.5, 17.5, 12.8

HRMS (ESI<sup>+</sup>):  $m/z$  calculated for  $[\text{C}_{13}\text{H}_{22}\text{NO}_2]^+$  = 224.1645, found 224.1643,  $\Delta = -0.9\text{ ppm}$

#### Epoxide **2.91**:


$R_f$  (EtOAc-hexane 30:70) = 0.15 ( $\text{KMnO}_4$  stain); IR (film,  $\text{cm}^{-1}$ ): 2279, 1391, 1329, 1161, 811, 516, 490

$^1\text{H}$  NMR (400 MHz,  $\text{C}_6\text{D}_6$ ):  $\delta$  2.53 (dd,  $J_1 = 2.7\text{ Hz}$ ,  $J_2 = 3.9\text{ Hz}$ , 1H), 2.49 (dd,  $J_1 = 2.8\text{ Hz}$ ,  $J_2 = 4.9\text{ Hz}$ , 1H), 2.25 (dd,  $J_1 = 4.2\text{ Hz}$ ,  $J_2 = 4.8\text{ Hz}$ , 1H), 2.05 (dd,  $J_1 = 8.6\text{ Hz}$ ,  $J_2 = 17.1\text{ Hz}$ , 1H), 1.92 (dd,  $J_1 = 6.4\text{ Hz}$ ,  $J_2 = 17.1\text{ Hz}$ , 1H), 1.60 (dd,  $J_1 = 6.4\text{ Hz}$ ,  $J_2 = 8.5\text{ Hz}$ , 1H), 1.55 (dd,  $J_1 = 6.7\text{ Hz}$ ,  $J_2 = 13.4\text{ Hz}$ , 1H), 1.13-1.04 (m, 4H), 0.98 (s, 3H), 0.89 (d,  $J = 6.7\text{ Hz}$ , 3H), 0.79 (d,  $J = 6.7\text{ Hz}$ , 3H)

$^{13}\text{C}$  NMR (100 MHz,  $\text{C}_6\text{D}_6$ ):  $\delta$  120.3, 79.9, 53.1, 51.2, 50.3, 43.2, 40.9, 37.6, 27.1, 24.3, 18.6, 12.9

HRMS (ESI<sup>+</sup>):  $m/z$  calculated for  $[\text{C}_{13}\text{H}_{22}\text{NO}_2\text{Na}]^+$  = 246.1465, found 246.1442,  $\Delta = -9.3\text{ ppm}$

#### 4.3.21 Ketodiol 2.96



A solution of compound **2.91** (0.04 g, 0.18 mmol, 1 equiv) in dry THF (2 mL) was cooled to 0 °C using an ice bath. *i*PrMgCl in THF (2 M, 0.54 mL, 1.07 mmol, 6 equiv) was added to the solution dropwise at 0 °C. After addition *i*PrMgCl, the ice bath was removed, the reaction mixture was allowed to warm to rt, and the mixture was stirred for 16 hours after which time sat. aq. NH<sub>4</sub>Cl solution (3 mL) was added. Phases were separated and the aqueous layer was extracted with DEE (3x5 mL). The combined organic layers were washed with brine (10 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated. Purification by column chromatography (70:30 DEE:pentane) resulted in compound **2.96** (0.01 g, 0.04 mmol, 21%) as a colourless oil.

$R_f$  (EtOAc-hexane 50:50) = 0.3 (KMnO<sub>4</sub> stain); IR (film, cm<sup>-1</sup>): 3446, 2959, 2925, 2873, 1738, 1692, 1465, 1384, 1369



<sup>1</sup>H NMR (500 MHz, CD<sub>2</sub>Cl<sub>2</sub>): δ 3.69 (dd,  $J_1 = 7.0$  Hz,  $J_2 = 10.3$  Hz, 1H), 3.60 (dd,  $J_1 = 8.5$  Hz,  $J_2 = 10.1$  Hz, 1H), 2.97 (dd,  $J_1 = 6.0$  Hz,  $J_2 = 7.9$  Hz, 1H), 2.86 (d,  $J = 6.8$  Hz, 1H), 2.49 (q,  $J = 7.7$  Hz, 1H), 2.16 (d,  $J = 5.7$  Hz, 1H), 2.00-1.94 (m, 1H), 1.72 (q,  $J = 6.9$  Hz, 1H), 1.64-1.57 (m, 2H), 1.38-1.33 (m, 1H), 1.04 (t,  $J = 6.4$  Hz, 6H), 0.84 (d,  $J = 6.8$  Hz, 3H), 0.78 (d,  $J = 6.8$  Hz, 3H)

<sup>13</sup>C NMR (125 MHz, CD<sub>2</sub>Cl<sub>2</sub>): δ 218.6 (derived from HMBC), 78.6, 63.3, 52.1, 50.5, 43.5, 41.0, 40.3, 38.0, 37.1, 28.7, 27.2, 18.9, 18.5, 18.1, 17.2

HRMS (ESI<sup>+</sup>):  $m/z$  calculated for [C<sub>16</sub>H<sub>28</sub>O<sub>3</sub>Na]<sup>+</sup> = 291.1931, found 291.1933,  $\Delta = 0.7$  ppm



## $^1\text{H}$ - $^1\text{H}$ -COSY Spectrum of ketodiol **2.96**

The  $^1\text{H}$ - $^1\text{H}$ -COSY spectrum of compound **2.96** was measured at room temperature on a 500MHz NMR spectrometer by dissolving the compound in deuterated DCM. The correlations between hydrogens H3/H2/H10/H11 helped in establishing the spin system of the 4-membered ring, while the correlations of H13/H14, H15/H16/H17, and H5/H6/H7 helped in determining the remaining spin systems present in the molecule.




## HSQC Spectrum of ketodiol 2.96

The phase sensitive HSQC spectrum of compound **2.96** was measured at room temperature on a 500 MHz NMR spectrometer by dissolving the compound in deuterated DCM. This spectrum helped us in constructing the core structure and identifying the carbon-hydrogen connections.



#### 4.3.22 Humilisin E core 2.85



A solution of **2.91** (0.023 g, 0.1 mmol, 1 equiv) in dry DEE (2 mL) was cooled to 0 °C using an ice bath. To this solution, a solution of *i*PrMgCl in THF (2 M, 0.15 mL, 0.3 mmol, 3 equiv) was added dropwise at 0 °C. After the addition, the ice bath was removed, the reaction mixture was allowed to stir for 6 h at rt, after which time sat. aq. NH<sub>4</sub>Cl solution (3 mL) was added. The phases were separated and the aqueous layer was extracted with DEE (3x5 mL). The combined organic layers were washed with brine (10 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated. Purification by column chromatography (70:30 DEE:Pentane) resulted in compound **2.85** (0.0072 g, 0.032 mmol, 31%) as a colourless oil.

*R*<sub>f</sub> (EtOAc-hexane 50:50) = 0.3 (KMnO<sub>4</sub> stain); IR (film, cm<sup>-1</sup>): 3400, 2959, 2874, 2235, 1466, 1387, 952, 708, 677


<sup>1</sup>H NMR (500 MHz, CD<sub>2</sub>Cl<sub>2</sub>): δ 3.72-3.67 (m, 2H), 2.81 (dd, *J*<sub>1</sub> = 5.9 Hz, *J*<sub>2</sub> = 8.3 Hz, 1H), 2.34 (d, *J* = 5.8 Hz, 1H), 1.89 (dt, *J*<sub>1</sub> = 7.9 Hz, *J*<sub>2</sub> = *J*<sub>3</sub> = 13.0 Hz, 1H), 1.74-1.62 (m, 3H), 1.38-1.32 (m, 1H), 1.27 (s, 3H), 0.94 (d, *J* = 6.8 Hz, 3H), 0.81 (d, *J* = 6.8 Hz, 3H)

<sup>13</sup>C NMR (125 MHz, CD<sub>2</sub>Cl<sub>2</sub>): δ 122.9, 78.2, 62.4, 53.5, 52.7, 43.8, 39.5, 37.3, 28.4, 27.5, 20.8, 18.0, 17.1

HRMS (ESI<sup>+</sup>): *m/z* calculated for [C<sub>13</sub>H<sub>21</sub>O<sub>2</sub>NNa]<sup>+</sup> = 246.1465, found 246.1459, Δ = -2.4 ppm

## $^1\text{H}$ - $^1\text{H}$ -COSY Spectrum of humilisin E core 2.85


The  $^1\text{H}$ - $^1\text{H}$ -COSY spectrum of compound **2.85** was measured at room temperature on a 500 MHz NMR spectrometer by dissolving the compound in deuterated DCM. The correlations between hydrogens H3/H2/H10/H11 helped in establishing the spin system of the 4-membered ring, while the correlations of H13/H14, H15/H16/H17, and H5/H6/H7 helped in determining the remaining spin systems present in the molecule.







## HSQC Spectrum of humilisin E core 2.85

The phase sensitive HSQC spectrum of compound **2.85** was measured at room temperature on a 500 MHz NMR spectrometer by dissolving the compound in deuterated DCM. This spectrum helped us in assignment of the key signals and identifying the carbon-hydrogen connections.



## 1D-NOE interactions of humilisin E core **2.85**

The relative stereochemistry was determined by selective 1D  $^1\text{H}$  NMR NOE experiments. Selectively irradiating the H3 protons (which are nearly overlapping) revealed NOE interactions with hydrogens H10, H14 and H13 helping us determine the relative stereochemistry of the cyclized product **2.85**.



## 4.4 X-ray data

The X-ray structure of epoxide **2.90** was determined by Mr. Anton Bannykh and Prof. Kari Rissanen using the instrument XtaLAB Synergy R diffractometer equipped with Hypix-Arc 100 HPC detector. The data reduction and absorption correction were made by program CrysAlisPro(version 1.171.42.80a, 2023, Rigaku Oxford Diffraction). The structure was solved by using SHELXT<sup>229</sup> intrinsic phasic method, in OleX 2-1.5<sup>230</sup>, and refined with SHELXL<sup>231</sup> least squares method. The structure was drawn with Mercury 2022.3.0 showing thermal ellipsoids at 50% probability level.

### 4.4.1 Epoxide 2.90

|  |   |
|--|---|
| Identification Code                    | <b>2.90</b>                                     |
| Empirical formula                      | C <sub>13</sub> H <sub>21</sub> NO <sub>2</sub> |
| Formula weight                         | 223.31  |
| Temperature/K                          | 120.00(10)                                      |
| Crystal system                         | Orthorhombic                                    |
| Space group                            | Pbca  |
| a, b, c (Å)                            | 11.7976(3), 9.0605(2), 22.6373(5)               |
| $\alpha, \beta, \gamma$ (°)            | 90, 90, 90                                      |
| Volume (Å <sup>3</sup> )               | 2419.75(10)                                     |
| Z                                      | 8   |
| $\rho_{\text{calc}}$ g/cm <sup>3</sup> | 1.226   |
| $\mu$ /mm <sup>-1</sup>                | 0.649   |
| F(000)                                 | 976.0   |
| Crystal size/mm <sup>3</sup>           | 0.275 x 0.19 x 0.129                            |

---

### Data collection & Refinement

|   |  |
|---|--|
| Radiation                                   | Cu K $\alpha$ ( $\lambda$ = 1.54184)                                   |
| 2 $\Theta$ range for data collection/°      | 7.81 to 133.498  |
| Index ranges                                | -13 $\leq$ h $\leq$ 14, -10 $\leq$ k $\leq$ 10, -25 $\leq$ l $\leq$ 26 |
| Reflections collected                       | 14560  |
| Independent reflections                     | 2146 [R <sub>int</sub> = 0.0538, R <sub>sigma</sub> = 0.0360]          |
| Data/restraints/parameters                  | 2146/0/149   |
| Goodness-of-fit on F <sup>2</sup>           | 1.093  |
| Final R indexes [I $\geq$ 2 $\sigma$ (I)]   | R <sub>1</sub> = 0.0806, wR <sub>2</sub> = 0.2372                      |
| Final R indexes [all data]                  | R <sub>1</sub> = 0.0851, wR <sub>2</sub> = 0.2410                      |
| Largest diff. peak/hole / e Å <sup>-3</sup> | 0.62/-0.33   |
| Absorption correction                       | Gaussian mode  |




Figure 21: ORTEP-figure of the crystal structure of **2.90**. Single crystal of compound used in X-ray diffraction was obtained by slow evaporation of **2.90** solution in Et<sub>2</sub>O-Pentane. The thermal displacement parameters are shown at 50% probability level.

## 5 REFERENCES

1. Gorbalenya, A. E.; Baker, S. C.; Baric, R. S.; de Groot, R. J.; Drosten, C.; Gulyaeva, A. A.; Haagmans, B. L.; Lauber, C.; Leontovich, A. M.; Neuman, B. W.; Penzar, D.; Perlman, S.; Poon, L. L. M.; Samborskiy, D. v.; Sidorov, I. A.; Sola, I. ja Ziebuhr, J., The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2, *Nat Microbiol*, **2020**, *5*, 536–544.
2. Li, G. ja de Clercq, E., Therapeutic options for the 2019 novel coronavirus (2019-nCoV), *Nat Rev Drug Discov*, **2020**, *19*, 149–150.
3. Plé, N. ja Fruit, C., Metalation of Pyrazine and Quinoxaline, *Top Heterocycl Chem*, **2012**, 131–170.
4. Turck, A.; Trohay, D.; Mojovic, L.; Plé, N. ja Quéguiner, G., Metalation of diazines. IV. Lithiation of sym-disubstituted pyrazines, *J Organomet Chem*, **1991**, *412*, 301–310.
5. Furuta, Y.; Gowen, B. B.; Takahashi, K.; Shiraki, K.; Smee, D. F. ja Barnard, D. L., Favipiravir (T-705), a novel viral RNA polymerase inhibitor, *Antiviral Res*, **2013**, *100*, 446–454.
6. Titova, Y. A. ja Fedorova, O. v., Favipiravir – a Modern Antiviral Drug: Synthesis and Modifications, *Chem Heterocycl Compd (N Y)*, **2020**, *56*, 659–662.
7. Harismah, K. ja Mirzaei, M., Favipiravir: Structural Analysis and Activity against COVID-19, *Advanced Journal of Chemistry, Section B*, **2020**, *2*, 55–60.
8. Shi, F.; Li, Z.; Kong, L.; Xie, Y.; Zhang, T. ja Xu, W., Synthesis and crystal structure of 6-fluoro-3-hydroxypyrazine-2-carboxamide, *Drug Discov Ther*, **2014**, *8*, 117–120.
9. Liu, F. L.; Li, C. Q.; Xiang, H. Y. ja Feng, S., A practical and step-economic route to Favipiravir, *Chemical Papers*, **2017**, *71*, 2153–2158.
10. Furuta, Y.; Komeno, T. ja Nakamura, T., Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, *Proc. Jpn. Acad., Ser B*, **2017**, *93*, 449–463.
11. Rhyman, L.; Tursun, M.; Abdallah, H. H.; Choong, Y.; Parlak, C.; Kharkar, P. ja Ramasami, P., Theoretical investigation of the derivatives of

- favipiravir (T-705) as potential drugs for Ebola virus, *Physical Sciences Reviews*, **2019**, 3, 1–10.
12. Furuta, Y.; Egawa, H.; Takahashi K.; Tsutsui, Y.; Uehara, S. ja Muratami, M., Nitrogenous heterocyclic carboxamide derivatives or salts thereof and antiviral agents containing both, WO, 2000/10569, March 2, 2000.
  13. Furuta, Y.; Hiroyuki, E. ja Nomura, N., Nitrogen-Containing Heterocyclic Carboxamide Derivatives or Salts Thereof and Antiviral Agents Comprising the Same, US 2002/0013316 A1, Januray 21, 2002.
  14. Furuta, Y.; Hiroyuki, E. ja Nomura, N., Nitrogen-Containing Heterocyclic Carboxamide Derivatives or Salts Thereof and Antiviral Agents Comprising the Same, US 6.787.544 B2, September 7, 2004.
  15. Egawa, H.; Furuta, Y.; Sugita, J.; Uehara, S.; Hamamoto, S. ja Yonezawa, K., Novel Pyrazine Derivatives or Salts Thereof, Pharmaceutical Compositions Containing the Derivatives or the Salts and Intermediates for the Preparation of Both, WO 2001/060834, August 23, 2001.
  16. Takamatsu, T. ja Yonezawa, K., Organic Amine Salt of 6-Fluoro-3-hydroxy-2-pyrazinecarbonitrile and Method for Producing the Same, WO 2009/041473, April 02, 2009.
  17. Hara, H.; Norimatsu, N.; Kurushima, H. ja Kano, T., Method for producing Dichloropyrazine derivative, US 2011/0275817 A1, November 10, 2011.
  18. Nakamura, K.; Murakami, T.; Naitou, H.; Hanaki, N. ja Watanabe, K., Pyrazino[2,3-d]isooxazole Derivative, US 2013/0245264 A1, September 19, 2013.
  19. Nakamura, K.; Murakami, T.; Naitou, H.; Hanaki, N. ja Watanabe, K., Pyrazino[2,3-d]isooxazole Derivative Which is Useful as a Production Intermediate of Pyrazine Carboxamide Derivative, US 8,901,302 B2, December 02, 2014.
  20. Nakamura, K.; Murakami, T.; Naitou, H.; Hanaki, N. ja Watanabe, K., Pyrazino[2,3-d]isooxazoles as Intermediates for the Synthesis of Substituted Pyrazinecarbonitriles and Substituted Pyrazinecarboxamides, US 9,181,203 B2, November 10, 2015.
  21. Zheng, J.; Zhang, T.; Liu, C.; Feng, B. ja Li, Z., Preparation of 6- Fluoro-3-hydroxy-2-pyrazinamide, CN 102775358, Nov 14, 2012.
  22. Zhang, T.; Kong, L.; Li, Z.; Yuan, H. ja Xu, W., Synthesis of Favipiravir, *Chinese Journal of Pharmaceuticals*, **2013**, 44, 841–843.
  23. Li, M., Favipiravir Synthesis Method, CN 107226794, July 17, 2017.
  24. Guo, Q.; Xu, M.; Guo, S.; Zhu, F.; Xie, Y. ja Shen, J., The complete synthesis of favipiravir from 2-aminopyrazine, *Chemical Papers*, **2019**, 73, 1043–1051.
  25. Naesens, L.; Guddat, L. W.; Keough, D. T.; van Kuilenburg, A. B. P.; Meijer, J.; vande Voorde, J. ja Balzarini, J., Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir), *Mol Pharmacol*, **2013**, 84, 615–629.
  26. Huchting, J.; Winkler, M.; Nasser, H. ja Meier, C., Synthesis of T-705-Ribonucleoside and T-705-Ribonucleotide and Studies of Chemical Stability, *ChemMedChem*, **2017**, 12, 652–659.

27. Zhong, B.; Fan, S.; Zhou, L.; Shi, W.; Yao, Y.; He, X. ja Jia, H., Pyrazine Derivative and Medical Application Thereof, CN 103833812A, June 04, 2014.
28. Li, S.; Li, X.; Zhong, W.; Zhang, Z.; Zhang, T.; Xiao, J.; Wang, L.; Zheng, Z.; Zhou, X.; Zhao, G. ja Wang, X., 3-oxo-3,4-dihydro-2-pyrazine-formamide derivative, pharmaceutical composition of same, method for preparing same, and use thereof, WO 2013/139206 A1, September 26, 2013.
29. Han, M.; Zhao, X.; Wu, X.; Huang, W.; Li, X. ja Yu, F., Synthesis of a Novel Class of 1,3-oxathiolane Nucleoside Derivatives of T- 705 and Evaluation of Their Anti-influenza A Virus and Anti-HIV Activity, *Med Chem*, **2018**, *14*, 595–603.
30. Liu, X.; Zhang, T.; Zhan, P.; Zhang, J. ja Ju, H., A kind of resisiting influenza virus compound and its preparation method and application, CN 108299316A, July 20, 2018.
31. Klejch, T.; Pohl, R.; Janeba, Z.; Sun, M.; Keough, D. T.; Guddat, L. W. ja Hocková, D., Acyclic nucleoside phosphonates with unnatural nucleobases, favipiravir and allopurinol, designed as potential inhibitors of the human and Plasmodium falciparum 6-oxopurine phosphoribosyltransferases, *Tetrahedron*, **2018**, *74*, 5886–5897.
32. Wu, Y., Pyrimidine amide derivatives and its salt, CN105884827B, March 13, 2018.
33. Ren, Q.; Luo, H.; Tang, C.; Zhang, J. ja Zhang, Y., Pyrazine compounds containing cyclobutane substituent and combinations thereof thing and purposes, CN104447583B, August 24, 2016.
34. Martin, D. ja Zitko, J., Pyrazine Derivatives: A Patent Review (June 2012-present), *Expert Opin Ther Pat*, **2015**, *25*, 33–47.
35. Cheeseman, G. W. H. ja Werstiuk, E. S. G., *Recent Advances in Pyazine Chemistry*, 1972, vol. 14.
36. Sato, N., Studies on Pyrazines, 8 (1). An Improved Synthesis of 2-Amino-3,5-dibromo- and 2-Amino-5-bromopyrazines, *J. Heterocyclic Chem*, **1982**, *19*, 673–674.
37. Aoyagi, Y.; Fujiwara, T. ja Ohta, A., Synthesis of Halohydroxypyrazines and their Synthetic Utility, *Heterocycles*, **1991**, *32*, 2407–2415.
38. Cheeseman, G. W. H., The synthesis and Tautomerism of Some 2-Substituted Pyrazines, *J. Chem. Soc*, **1960**, 242–247.
39. Sato, N., Studies on Pyrazines. 13 [1]. Chlorination of 1-Hydroxy-2(1H)-pyrazinones with Phosphoryl Chloride. Formation of 2,5-Dichloro-3-phenylpyrazine from 1-Hydroxy-3-phenyl-2(1H)-pyrazinone, *J. Heterocyclic Chem*, **1986**, *23*, 149–151.
40. Palamidessi, G.; Vigevani, A. ja Zarini, F., On the Reaction of Phosphorous Oxychloride with Pyrazinecarboxamide 4-Oxide, *J. Heterocyclic Chem*, **1974**, *11*, 607–610.
41. Sato, N. ja Arai, S., Studies on Pyrazines. 7 (1). The Synthesis of 5-Chloropyrazinecarboxylic Acid, *J. Heterocyclic Chem*, **1982**, *19*, 407–408.

42. Schneller, S. W. ja May, J. L., Formycin Analogs. 1. Model Studies in the Preparation of an Isomer of Formycin and Related Derivatives (s-Triazolo [4,3-a] pyrazines), *J. Heterocyclic Chem*, **1978**, *15*, 987–992.
43. Roberts, D. A.; Bradbury, R. H.; Brown, D.; Faull, A.; Griffiths, D.; Major, J. S.; Oldham, A. A.; Pearce, R. J.; Ratcliffe, A. H.; Revill, J. ja Waterson, D., 1,2,4-Triazolo[4,3-a]pyrazine Derivatives with Human Renin Inhibitory Activity. 1. Synthesis and Biological Properties of Alkyl Alcohol and Statine Derivatives, *J Med Chem*, **1990**, *9*, 2326–2334.
44. Ohta, A. ja Ohta, M., Syntheses of Mutaaspergillic and dl-Hydroxyaspergillic Acids, *Chem Pharm Bull (Tokyo)*, **1983**, *31*, 20–24.
45. Hino, T. ja Sato, T., Synthesis of 3,6-Diethoxycarbonyl-3,6-epidithia-1,4-dimethyl-2,5-piperazinedione and related Compounds. Formation of C-S Bond by the Reaction of Carbanion and Sulfur Monochloride, *Chem Pharm Bull (Tokyo)*, **1974**, *22*, 2866–2874.
46. Botta, M.; de Angleis, F. ja Nicoletti, R., Synthesis of 2-Amino-3-methoxypyrazine, *J. Heterocyclic Chem*, **1979**, *16*, 193–194.
47. Jung, J.; Jung, Y. ja Park, O., Preparation of 2-chloropyridine, *Synth Commun*, **2001**, *31*, 2507–2511.
48. Hashimoto, M.; Izuchi, N. ja Sakata, K., Preparation and Characterization of Nickel(II), Copper(II) and Palladium(II) Complexes with 5,14-Dihydro-7,16-diethyl-dipyrazo[b,i][1,4,8,11]tetraazacyclotetradecine, *J. Heterocyclic Chem*, **1988**, *25*, 1705–1708.
49. Sato, N.; Matsumoto, K.; Takishima, M. ja Mochizuki, K., Studies on pyrazines. Part 34. Synthetic approach, stability and tautomerism of 2,6-dihydroxypyrazines, *J Chem Soc Perkin 1*, **1997**, 3167–3172.
50. Ohta, A.; Masano, S.; Tsutsui, M.; Yamamoto, F.; Suzuki, S.; Makita, H.; Tamamura, H. ja Akita, Y., Syntheses of Some 2-Hydroxypyrazine 1-Oxides, *J. Heterocyclic Chem*, **1981**, *18*, 555–558.
51. Ohta, A.; Watanabe, T.; Akita, Y.; Yoshida, M.; Toda, S.; Akamatsu, T.; Ohno, H. ja Suzuki, A., Some reactions of Mono Substituted Pyrazine Monoxides, *J. Heterocyclic Chem*, **1982**, *19*, 1061–1067.
52. Klein, B.; Hetman, N. E. ja O'Donnell, M. E., Pyrazines. III. The Action of Phosphoroyl Chloride on Pyrazine N-Oxides, *Journal of Organic Chemistry*, **1963**, *28*, 1682–1686.
53. Palamidessi, Giorgio. ja Bernardi, Luigi., On 2,5-Dichloropyrazine, *Journal of Organic Chemistry*, **1964**, *29*, 2491–2492.
54. Sato, N. ja Fujii, M., High regioselective synthesis of chloropyrazines from 3-Substituted Pyrazine 1-Oxides, *J. Heterocyclic Chem*, **1994**, *31*, 1177–1180.
55. Tuntiwachwuttikul, P. ja Bardos, T. J., Pyrazine Nucleoside Analogs. Synthesis and Reactions of Some 5-Thio-substituted Pyrazines, *J. Heterocyclic Chem*, **1991**, *28*, 1131–1137.
56. Yudin, I. L.; Sheremetev, A. B.; Shitov, O. P. ja Tartakovskii, V. A., Facile Synthesis of Polyhalo- and Nitro-pyrazines, *Mendeleev Communications*, **1995**, *5*, 196–197.



57. Ellsworth, B. A.; Wang, Y.; Zhu, Y.; Pendri, A.; Gerritz, S. W.; Sun, C.; Carlson, K. E.; Kang, L.; Baska, R. .; Yang, Y.; Huang, Q.; Burford, N. T.; Cullen, M. J.; Johnghar, S.; Behnia, K.; Pelleymounter, M. A.; Washburn, W. N. ja Ewing, W. R., Discovery of pyrazine carboxamide CB1 antagonists: The introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series, *Bioorg Med Chem Lett*, **2007**, *17*, 3978–3982.
58. Zhang, Y. ja Mitchison, D., The curious characteristics of pyrazinamide: a review, *INT J TUBERC LUNG DIS*, **2003**, *7*, 6–21.
59. Mason, T. A., Pyrazine Derivatives, *Journal of the Chemical Society, Transactions*, **1889**, *55*, 97–107.
60. Mason, T. A., Pyrazine Derivatives II, *Journal of the Chemical Society, Transactions*, **1893**, 12844–1293.
61. Colbon, P. J. J.; Foster, A. C.; Giles, M. E.; Patel, Z. ja Singleton, J. T., A General and Efficient Route to 6-Methyl-pyrazin-2-yl-amines: Alkylation of 2,6-Dichloropyrazine via Malonate Derivatives, *J. Heterocyclic Chem*, **2008**, *45*, 1451–1456.
62. Carver, D. R.; Komin, A. P.; Hubbard, J. S. ja Wolfe, J. F., SRN1 Mechanism in Heteroaromatic Nucleophilic Substitution. Reactions Involving Halogenated Pyrimidines, Pyridazines, and Pyrazines, *Journal of Organic Chemistry*, **1981**, *46*, 294–299.
63. Barlin, G. B., Purine Analogues as Amplifiers of Phleomycin. VII\* Some 1H-Imidazo[4,5-b]pyrazines and Related Compounds, *Aust J Chem*, **1982**, *35*, 2299–2306.
64. Hartman, G. D. ja Schwering, J. E., Nucleophilic Substitution by 3-Amino-1,2-propanediol in Nitropyrazines and Nitroquinoxalines, *J. Heterocyclic Chem*, **1983**, *20*, 947–950.
65. Thompson, W. J.; Jones, J. H.; Lyle, P. A. ja Thies, J. E., An Efficient Synthesis of Arylpyrazines and Bipyridines, *Journal of Organic Chemistry*, **1988**, *53*, 2052–2055.
66. Tapolcsányi, P.; Krajsovsky, G.; Andó, R.; Lipcsey, P.; Horváth, G.; Mátyus, P.; Riedl, Z.; Hajós, G.; Maes, B. U. W. ja Lemiè, G. L. F., Synthesis of some diazino-fused tricyclic systems via Suzuki cross-coupling and regioselective nitrene insertion reactions, *Tetrahedron*, **2002**, *58*, 10137–10143.
67. Nikishkin, N. I.; Huskens, J. ja Verboom, W., Transition metal-catalyzed functionalization of pyrazines, *Org Biomol Chem*, **2013**, *11*, 3583–3602.
68. Rizzi, G. P., Reaction of 2,3-Dialkylpyrazines and Methyllithium. Indirect Evidence for Ring Metalation, *Journal of Organic Chemistry*, **1974**, *39*, 3598–3599.
69. Cook, J. D. ja Wakefield, B. J., Reaction of 4-Substituted tetrachloropyridines with n-butyl-lithium, the Generation of 2-Pyridynes, and their Trapping as Adducts with Furan, *Journal of Chemical Society C*, **1969**, 1973–1978.

70. Turck, A.; Mojovic, L. ja Queguiner, G., A New Route to 2,3-Disubstituted Pyrazines;; Regioselective Metalation of Chloropyrazine, *Synthesis (Stuttg)*, **1988**, 7, 881–884.
71. Turck, A.; Ple, N.; Trohay, D.; Ndzi, B. ja Queguiner, G., Metalation of Pivaloylaminopyrazine and N-t-Butylpyrazinamide. Unusual Regioselectivity in the Metalation Reaction, *J. Heterocyclic Chem*, **1992**, 29, 699–702.
72. Ple, N.; Turck, A.; Fiquet, E. ja Queguiner, G., New Synthesis of Analogues of Trimethoprim and of Bacimethrin, *J. Heterocyclic Chem*, **1991**, 28, 283–287.
73. Turck, A.; Ple, N.; Mojovic, L. ja Queguiner, G., First Metallation of Pyridazine, Metallation of 2,4-Dichloropyrimidine, *J. Heterocyclic Chem*, **1990**, 27, 1377–1381.
74. Pié, N.; Turck, A.; Couture, K. ja Quéguiner, G., Metalation without Ortho-Directing Group. Functionalization of Diazines via Direct Metalation, *Journal of Organic Chemistry*, **1995**, 60, 3781–3786.
75. Plé, N.; Turck, A.; Heynderickx, A. ja Quéguiner, G., Functionalization by metallation of fluoropyrazine. Diazines XXI, *Tetrahedron*, **1998**, 54, 4899–4912.
76. Turck, A.; Ple, N.; Mongin, F. ja Queguiner, G., Advances in the directed metallation of azines and diazines (pyridines, pyrimidines, pyrazines, pyridazines, quinolines, benzodiazines and carbolines). Part 2: Metallation of pyrimidines, pyrazines, pyridazines and benzodiazines, *Tetrahedron*, **2001**, 57, 4489–4505.
77. Evans, D. A.; Fitch, D. M.; Smith, T. E. ja Cee, V. J., Application of Complex Aldol Reactions to the Total Synthesis of Phorboxazole B, *J Am Chem Soc*, **2000**, 122, 10033–10046.
78. Zhang, M. ja Eaton, P. E., BuMgNi-Pr<sub>2</sub>: A New Base for Stoichiometric, Positoin-Selective Deprotonation of Cyclopropane Carboxamides and Other Weak CH Acids, *Angewandte Chemie - International Edition*, **2002**, 41, 2169–2171.
79. Eaton, P. E.; Lee, C. ja Xiong, Y., Magnesium Amide Bases and Amido-Grignards. 1. Ortho Magnesiumation, *Journal of American Chemical Society*, **1989**, 111, 8016–8018.
80. Gros, P. ja Fort, Y., nBuLi/Lithium Aminoalkoxide Aggregates: New and Promising Lithiating Agents for Pyridine Derivatives, *European J Org Chem*, **2002**, 33753383.
81. Ren, H.; Krasovskiy, A. ja Knochel, P., Stereoselective preparation of functionalized acyclic alkenylmagnesium reagents using i-PrMgCl-LiCl, *Org Lett*, **2004**, 6, 4215–4217.
82. Krasovskiy, A. ja Knochel, P., A LiCl-Mediated Br/Mg Exchange Reaction for the Preparation of Functionalized Aryl- and Heteroarylmagnesium Compounds from Organic Bromides, *Angewandte Chemie - International Edition*, **2004**, 43, 3333–3336.
83. Krasovskiy, A.; Krasovskaya, V. ja Knochel, P., Mixed Mg/Li Amides of the Type R<sub>2</sub>NMgCl·LiCl as Highly Efficient Bases for the Regioselective

- Generation of Functionalized Aryl and Heteroaryl Magnesium Compounds, *Angewandte Chemie - International Edition*, **2006**, *45*, 2958–2961.
84. Mosrin, M. ja Knochel, P., TMPZnCl·LiCl: A New Active Selective Base for the Directed Zincation of Sensitive Aromatics and Heteroaromatics, *Org Lett*, **2009**, *11*, 1837–1840.
  85. Mosrin, M.; Monzon, G.; Bresser, T. ja Knochel, P., High temperature zincation of functionalized aromatics and heteroaromatics using TMPZnCl·LiCl and microwave irradiation, *Chemical Communications*, **2009**, 5615–5617.
  86. Bresser, T.; Mosrin, M.; Monzon, G. ja Knochel, P., Regio- and Chemoselective Zincation of Sensitive and Moderately Activated Aromatics and Heteroaromatics Using TMPZnCl·LiCl, *Journal of Organic Chemistry*, **2010**, *75*, 4686–4695.
  87. Bresser, T.; Monzon, G.; Mosrin, M. ja Knochel, P., Scalable Preparation of Sensitive Functionalized Aromatics and Heteroaromatics via Directed Metalation Using tmpZnCl·LiCl, *Org Process Res Dev*, **2010**, *14*, 1299–1303.
  88. Unsinn, A.; Ford, M. J. ja Knochel, P., New preparation of TMPZnCl·LiCl by Zn insertion into TMPCl. Application to the functionalization of dibromodiazines, *Org Lett*, **2013**, *15*, 1128–1131.
  89. Mosrin, M.; Bresser, T. ja Knochel, P., Regio- and Chemoselective Multiple Functionalization of Chloropyrazine Derivatives. Application to the Synthesis of Coelenterazine, *Org Lett*, **2009**, *11*, 3406–3409.
  90. Fleming I., *Molecular Orbitals and Organic Chemical Reactions*, 2010.
  91. Minisci, F.; Vismara, E. ja Fontana, F., Recent Developments of Free-Radical Substitutions of Heteroaromatic Bases, *Heterocycles*, **1989**, *28*, 489–519.
  92. O'Hara, F.; Blackmond, D. G. ja Baran, P. S., Radical-Based Regioselective C-H Functionalization of Electron-Deficient Heteroarenes: Scope, Tunability, and Predictability, *J Am Chem Soc*, **2013**, *135*, 12122–12134.
  93. Duncton, M. A. J., Minisci Reactions: Versatile CH-Functionalizations for Medicinal Chemists, *Med. Chem. Commun*, **2011**, *2*, 1135–1161.
  94. Gomberg, M. ja Bachmann, W. E., The Synthesis of Biaryl Compounds by Means of The Diazo Reaction, *J Am Chem Soc*, **1924**, *46*, 2339–2343.
  95. Harrowven, D. C.; Sutton, B. J. ja Coulton, S., Intramolecular Radical Additions to Quinolines, *Tetrahedron*, **2002**, *58*, 3387–3400.
  96. Harrowven, D. C.; Sutton, B. J. ja Coulton, S., Intramolecular Radical Additions to Pyridines, *Org Biomol Chem*, **2003**, *1*, 4047–4057.
  97. Mohlau, R. ja Berger, R., Ueber Phenyl-naphtaline und Zincke's Kohlenwasserstoff C<sub>16</sub>H<sub>12</sub>, *Ber. Dtsch. Chem. Ges*, **1893**, *26*, 1196–1200.
  98. Mohlau, R. ja Berger, R., Ueber Die Einfuhrung der Phenylgruppe in Cyclische verbindungen Mittels Diazobenzol, *Ber. Dtsch. Chem. Ges*, **1893**, *26*, 1994–2004.
  99. Dyll, L. K. ja Pausacker, K. H., Free-Radical Substitution of Pyridine 1-Oxide, *Journal of Chemical Society*, **1961**, 18–23.

100. Lynch, B. M. ja Chang, H. S., Concentration-Dependent Orientations in Free-Radical Phenylations of Heteroaromatic Compounds, *Tetrahedron Lett*, **1964**, *40*, 2965–2968.
101. Lynch, B. M. ja Chang, H. S., Free-Radical Phenylations of 1-Methyldiazoles, *Tetrahedron Lett*, **1964**, 617–620.
102. Dow, H. J. M. ja Lurch, B. M., Selective Free-Radical Phenylations: Nitrogen-Heteroaromatic Compounds in Acidic Media, *Tetrahedron Lett*, **1965**, *14*, 897–901.
103. Tauber, J.; Imbri, D. ja Opatz, T., Radical Addition to Iminium Ions and Cationic Heterocycles, *Molecules*, **2014**, *19*, 16190–16222.
104. Minisci, F.; Bernardi, R.; Bertini, F.; Galli, R. ja Perchinijmmo, M., Nucleophilic Character of Alkyl Radicals-VI: A New Convenient Selective Alkylation of Heteroaromatic Bases, *Tetrahedron*, **1971**, *27*, 3575–3579.
105. Caronna, T.; Fronza, G.; Minisci, F. ja Porta, O., Homolytic Acylation of Protonated Pyridine and Pyrazine Derivatives, *Journal of Chemical Society, Perkin Transactions 2*, **1972**, 2035–2038.
106. Heinisch, G. ja Lotsch, G., Homolytic Alkoxyacylation Reactions in Two-Phase Systems. Part II Studies on the Ethoxyacylation of Some Selected pi-Deficient N-Heteroaromatic Systems, *Tetrahedron*, **1986**, *42*, 5973–5977.
107. Heinisch, G. ja Lötsch, G., Marked Increase in the Regioselectivity of Radical Substitution: Minisci Reaction in a Two-Phase System, *Angewandte Chemie International Edition*, **1985**, *24*, 692–693.
108. Houminer, Y.; Southwick, E. W. ja Williams, D. L., Substituent-Directing Effects in the Homolytic Acylation of Pyrazine Derivatives, *Journal of Organic Chemistry*, **1989**, *54*, 640–643.
109. Gardini, G. P. ja Minisci, F., Nucleophilic Character of Acyl Radicals. Homolytic Acylation of Quinoxaline, *Journal of Chemical Society C*, **1970**, 929.
110. Minisci, F.; Citterio, A. ja Vismara, E., Polar Effects in Free-Radical Reactions. New Synthetic Developments in The Functionalization of Heteroaromatic Bases by Nucleophilic radicals, *Tetrahedron*, **1985**, *41*, 4157–4170.
111. Seiple, I. B.; Su, S.; Rodriguez, R. A.; Gianatassio, R.; Fujiwara, Y.; Sobel, A. L. ja Baran, P. S., Direct C-H Arylation of Electron-Deficient Heterocycles with Arylboronic Acids, *J Am Chem Soc*, **2010**, *132*, 13194–13196.
112. Xue, D.; Jia, Z.; Zhao, C.; Zhang, Y.; Wang, C. ja Xiao, J., Direct Arylation of N-Heteroarenes With Aryldiazonium Salts by Photoredox Catalysis in Water, *Chemistry - A European Journal*, **2014**, *20*, 2960–2965.
113. Bowman, W. R. ja Storey, J. M. D., Synthesis Using Aromatic Homolytic Substitution—Recent Advances, *Chem Soc Rev*, **2007**, *36*, 1803–1822.
114. Minisci F.; Fontana, F. ja Vismara, E., Substitutions by Nucleophilic Radicals: A New generation Reaction of Heteroaromatic Bases, *J. heterocyclic Chem*, **1990**, *27*, 79–96.
115. Gambarotti, C.; Melone, L.; Punta, C. ja Raffaini, G., Photocatalytic Minisci Reaction: A Promising and Eco-friendly Route to Functionalize

- Heteroaromatics of Biological Interest, *Green Synthetic Approaches for Biologically Relevant Heterocycles*, **2015**, 339–352.
116. Keshava Murthy, K. S. ja Knaus, E. E., Synthesis of pyrimido[1,4]diazepin-2-one Analogs and Their Evaluation as Anticonvulsant Agents, *Drug Dev Res*, **1999**, *46*, 155–162.
  117. Martin, I.; Anvelt, J.; Vares, L.; Kuhn, I. ja Claesson, A., An Alternative Synthesis of the NMDA Antagonist CGS 19755 via Free Radical Carbamoylation of Ethyl Isonicotinate, *Acta Chemica Scandinavica*, **1995**, *49*, 230–232.
  118. Demirci, S.; Goksu, S.; Boztas, M.; Tumer, F. ja Secen, H., Synthesis of Vertilecanin C and Two New Derivatives of Vertilecanin A via Nicotinic Acid, *Turk J Chem*, **2008**, *32*, 287–295.
  119. Mete, T. B.; Singh, A. ja Bhat, R. G., Transition-Metal-Free Synthesis of Primary to Tertiary Carboxamides: A Quick Access to Prodrug-Pyrazinecarboxamide, *Tetrahedron Lett*, **2017**, *58*, 4709–4712.
  120. Sun, L.; Li, W.; Li, J.; Zhang, H.; Yao, L.; Luo, H.; Guo, Y. ja Li, X., Uncommon Diterpenoids from the South China Sea Soft Coral *Sinularia humilis* and Their Stereochemistry, *Journal of Organic Chemistry*, **2021**, *86*, 3367–3376.
  121. Miesch, M., Natural Products Bearing a Bicyclo[3.2.0]Heptane Skeleton, *Curr Org Synth*, **2006**, *3*, 327–340.
  122. Ohashi, K.; Kawai, M.; Ninomiya, N.; Taylor, C. ja Kurebayashi, Y., Effect of a New  $\alpha\delta$  Ligand PD-217014 On Visceral Hypersensitivity Induced By 2,4,6-Trinitrobenzene Sulfonic Acid in Rats, *Pharmacology*, **2008**, *81*, 144–150.
  123. le Liepvre, M.; Ollivier, J. ja Aitken, D. J., Synthesis of Functionalized Bicyclo[3.2.0]heptanes - A Study of the [2+2] Photocycloaddition Reactions of 4-Hydroxycyclopent-2-enone Derivatives, *European J Org Chem*, **2009**, 5953–5962.
  124. Fu, J.; Takis, I. R. T.; Chen, P.; Liu, W.; Jiang, C.; Yao, W.; Zeng, X.; Wang, Y. ja Han, X., Synthesis of 2-Chromanone-Fused [3.2.0] Bicycles Through a Phosphine-Mediated Tandem [3 + 2] Cyclization/Intramolecular Wittig Reaction, *Organic Chemistry Frontiers*, **2021**, *8*, 6323–6329.
  125. Takasu, K.; Nagao, S. ja Ihara, M., Synthesis Of Medium-Sized Cyclic  $\gamma$ -Haloketones By Radical Mediated Ring-Opening Reaction Of Lewis Acid Catalyzed (2+2)-Cycloaddition Products, *Tetrahedron Lett*, **2005**, *46*, 1005–1008.
  126. Poplata, S.; Tröster, A.; Zou, Y. ja Bach, T., Recent Advances in the Synthesis of Cyclobutanes by Olefin [2 + 2] Photocycloaddition Reactions, *Chem Rev*, **2016**, *116*, 9748–9815.
  127. Crimmins, M. T., Synthetic Applications of Intramolecular Enone-Olefin Photocycloadditions, *Chem. Rev*, **1988**, *88*, 1453–1473.
  128. Bach, T., Stereoselective Intermolecular [2+2]-Photocycloaddition Reactions and Their Application in Synthesis, *Synthesis (Stuttg)*, **1998**, *5*, 683–703.

129. White, J. D. ja Gupta, D. N., The Total Synthesis of  $\alpha$ - and  $\beta$ -Bourbonene, *J Am Chem Soc*, **1966**, *90*, 6171–6177.
130. White, J. D. ja Gupta, D. N., The Total Synthesis of the ( $\pm$ )-Bourbonenes, *J Am Chem Soc*, **1968**, *88*, 5364–5365.
131. Hansson, T. ja Wickberg, B., A Short Enantiospecific Route to Isodaucane Sesquiterpenes from Limonene. On the Absolute Configuration of (+)-Aphanamol I and II, *J. Org. Chem*, **1992**, *57*, 5370–5376.
132. Tomioka, K.; Tanaka, M. ja Koga, K., An Asymmetric Synthesis of Cis, Anti, Cis-Tricyclo[5,3,0,0 2,6]Decanes Applying  $\gamma$ -Hydroxymethyl- $\gamma$ -Butyrolactone as A Chiral Synthone. First Asymmetric Total Synthesis of (-)- $\beta$ -Bourbonene, *Tetrahedron Lett*, **1982**, *23*, 3401–3404.
133. Mehta, G. ja Srinivas, K., A Stereoselective Total Synthesis of the Novel Sesquiterpene Kelsoene, *Tetrahedron Lett*, **1999**, *40*, 4877–4880.
134. Mehta, G. ja Srinivas, K., Enantioselective Total Syntheses of The Novel Tricyclic Sesquiterpene Hydrocarbons (+)-and (-)-Kelsoene. Absolute Configuration of The Natural Product, *Tetrahedron Lett*, **2001**, *42*, 2855–2857.
135. Piers, E. ja Orellana, A., Total Synthesis of ( $\pm$ )-Kelsoene, *Synthesis (Stuttg)*, **2001**, 2138–2142.
136. Fietz-Razavian, S.; Schulz, S.; Dixa, I. ja Jones, P. G., Revision of the Absolute Configuration of the Tricyclic Sesquiterpene (+)-Kelsoene by Chemical Correlation and Enantiospecific Total Synthesis of Its Enantiomer, *Chemical Communications*, **2001**, *1*, 2154–2155.
137. Mehta, G. ja Sreenivas, K., Total synthesis of the novel tricyclic sesquiterpene sulcatine G, *Chemical Communications*, **2001**, *1*, 1892–1893.
138. Mehta, G. ja Sreenivas, K., Enantioselective Total Synthesis of the Novel Tricyclic Sesquiterpene (-)-Sulcatine G. Absolute Configuration of the Natural Product, *Tetrahedron Lett*, **2002**, *43*, 3319–3321.
139. Salomon, R. G.; Sachinvala, N. D.; Raychaudhuri, S. R. ja Miller, D. B., Stereocontrol of Michael Hydride Reduction by a Remote Hydroxyl group. A Strategy for Stereoselective Total Synthesis of Spatane Diterpenes, *J. Am. Chem. Soc*, **1984**, *106*, 2211–2213.
140. Ruider, S. A.; Sandmeier, T. ja Carreira, E. M., Total Synthesis of ( $\pm$ )-Hippolachnin A, *Angewandte Chemie - International Edition*, **2015**, *54*, 2378–2382.
141. William D. G. ja Kowalczyk, B. A., Total Synthesis of (13z)-Spatane-13(15),17-diene, and the Formal Synthesis of Spatane, *Tetrahedron Lett*, **1990**, *31*, 635–638.
142. Kowalczyk, B. A.; Smith, T. C. ja Dauben, W. G., Synthesis of the Spatane Nucleus (cis-anti-cis-tricyclo[5.3.0.0 2,6 ]decane) using the Pauson-Khand Reaction with a Remarkable Reversal in Regioselectivity, *Journal of Organic Chemistry*, **1998**, *63*, 1379–1389.
143. Salomon, R. G.; Basu, B.; Roy, S. ja Sachinvala, N. D., Total Synthesis of Spatane and Other Spatane Diterpenes, *J. Am. Chem. Soc*, **1991**, *113*, 3096–3106.

144. Salomon, R. G.; Sachinvala, N. D.; Roy, S.; Basu, B.; Raychaudhuri, S. R.; Miller, D. B. ja Sharma, R. B., Total Synthesis of Spatane Diterpenes: The Tricyclic Nucleus, *J. Am. Chem. Soc.*, **1991**, *113*, 3085–3095.
145. Ito, H.; Hasegawa, M.; Takenaka, Y.; Kobayashi, T. ja Iguchi, K., Enantioselective Total Synthesis of (+)-Tricycloclavulone, *J Am Chem Soc*, **2004**, *126*, 4520–4521.
146. Ito, H.; Kobayashi, T.; Hasegawa, M. ja Iguchi, K., An Efficient Constructive Method for a Tricyclic System: An Important Intermediate For The Synthesis of Tricycloclavulone, *Tetrahedron Lett*, **2003**, *44*, 1259–1261.
147. Miesch, M.; Cotte, A. ja Franck-Neumann, M., Total Synthesis of ( $\pm$ ) Stoechospermol, *Tetrahedron Lett*, **1994**, *35*, 7031–7032.
148. Miesch, M.; Cottb, A. ja Franck-Neumann, M., Non Photochemical Synthesis of Condensed Cyclobutenes. Syntheses of the cis-anti-cis-tricyclo [5.3.0.024] Decane Skeleton, *Tetrahedron Lett*, **1993**, *34*, 8085–8086.
149. Brown, M., The Photolysis of Some 1,6-Dienes. Total Synthesis of ( $\pm$ )- $\alpha$ -Bourbonene, *J Org Chem*, **1968**, *33*, 162–166.
150. McMurry, J. E. ja Choy, W., Total Synthesis of  $\alpha$ - and  $\beta$ -Panasinsene, *Tetrahedron Lett*, **1980**, *21*, 2477–2480.
151. Johnson, C. R. ja Meanwell, N. A., Ketone Methylenation with Optical Resolution. Total Synthesis of the Ginseng Sesquiterpene ( $-$ )- $\beta$ -Panasinsene and Its Enantiomer, *J. Am. Chem. Soc.*, **1981**, *103*, 7667–7669.
152. Faure, S. ja Piva, O., Application of Chiral Tethers to Intramolecular [2+2] Photocycloadditions: Synthetic Approach to ( $-$ )-Italicene and (  $+$ )-Isoitalicene, *Tetrahedron Lett*, **2001**, *42*, 255–259.
153. Paduraru, M. P. ja Wilson, P. D., Synthesis of the Polycyclic Ring Systems of Artocarpol A and D, *Org Lett*, **2003**, *5*, 4911–4913.
154. Tanaka, M.; Tomioka, K. ja Koga, K., Asymmetric Total Synthesis of Stoechospermol Using Intramolecular [2+2] Photocycloaddition Reaction, *Tetrahedron Lett*, **1985**, *26*, 3035–3038.
155. Tanaka, M.; Tomioka, K. ja Koga, K., Enantioselective Total Synthesis of (+)-Stoechospermol Via Stereoselective Intramolecular (2+2) Photocycloaddition of the Chiral Butenolide, *Tetrahedron*, **1994**, *50*, 12829–12842.
156. Tanaka, M.; Tomioka, K. ja Koga, K., Total Synthesis of Natural (+)-Spatol. Confirmation of The Absolute Stereostructure, *Tetrahedron*, **1994**, *50*, 12843–12852.
157. Kurdyumov, A. v.; Hsung, R. P.; Ihlen, K. ja Wang, J., Formal [3 + 3] Cycloaddition Approach to Chromenes and Chromanes. Concise Total Syntheses of ( $\pm$ )-Rhododaurichromanic Acids A and B and Methyl ( $\pm$ )-Daurichromenic Ester, *Org Lett*, **2003**, *5*, 3935–3938.
158. Kang, Y.; Mei, Y.; Du, Y. ja Jin, Z., Total Synthesis of the Highly Potent Anti-HIV Natural Product Daurichromenic Acid along with Its Two Chromane Derivatives, Rhododaurichromanic Acids A and B, *Org Lett*, **2003**, *5*, 4481–4484.

159. Datta, R.; Dixon, R. J. ja Ghosh, S., A Convenient Access to the Tricyclic Core Structure of Hippolachnin A, *Tetrahedron Lett*, **2016**, 57, 29–31.
160. Xu, Z. ja Wu, Y., Efficient Synthetic Routes to (±)-Hippolachnin A, (±)-Gracilioethers E and F and the Alleged Structure of (±)-Gracilioether I, *Chemistry - A European Journal*, **2017**, 23, 2026–2030.
161. Li, Q.; Zhao, K.; Peuronen, A.; Rissanen, K.; Enders, D. ja Tang, Y., Enantioselective Total Syntheses of (+)-Hippolachnin A, (+)-Gracilioether A, (-)-Gracilioether E, and (-)-Gracilioether F, *J Am Chem Soc*, **2018**, 140, 1937–1944.
162. Doroh, B. ja Sulikowski, G. A., Progress Toward the Total Synthesis of Bielschowskysin: A Stereoselective [2 + 2] Photocycloaddition, *Org Lett*, **2006**, 8, 903–906.
163. Townsend, S. D. ja Sulikowski, G. A., Progress Toward The Total Synthesis Of Bielschowskysin, *Org Lett*, **2013**, 15, 5096–5098.
164. Yang, E. G.; Sekar, K. ja Lear, M. J., A Macrolactonisation Approach to The Cembrane Carbocycle of Bielschowskysin, *Tetrahedron Lett*, **2013**, 54, 4406–4408.
165. Miao, R.; Gramani, S. G. ja Lear, M. J., Stereocontrolled Entry to The Tricyclo[3.3.0]oxoheptane Core of Bielschowskysin By a [2+2] Cycloaddition of An Allene-Butenolide, *Tetrahedron Lett*, **2009**, 50, 1731–1733.
166. Nicolaou, K. C.; Adsool, V. A. ja Hale, C. R. H., An Expedient Synthesis of A Functionalized Core Structure of Bielschowskysin, *Angewandte Chemie - International Edition*, **2011**, 50, 5149–5152.
167. Pirrung, M. C., Total Synthesis of (±)-Isocomene and Related Studies, *J Am Chem Soc*, **1981**, 103, 82–87.
168. Crimmins, M. T.; Pace, J. M.; Nantermet, P. G.; Kim-Meade, A. S.; Thomas, J. B.; Watterson, S. H. ja Wagman, A. S., The Total Synthesis of (±)-Ginkgolide B, *J Am Chem Soc*, **2000**, 122, 8453–8463.
169. Crimmins, M. T.; Pace, J. M.; Nantermet, P. G.; Kim-Meade, A. S.; Thomas, J. B.; Watterson, S. H. ja Wagman, A. S., Total Synthesis of (±)-Ginkgolide B, *J Am Chem Soc*, **1999**, 121, 10249–10250.
170. Salomon, R. G., Homogeneous Metal-Catalysis In Organic Photochemistry, *Tetrahedron*, **1983**, 39, 485–575.
171. Bach, T. ja Spiegel, A., Stereoselective Total Synthesis of the Tricyclic Sesquiterpene (±)-Kelsoene by an Intramolecular Cu(I)-Catalyzed [2+2]-Photocycloaddition Reaction, *Synlett*, **2002**, 8, 1305–1307.
172. Jana, A.; Mondal, S.; Firoj Hossain, Md. ja Ghosh, S., Stereocontrolled Approach to the Highly Functionalized Bicyclo[3.2.0] Heptane Core of Bielschowskysin Through Intramolecular Cu(I)-Catalyzed [2+2] Photocycloaddition, *Tetrahedron Lett*, **2012**, 53, 6830–6833.
173. Jana, A.; Mondal, S. ja Ghosh, S., Studies Towards the Synthesis of Bielschowskysin. Construction of the Highly Functionalized Bicyclo[3.2.0]heptane Segment, *Org Biomol Chem*, **2015**, 13, 1846–1859.



174. Rosini, G.; Marotta, E.; Petrini, M. ja Ballini, R., Stereoselective Total Synthesis of Racemic Grandisol. An Improved Convenient Procedure, *Tetrahedron*, **1985**, *41*, 4633–4638.
175. Rosini, G.; Geier, M.; Marotta, E.; Petrini, M. ja Ballini, R., Stereoselective Total Synthesis Of Racemic grandisol via 3-Oximino-1,4,4-Trimethylbicyclo[3.2.0]heptane. An Improved Practical Procedure, *Tetrahedron*, **1986**, *42*, 6027–6032.
176. Rosini, G.; Marotta, E.; Raimondi, A. ja Righi, P., Resolution and EPC Synthesis of Both Enantiomers of 2,5-Dimethylbicyclo[3.2.0]heptan-endo-2-01, Key Intermediate in the Synthesis of Grandisol, *Tetrahedron Asymmetry*, **1991**, *2*, 123–138.
177. Rosini, G.; Carloni, P.; Iapalucci, M. C. ja Marotta, E., Resolution, Specific Rotation and Absolute Configuration of 2,6,6-Trimethylbicyclo[3.2.0]heptan-endo-2-01 and of 2,5-Dimethylbicyclo[3.2.0]heptan-endo-2-01, Key Intermediate in the Synthesis of Grandisol, *Tetrahedron Asymmetry*, **1990**, *1*, 751–758.
178. Langer, K.; Mattay, J.; Heidebreder, A. ja Moller, M., A New Stereoselective Synthesis of Grandisol, *Liebigs Ann. Chem*, **1992**, 257–260.
179. Marotta, E.; Righi, P. ja Rosini, G., A New, Effective Route to Methyl Substituted 3,3a,4,6a-Tetrahydro-2H-cyclopenta[b]furan-2-ones, *Tetrahedron Lett*, **1994**, *35*, 2949–2950.
180. Marotta, E.; Medici, M.; Righi, P. ja Rosini, G., The Conversion of 3-Hydroxy-6-heptenoic Acids into Bicyclo[3.2.0]hept-3-en-6-ones, *J. Org. Chem*, **1994**, *59*, 7529–7531.
181. Confalonieri, G.; Marotta, E.; Rama, F.; Righi, P.; Rosini, G.; Serra, R. ja Venturelli, F., Practical Preparation of Bicyclo[3.2.0]hept-3-en-6-ones and its Utilisation in Stereoselective Total Synthesis of Grandisol and Lineatin via a Versatile Intermediate, *Tetrahedron*, **1994**, *50*, 3235–3250.
182. Rosini, G.; Confalonieri, G.; Marotta, E.; Rama, F. ja Righi, P., Preparation Of Bicyclo[3.2.0]Hept-3-en-6-ones: 1,4-Dimethylbicyclo[3.2.0]Hept-3-en-6-one, *Organic Syntheses*, **1997**, *74*, 158.
183. Rosini, G.; Laffi, F.; Marotta, E.; Pagani, I. ja Righi, P., Total Synthesis of the Marine Sesquiterpenoid Raikovenal through a Novel Utilization of the Bicyclo[3.2.0]heptenone Approach, *Journal of Organic Chemistry*, **1998**, *63*, 2389–2391.
184. Stadler, H.; Rey, M. ja Dreiding, A. S., Addition von Dimethylketen an 6-heterosubstituierte Fulvene. Synthese von (±)-Filifolon, **1984**, *67*, 1854–1858.
185. Ko, C.; Feltenberger, J. B.; Ghosh, S. K. ja Hsung, R. P., Gassman's Intramolecular [2 + 2] Cationic Cycloaddition. Formal Total Syntheses of Raikovenal and epi-Raikovenal, *Org Lett*, **2008**, *10*, 1971–1974.
186. Luzung, M. R.; Mauleón, P. ja Toste, F. D., Gold(I)-catalyzed [2 + 2]-Cycloaddition of Allenenes, *J Am Chem Soc*, **2007**, *129*, 12402–12403.
187. Adam, J.; Ghosez, L. ja Houk, K. N., A Convergent Strategy for the Asymmetric Synthesis of Enantiomerically Pure Bicyclic Compounds by Using a Silicon-Directed Cycloaddition Reaction: The Synthesis of

- Enantiomerically Pure Bicyclo[3.2.0]-hept-2-en-6-one, *Angewandte Chemie - International Edition*, **1999**, *38*, 2728–2730.
188. Depré, D.; Chen, L. ja Ghosez, L., A Short Multigram Asymmetric Synthesis of Prostanoid Scaffolds, *Tetrahedron*, **2003**, *59*, 6797–6812.
  189. McCaleb, K. L. . ja Halcomb, R. L., Intramolecular Ketene-Allene Cycloadditions, *Org Lett*, **2000**, *2*, 2631–2634.
  190. Baik, T. G.; Luis, A. L.; Wang, L. C. ja Krische, M. J., A Diastereoselective Metal-Catalyzed [2 + 2] Cycloaddition of Bis-enones, *J Am Chem Soc*, **2001**, *123*, 6716–6717.
  191. Ischay, M. A.; Anzovino, M. E.; Du, J. ja Yoon, T. P., Efficient Visible Light Photocatalysis of [2+2] Enone Cycloadditions, *J Am Chem Soc*, **2008**, *130*, 12886–12887.
  192. Joseph, B. K.; Verghese, B.; Sudarsanakumar, C.; Deepa, S.; Viswam, D.; Chandran, P. ja Asokan, C. v., Highly Facile and Stereoselective Intramolecular [2+2] Photocycloadditions of Bis(alkenoyl)ketenedithioacetals, *Chemical Communications*, **2002**, *7*, 736–737.
  193. Felton, G. A. N. ja Bauld, N. L., Efficient Electrocatalytic Intramolecular Anion Radical Cyclobutanation Reactions, *Tetrahedron*, **2004**, *60*, 10999–11010.
  194. Yang, J.; Felton, G. A. N.; Bauld, N. L. ja Krische, M. J., Chemically Induced Anion Radical Cycloadditions: Intramolecular Cyclobutanation of Bis(enones) via Homogeneous Electron Transfer, *J Am Chem Soc*, **2004**, *126*, 1634–1635.
  195. Roh, Y.; Jang, H.; Lynch, V.; Bauld, N. ja Krische, M. J., Anion Radical Chain Cycloaddition Of Tethered Enones: Intramolecular Cyclobutanation and Diels-Alder Cycloaddition, *Org Lett*, **2002**, *4*, 611–613.
  196. Ishihara, K. ja Nakano, K., Enantioselective [2 + 2] Cycloaddition of Unactivated Alkenes with  $\alpha$ -Acyloxyacroleins Catalyzed by Chiral Organoammonium Salts, *J Am Chem Soc*, **2007**, *129*, 8930–8931.
  197. Trost, B. M.; Seganish, W. M.; Chung, C. K. ja Amans, D., Total synthesis of laulimalide: Synthesis of the northern and southern fragments, *Chemistry - A European Journal*, **2012**, *18*, 2948–2960.
  198. Wang, H.; Li, H.; Wang, J. ja Wu, Y., Protecting-group-free synthesis of haterumadienone- and puupehenone-type marine natural products, *Green Chemistry*, **2017**, *19*, 2140–2144.
  199. Bols, M. ja Skrydstrup, T., Silicon-Tethered Reactions, *Chem. Rev*, **1995**, *95*, 1253–1277.
  200. Fensterbank, L.; Malacria, M. ja Sieburth, S. M., Intramolecular Reactions of Temporarily Silicon-Tethered Molecules, *Synthesis (Stuttg)*, **1997**, *8*, 813–854.
  201. Stork, G.; Cama, L. D. ja Coulson, D. R., Epoxynitrile Cyclization. A General Method of Ring Formation., *Journal of the American Chemistry Society*, **1974**, *96*, 5268–5270.

202. Stork, G. ja Cohen, J. F., Ring Size in Epoxynitrile Cyclization. A General Synthesis of Functionally Substituted Cyclobutanes. Application to ( $\pm$ )-Grandisol, *J. Amer. Chem. Soc.*, **1974**, *96*, 5270–5272.
203. Phipps, E. J. T. ja Rovis, T., Rh(III)-Catalyzed C-H Activation-Initiated Directed Cyclopropanation of Allylic Alcohols, *J Am Chem Soc*, **2019**, *141*, 6807–6811.
204. Sibi, M. P. ja Manyem, S., Enantioselective Conjugate Additions, *Tetrahedron*, **2000**, 8033–8061.
205. Harutyunyan, S. R.; den Hartog, T.; Geurts, K.; Minnaard, A. J. ja Feringa, B. L., Catalytic Asymmetric Conjugate Addition and Allylic Alkylation with Grignard Reagents, *Chem Rev*, **2008**, *108*, 2824–2852.
206. Alexakis, A. ja Benhaim, C., Enantioselective Copper-Catalysed Conjugate Addition, *European J Org Chem*, **2002**, 3221–3236.
207. Yang, X. ja Fleming, F. F., C- and N-Metalated Nitriles: The Relationship between Structure and Selectivity, *Acc Chem Res*, **2017**, *50*, 2556–2568.
208. Yang, X.; Nath, D. ja Fleming, F. F., Chemoselective Alkylations with N- and C-Metalated Nitriles, *Org Lett*, **2015**, *17*, 4906–4909.
209. Mycka, R. J.; Steward, O. W. ja Fleming, F. F.,  $\gamma$ -Hydroxynitrile Alkylations: Electrophile-Dependent Stereoselectivity, *Org Lett*, **2010**, *12*, 3030–3033.
210. Fleming, F. F.; Viet, A.; Shook, B. C.; Rahman, M. ja Steward, O. W., Metalated Nitriles: Chelation-Controlled Cyclizations to cis and trans Hydrindanes and Decalins, *Journal of Organic Chemistry*, **2007**, *72*, 1431–1436.
211. Fleming, F. F.; Zhang, Z.; Wei, G. ja Steward, O. W., Metalated Nitriles: Electrophile-Dependent Alkylations, *Org Lett*, **2005**, *7*, 447–449.
212. Fleming, F. F.; Zhang, Z.; Wei, G. ja Steward, O. W., C-Metalated Nitriles: Electrophile-Dependent Alkylations and Acylations., *Journal of Organic Chemistry*, **2006**, *71*, 1430–1435.
213. Fleming, F. F.; Wei, Y.; Liu, W. ja Zhang, Z., Metalated Nitriles: Cation-Controlled Cyclizations, *Org Lett*, **2007**, *9*, 2733–2736.
214. van der Kolk, M. R.; Janssen, M. A. C. H.; Rutjes, F. P. J. T. ja Blanco-Ania, D., Cyclobutanes in Small-Molecule Drug Candidates, *ChemMedChem*, **2022**, *17*.
215. Bauer, M. R.; di Fruscia, P.; Lucas, S. C. C.; Michaelides, I. N.; Nelson, J. E.; Storer, R. I. ja Whitehurst, B. C., Put a ring on it: application of small aliphatic rings in medicinal chemistry, *RSC Med Chem*, **2021**, *12*, 448–471.
216. Fan, Y.; Gao, X. ja Yue, J., Attractive natural products with strained cyclopropane and/or cyclobutane ring systems, *Sci China Chem*, **2016**, *59*, 1126–1141.
217. Dembitsky, V. M., Naturally occurring bioactive Cyclobutane-containing (CBC) alkaloids in fungi, fungal endophytes, and plants, *Phytomedicine*, **2014**, *21*, 1559–1581.
218. Martín-Matute, B. ja Bäckvall, J., Ruthenium- and Enzyme-Catalyzed Dynamic Kinetic Asymmetric Transformation of 1,4-Diols: Synthesis of  $\gamma$ -Hydroxy Ketones, *Journal of Organic Chemistry*, **2004**, *69*, 9191–9195.

219. Cameron, K. O. ja Molander, G. A., Neighbouring Group Participation in Lewis Acid-Promoted [3 + 4] and [3+5] Annulations. The Synthesis of Oxabicyclo[3.n.1]alka-3-ones, *Journal of the American Chemical Society*, **1993**, *115*, 830–846.
220. Fanta, W. I. ja Erman, W. F., Total Synthesis of dl-Sabinene, dl-trans-Sabinene Hydrate, and Related Monoterpenes, *Journal of Organic Chemistry*, **1968**, *33*, 1656–1658.
221. Wang, H.; Li, H.; Wang, J. ja Wu, Y., Protecting-group-free synthesis of haterumadienone- and puupehenone-type marine natural products, *Green Chemistry*, **2017**, *19*, 2140–2144.
222. Weidkamp, A. J. ja Oestreich, M., Metal-free transfer hydrochlorination of internal C-C triple bonds with a bicyclo[3.1.0]hexane-based surrogate releasing two molecules of hydrogen chloride, *Chemical Communications*, **2022**, *58*, 973–976.
223. Coote, S. C.; O'Brien, P. ja Whitwood, A. C., Stereoselective aziridination of cyclic allylic alcohols using chloramine-T, *Org Biomol Chem*, **2008**, *6*, 4299–4314.
224. Gillard, J. W.; Fortin, R.; Grimm, E. L.; Maillard, M.; Tjepkema, M.; Bernstein, M. A. ja Glaser, R., The Unsymmetrical Silaketal as a Neutral, Removable Tether for Effecting Intramolecular Diels-Alder Reactions, *Tetrahedron Lett*, **1991**, *32*, 1145–1148.
225. Kreuzer, A.; Kerres, S.; Ertl, T.; Rücker, H.; Amslinger, S. ja Reiser, O., Asymmetric Synthesis of Both Enantiomers of Arteludovicinolide A, *Org Lett*, **2013**, *15*, 3420–3423.
226. Hwang, M.; Han, S. ja Lee, D., Convergent and Enantioselective Total Synthesis of (-)-Amphidinolide O and (-)-Amphidinolide P, *Org Lett*, **2013**, *15*, 3318–3321.
227. Richter, A.; Hedberg, C. ja Waldmann, H., Enantioselective Synthesis of the C10-C20 Fragment of Fusicocin A, *Journal of Organic Chemistry*, **2011**, *76*, 6694–6702.
228. Bellotti, P.; Rogge, T.; Paulus, F.; Laskar, R.; Rendel, N.; Ma, J.; Houk, K. N. ja Glorius, F., Visible-Light Photocatalyzed peri-(3 + 2) Cycloadditions of Quinolines, *J Am Chem Soc*, **2022**, *144*, 15662–15671.
229. Sheldrick, G. M., SHELXT - Integrated space-group and crystal-structure determination, *Acta Crystallogr A*, **2015**, *71*, 3–8.
230. Dolomanov, O. v.; Bourhis, L. J.; Gildea, R. J.; Howard, J. A. K. ja Puschmann, H., OLEX2: A complete structure solution, refinement and analysis program, *J Appl Crystallogr*, **2009**, *42*, 339–341.
231. Sheldrick, G. M., Crystal structure refinement with SHELXL, *Acta Crystallogr C Struct Chem*, **2015**, *71*, 3–8.

DEPARTMENT OF CHEMISTRY, UNIVERSITY OF JYVÄSKYLÄ  
RESEARCH REPORT SERIES

1. Vuolle, Mikko: Electron paramagnetic resonance and molecular orbital study of radical ions generated from (2.2)metacyclophane, pyrene and its hydrogenated compounds by alkali metal reduction and by thallium(III)trifluoroacetate oxidation. (99 pp.) 1976
2. Pasanen, Kaija: Electron paramagnetic resonance study of cation radical generated from various chlorinated biphenyls. (66 pp.) 1977
3. Carbon-13 Workshop, September 6-8, 1977. (91 pp.) 1977
4. Laihia, Katri: On the structure determination of norbornane polyols by NMR spectroscopy. (111 pp.) 1979
5. Nyrönen, Timo: On the EPR, ENDOR and visible absorption spectra of some nitrogen containing heterocyclic compounds in liquid ammonia. (76 pp.) 1978
6. Talvitie, Antti: Structure determination of some sesquiterpenoids by shift reagent NMR. (54 pp.) 1979
7. Häkli, Harri: Structure analysis and molecular dynamics of cyclic compounds by shift reagent NMR. (48 pp.) 1979
8. Pitkänen, Ilkka: Thermodynamics of complexation of 1,2,4-triazole with divalent manganese, cobalt, nickel, copper, zinc, cadmium and lead ions in aqueous sodium perchlorate solutions. (89 pp.) 1980
9. Asunta, Tuula: Preparation and characterization of new organometallic compounds synthesized by using metal vapours. (91 pp.) 1980
10. Sattar, Mohammad Abdus: Analyses of MCPA and its metabolites in soil. (57 pp.) 1980
11. Bibliography 1980. (31 pp.) 1981
12. Knuuttila, Pekka: X-Ray structural studies on some divalent 3d metal compounds of picolinic and isonicotinic acid N-oxides. (77 pp.) 1981
13. Bibliography 1981. (33 pp.) 1982
14. 6<sup>th</sup> National NMR Symposium, September 9-10, 1982, Abstracts. (49 pp.) 1982
15. Bibliography 1982. (38 pp.) 1983
16. Knuuttila, Hilka: X-Ray structural studies on some Cu(II), Co(II) and Ni(II) complexes with nicotinic and isonicotinic acid N-oxides. (54 pp.) 1983
17. Symposium on inorganic and analytical chemistry May 18, 1984, Program and Abstracts. (100 pp.) 1984
18. Knuutinen, Juha: On the synthesis, structure verification and gas chromatographic determination of chlorinated catechols and guaiacols occurring in spent bleach liquors of kraft pulp mill. (30 pp.) 1984
19. Bibliography 1983. (47 pp.) 1984
20. Pitkänen, Maija: Addition of BrCl, B<sub>2</sub> and Cl<sub>2</sub> to methyl esters of propenoic and 2-butenic acid derivatives and <sup>13</sup>C NMR studies on methyl esters of saturated aliphatic mono- and dichlorocarboxylic acids. (56 pp.) 1985
21. Bibliography 1984. (39 pp.) 1985
22. Salo, Esa: EPR, ENDOR and TRIPLE spectroscopy of some nitrogen heteroaromatics in liquid ammonia. (111 pp.) 1985

DEPARTMENT OF CHEMISTRY, UNIVERSITY OF JYVÄSKYLÄ  
RESEARCH REPORT SERIES

23. Humppi, Tarmo: Synthesis, identification and analysis of dimeric impurities of chlorophenols. (39 pp.) 1985
24. Aho, Martti: The ion exchange and adsorption properties of sphagnum peat under acid conditions. (90 pp.) 1985
25. Bibliography 1985 (61 pp.) 1986
26. Bibliography 1986. (23 pp.) 1987
27. Bibliography 1987. (26 pp.) 1988
28. Paasivirta, Jaakko (Ed.): Structures of organic environmental chemicals. (67 pp.) 1988
29. Paasivirta, Jaakko (Ed.): Chemistry and ecology of organo-element compounds. (93 pp.) 1989
30. Sinkkonen, Seija: Determination of crude oil alkylated dibenzothiophenes in environment. (35 pp.) 1989
31. Kolehmainen, Erkki (Ed.): XII National NMR Symposium Program and Abstracts. (75 pp.) 1989
32. Kuokkanen, Tauno: Chlorocymenes and Chlorocymenenes: Persistent chlorocompounds in spent bleach liquors of kraft pulp mills. (40 pp.) 1989
33. Mäkelä, Reijo: ESR, ENDOR and TRIPLE resonance study on substituted 9,10-anthraquinone radicals in solution. (35 pp.) 1990
34. Veijanen, Anja: An integrated sensory and analytical method for identification of off-flavour compounds. (70 pp.) 1990
35. Kasa, Seppo: EPR, ENDOR and TRIPLE resonance and molecular orbital studies on a substitution reaction of anthracene induced by thallium(III) in two fluorinated carboxylic acids. (114 pp.) 1990
36. Herve, Sirpa: Mussel incubation method for monitoring organochlorine compounds in freshwater recipients of pulp and paper industry. (145 pp.) 1991
37. Pohjola, Pekka: The electron paramagnetic resonance method for characterization of Finnish peat types and iron (III) complexes in the process of peat decomposition. (77 pp.) 1991
38. Paasivirta, Jaakko (Ed.): Organochlorines from pulp mills and other sources. Research methodology studies 1988-91. (120 pp.) 1992
39. Veijanen, Anja (Ed.): VI National Symposium on Mass Spectrometry, May 13-15, 1992, Abstracts. (55 pp.) 1992
40. Rissanen, Kari (Ed.): The 7. National Symposium on Inorganic and Analytical Chemistry, May 22, 1992, Abstracts and Program. (153 pp.) 1992
41. Paasivirta, Jaakko (Ed.): CEOEC'92, Second Finnish-Russian Seminar: Chemistry and Ecology of Organo-Element Compounds. (93 pp.) 1992
42. Koistinen, Jaana: Persistent polychloroaromatic compounds in the environment: structure-specific analyses. (50 pp.) 1993
43. Virkki, Liisa: Structural characterization of chlorolignins by spectroscopic and liquid chromatographic methods and a comparison with humic substances. (62 pp.) 1993
44. Helenius, Vesa: Electronic and vibrational excitations in some

DEPARTMENT OF CHEMISTRY, UNIVERSITY OF JYVÄSKYLÄ  
RESEARCH REPORT SERIES

- biologically relevant molecules. (30 pp.) 1993
45. Leppä-aho, Jaakko: Thermal behaviour, infrared spectra and x-ray structures of some new rare earth chromates(VI). (64 pp.) 1994
46. Kotila, Sirpa: Synthesis, structure and thermal behavior of solid copper(II) complexes of 2-amino-2-hydroxymethyl-1,3-propanediol. (111 pp.) 1994
47. Mikkonen, Anneli: Retention of molybdenum(VI), vanadium(V) and tungsten(VI) by kaolin and three Finnish mineral soils. (90 pp.) 1995
48. Suontamo, Reijo: Molecular orbital studies of small molecules containing sulfur and selenium. (42 pp.) 1995
49. Hämäläinen, Jouni: Effect of fuel composition on the conversion of fuel-N to nitrogen oxides in the combustion of small single particles. (50 pp.) 1995
50. Nevalainen, Tapio: Polychlorinated diphenyl ethers: synthesis, NMR spectroscopy, structural properties, and estimated toxicity. (76 pp.) 1995
51. Aittola, Jussi-Pekka: Organochloro compounds in the stack emission. (35 pp.) 1995
52. Harju, Timo: Ultrafast polar molecular photophysics of (dibenzylmethine)borondifluoride and 4-aminophthalimide in solution. (61 pp.) 1995
53. Maatela, Paula: Determination of organically bound chlorine in industrial and environmental samples. (83 pp.) 1995
54. Paasivirta, Jaakko (Ed.): CEOEC'95, Third Finnish-Russian Seminar: Chemistry and Ecology of Organo-Element Compounds. (109 pp.) 1995
55. Huuskonen, Juhani: Synthesis and structural studies of some supramolecular compounds. (54 pp.) 1995
56. Palm, Helena: Fate of chlorophenols and their derivatives in sawmill soil and pulp mill recipient environments. (52 pp.) 1995
57. Rantio, Tiina: Chlorohydrocarbons in pulp mill effluents and their fate in the environment. (89 pp.) 1997
58. Ratilainen, Jari: Covalent and non-covalent interactions in molecular recognition. (37 pp.) 1997
59. Kolehmainen, Erkki (Ed.): XIX National NMR Symposium, June 4-6, 1997, Abstracts. (89 pp.) 1997
60. Matilainen, Rose: Development of methods for fertilizer analysis by inductively coupled plasma atomic emission spectrometry. (41 pp.) 1997
61. Koistinen, Jari (Ed.): Spring Meeting on the Division of Synthetic Chemistry, May 15-16, 1997, Program and Abstracts. (36 pp.) 1997
62. Lappalainen, Kari: Monomeric and cyclic bile acid derivatives: syntheses, NMR spectroscopy and molecular recognition properties. (50 pp.) 1997
63. Laitinen, Eira: Molecular dynamics of cyanine dyes and phthalimides in solution: picosecond laser studies. (62 pp.) 1997
64. Eloranta, Jussi: Experimental and theoretical studies on some

DEPARTMENT OF CHEMISTRY, UNIVERSITY OF JYVÄSKYLÄ  
RESEARCH REPORT SERIES

- quinone and quinol radicals. (40 pp.) 1997
65. Oksanen, Jari: Spectroscopic characterization of some monomeric and aggregated chlorophylls. (43 pp.) 1998
66. Häkkänen, Heikki: Development of a method based on laser-induced plasma spectrometry for rapid spatial analysis of material distributions in paper coatings. (60 pp.) 1998
67. Virtapohja, Janne: Fate of chelating agents used in the pulp and paper industries. (58 pp.) 1998
68. Airola, Karri: X-ray structural studies of supramolecular and organic compounds. (39 pp.) 1998
69. Hyötyläinen, Juha: Transport of lignin-type compounds in the receiving waters of pulp mills. (40 pp.) 1999
70. Ristolainen, Matti: Analysis of the organic material dissolved during totally chlorine-free bleaching. (40 pp.) 1999
71. Eklin, Tero: Development of analytical procedures with industrial samples for atomic emission and atomic absorption spectrometry. (43 pp.) 1999
72. Välisaari, Jouni: Hygiene properties of resol-type phenolic resin laminates. (129 pp.) 1999
73. Hu, Jiwei: Persistent polyhalogenated diphenyl ethers: model compounds syntheses, characterization and molecular orbital studies. (59 pp.) 1999
74. Malkavaara, Petteri: Chemometric adaptations in wood processing chemistry. (56 pp.) 2000
75. Kujala Elena, Laihia Katri, Nieminen Kari (Eds.): NBC 2000, Symposium on Nuclear, Biological and Chemical Threats in the 21<sup>st</sup> Century. (299 pp.) 2000
76. Rantalainen, Anna-Lea: Semipermeable membrane devices in monitoring persistent organic pollutants in the environment. (58 pp.) 2000
77. Lahtinen, Manu: *In situ* X-ray powder diffraction studies of Pt/C, CuCl/C and Cu<sub>2</sub>O/C catalysts at elevated temperatures in various reaction conditions. (92 pp.) 2000
78. Tamminen, Jari: Syntheses, empirical and theoretical characterization, and metal cation complexation of bile acid-based monomers and open/closed dimers. (54 pp.) 2000
79. Vatanen, Virpi: Experimental studies by EPR and theoretical studies by DFT calculations of  $\alpha$ -amino-9,10-anthraquinone radical anions and cations in solution. (37 pp.) 2000
80. Kotilainen, Risto: Chemical changes in wood during heating at 150-260 °C. (57 pp.) 2000
81. Nissinen, Maija: X-ray structural studies on weak, non-covalent interactions in supramolecular compounds. (69 pp.) 2001
82. Wegelius, Elina: X-ray structural studies on self-assembled hydrogen-bonded networks and metallosupramolecular complexes. (84 pp.) 2001
83. Paasivirta, Jaakko (Ed.): CEOEC'2001, Fifth Finnish-Russian Seminar: Chemistry and Ecology of Organo-Element Compounds. (163 pp.) 2001
84. Kiljunen, Toni: Theoretical studies on spectroscopy and



DEPARTMENT OF CHEMISTRY, UNIVERSITY OF JYVÄSKYLÄ  
RESEARCH REPORT SERIES

- atomic dynamics in rare gas solids. (56 pp.) 2001
85. Du, Jin: Derivatives of dextran: synthesis and applications in oncology. (48 pp.) 2001
86. Koivisto, Jari: Structural analysis of selected polychlorinated persistent organic pollutants (POPs) and related compounds. (88 pp.) 2001
87. Feng, Zhinan: Alkaline pulping of non-wood feedstocks and characterization of black liquors. (54 pp.) 2001
88. Halonen, Markku: Lahon havupuun käyttö sulfaattiprosessin raaka-aineena sekä havupuun lahontorjunta. (90 pp.) 2002
89. Falábu, Dezső: Synthesis, conformational analysis and complexation studies of resorcarene derivatives. (212 pp.) 2001
90. Lehtovuori, Pekka: EMR spectroscopic studies on radicals of ubiquinones Q-*n*, vitamin K<sub>3</sub> and vitamine E in liquid solution. (40 pp.) 2002
91. Perkkalainen, Paula: Polymorphism of sugar alcohols and effect of grinding on thermal behavior on binary sugar alcohol mixtures. (53 pp.) 2002
92. Ihalainen, Janne: Spectroscopic studies on light-harvesting complexes of green plants and purple bacteria. (42 pp.) 2002
93. Kunttu, Henrik, Kiljunen, Toni (Eds.): 4<sup>th</sup> International Conference on Low Temperature Chemistry. (159 pp.) 2002
94. Väisänen, Ari: Development of methods for toxic element analysis in samples with environmental concern by ICP-AES and ETAAS. (54 pp.) 2002
95. Luostarinen, Minna: Synthesis and characterisation of novel resorcarene derivatives. (200 pp.) 2002
96. Louhelainen, Jarmo: Changes in the chemical composition and physical properties of wood and nonwood black liquors during heating. (68 pp.) 2003
97. Lahtinen, Tanja: Concave hydrocarbon cyclophane  $\pi$ -prismans. (65 pp.) 2003
98. Laihia, Katri (Ed.): NBC 2003, Symposium on Nuclear, Biological and Chemical Threats – A Crisis Management Challenge. (245 pp.) 2003
99. Oasmaa, Anja: Fuel oil quality properties of wood-based pyrolysis liquids. (32 pp.) 2003
100. Virtanen, Elina: Syntheses, structural characterisation, and cation/anion recognition properties of nano-sized bile acid-based host molecules and their precursors. (123 pp.) 2003
101. Nättinen, Kalle: Synthesis and X-ray structural studies of organic and metallo-organic supramolecular systems. (79 pp.) 2003
102. Lampiselkä, Jarkko: Demonstraatio lukion kemian opetuksessa. (285 pp.) 2003
103. Kallioinen, Jani: Photoinduced dynamics of Ru(dcbpy)<sub>2</sub>(NCS)<sub>2</sub> – in solution and on nanocrystalline titanium dioxide thin films. (47 pp.) 2004
104. Valkonen, Arto (Ed.): VII Synthetic Chemistry Meeting and XXVI Finnish NMR Symposium. (103 pp.) 2004

DEPARTMENT OF CHEMISTRY, UNIVERSITY OF JYVÄSKYLÄ  
RESEARCH REPORT SERIES

105. Vaskonen, Kari: Spectroscopic studies on atoms and small molecules isolated in low temperature rare gas matrices. (65 pp.) 2004
106. Lehtovuori, Viivi: Ultrafast light induced dissociation of Ru(dcbpy)(CO)<sub>2</sub>I<sub>2</sub> in solution. (49 pp.) 2004
107. Saarenketo, Pauli: Structural studies of metal complexing Schiff bases, Schiff base derived *N*-glycosides and cyclophane  $\pi$ -prismoids. (95 pp.) 2004
108. Paasivirta, Jaakko (Ed.): CEOEC'2004, Sixth Finnish-Russian Seminar: Chemistry and Ecology of Organo-Element Compounds. (147 pp.) 2004
109. Suontamo, Tuula: Development of a test method for evaluating the cleaning efficiency of hard-surface cleaning agents. (96 pp.) 2004
110. Güneş, Minna: Studies of thiocyanates of silver for nonlinear optics. (48 pp.) 2004
111. Ropponen, Jarmo: Aliphatic polyester dendrimers and dendrons. (81 pp.) 2004
112. Vu, Mân Thi Hong: Alkaline pulping and the subsequent elemental chlorine-free bleaching of bamboo (*Bambusa procera*). (69 pp.) 2004
113. Mansikkamäki, Heidi: Self-assembly of resorcinarenes. (77 pp.) 2006
114. Tuononen, Heikki M.: EPR spectroscopic and quantum chemical studies of some inorganic main group radicals. (79 pp.) 2005
115. Kaski, Saara: Development of methods and applications of laser-induced plasma spectroscopy in vacuum ultraviolet. (44 pp.) 2005
116. Mäkinen, Riika-Mari: Synthesis, crystal structure and thermal decomposition of certain metal thiocyanates and organic thiocyanates. (119 pp.) 2006
117. Ahokas, Jussi: Spectroscopic studies of atoms and small molecules isolated in rare gas solids: photodissociation and thermal reactions. (53 pp.) 2006
118. Busi, Sara: Synthesis, characterization and thermal properties of new quaternary ammonium compounds: new materials for electrolytes, ionic liquids and complexation studies. (102 pp.) 2006
119. Mäntykoski, Keijo: PCBs in processes, products and environment of paper mills using wastepaper as their raw material. (73 pp.) 2006
120. Laamanen, Pirkko-Leena: Simultaneous determination of industrially and environmentally relevant aminopolycarboxylic and hydroxycarboxylic acids by capillary zone electrophoresis. (54 pp.) 2007
121. Salmela, Maria: Description of oxygen-alkali delignification of kraft pulp using analysis of dissolved material. (71 pp.) 2007
122. Lehtovaara, Lauri: Theoretical studies of atomic scale impurities in superfluid <sup>4</sup>He. (87 pp.) 2007
123. Rautiainen, J. Mikko: Quantum chemical calculations of structures, bonding, and spectroscopic properties of some sulphur and selenium iodine cations. (71 pp.) 2007
124. Nummelin, Sami: Synthesis, characterization, structural and

- retrostructural analysis of self-assembling pore forming dendrimers. (286 pp.) 2008
125. Sopo, Harri: Uranyl(VI) ion complexes of some organic aminobisphenolate ligands: syntheses, structures and extraction studies. (57 pp.) 2008
126. Valkonen, Arto: Structural characteristics and properties of substituted cholanoates and *N*-substituted cholanamides. (80 pp.) 2008
127. Lähde, Anna: Production and surface modification of pharmaceutical nano- and microparticles with the aerosol flow reactor. (43 pp.) 2008
128. Beyeh, Ngong Kodiah: Resorcinarenes and their derivatives: synthesis, characterization and complexation in gas phase and in solution. (75 pp.) 2008
129. Välisaari, Jouni, Lundell, Jan (Eds.): Kemian opetuksen päivät 2008: uusia oppimisympäristöjä ja ongelmalähtöistä opetusta. (118 pp.) 2008
130. Myllyperkiö, Pasi: Ultrafast electron transfer from potential organic and metal containing solar cell sensitizers. (69 pp.) 2009
131. Käkölä, Jaana: Fast chromatographic methods for determining aliphatic carboxylic acids in black liquors. (82 pp.) 2009
132. Koivukorpi, Juha: Bile acid-arene conjugates: from photoswitchability to cancer cell detection. (67 pp.) 2009
133. Tuuttila, Tero: Functional dendritic polyester compounds: synthesis and characterization of small bifunctional dendrimers and dyes. (74 pp.) 2009
134. Salorinne, Kirsi: Tetramethoxy resorcinarene based cation and anion receptors: synthesis, characterization and binding properties. (79 pp.) 2009
135. Rautiainen, Riikka: The use of first-thinning Scots pine (*Pinus sylvestris*) as fiber raw material for the kraft pulp and paper industry. (73 pp.) 2010
136. Ilander, Laura: Uranyl salophens: synthesis and use as ditopic receptors. (199 pp.) 2010
137. Kiviniemi, Tiina: Vibrational dynamics of iodine molecule and its complexes in solid krypton - Towards coherent control of bimolecular reactions? (73 pp.) 2010
138. Ikonen, Satu: Synthesis, characterization and structural properties of various covalent and non-covalent bile acid derivatives of N/O-heterocycles and their precursors. (105 pp.) 2010
139. Siitonen, Anni: Spectroscopic studies of semiconducting single-walled carbon nanotubes. (56 pp.) 2010
140. Raatikainen, Kari: Synthesis and structural studies of piperazine cyclophanes – Supramolecular systems through Halogen and Hydrogen bonding and metal ion coordination. (69 pp.) 2010
141. Leivo, Kimmo: Gelation and gel properties of two- and three-component Pyrene based low molecular weight organogelators. (116 pp.) 2011
142. Martiskainen, Jari: Electronic energy transfer in light-harvesting complexes isolated from *Spinacia oleracea* and from three

- photosynthetic green bacteria *Chloroflexus aurantiacus*, *Chlorobium tepidum*, and *Prosthecochloris aestuarii*. (55 pp.) 2011
143. Wichmann, Oula: Syntheses, characterization and structural properties of [O,N,O,X'] aminobisphenolate metal complexes. (101 pp.) 2011
144. Ilander, Aki: Development of ultrasound-assisted digestion methods for the determination of toxic element concentrations in ash samples by ICP-OES. (58 pp.) 2011
145. The Combined XII Spring Meeting of the Division of Synthetic Chemistry and XXXIII Finnish NMR Symposium. Book of Abstracts. (90 pp.) 2011
146. Valto, Piia: Development of fast analysis methods for extractives in papermaking process waters. (73 pp.) 2011
147. Andersin, Jenni: Catalytic activity of palladium-based nanostructures in the conversion of simple olefinic hydro- and chlorohydrocarbons from first principles. (78 pp.) 2011
148. Aumanen, Jukka: Photophysical properties of dansylated poly(propylene amine) dendrimers. (55 pp.) 2011
149. Kärnä, Minna: Ether-functionalized quaternary ammonium ionic liquids – synthesis, characterization and physicochemical properties. (76 pp.) 2011
150. Jurček, Ondřej: Steroid conjugates for applications in pharmacology and biology. (57 pp.) 2011
151. Nauha, Elisa: Crystalline forms of selected Agrochemical actives: design and synthesis of cocrystals. (77 pp.) 2012
152. Ahkola, Heidi: Passive sampling in monitoring of nonylphenol ethoxylates and nonylphenol in aquatic environments. (92 pp.) 2012
153. Helttunen, Kaisa: Exploring the self-assembly of resorcinarenes: from molecular level interactions to mesoscopic structures. (78 pp.) 2012
154. Linnanto, Juha: Light excitation transfer in photosynthesis revealed by quantum chemical calculations and exciton theory. (179 pp.) 2012
155. Roiko-Jokela, Veikko: Digital imaging and infrared measurements of soil adhesion and cleanability of semihard and hard surfaces. (122 pp.) 2012
156. Noponen, Virpi: Amides of bile acids and biologically important small molecules: properties and applications. (85 pp.) 2012
157. Hulkko, Eero: Spectroscopic signatures as a probe of structure and dynamics in condensed-phase systems – studies of iodine and gold ranging from isolated molecules to nanoclusters. (69 pp.) 2012
158. Lappi, Hanna: Production of Hydrocarbon-rich biofuels from extractives-derived materials. (95 pp.) 2012
159. Nykänen, Lauri: Computational studies of Carbon chemistry on transition metal surfaces. (76 pp.) 2012
160. Ahonen, Kari: Solid state studies of pharmaceutically important molecules and their derivatives. (65 pp.) 2012

DEPARTMENT OF CHEMISTRY, UNIVERSITY OF JYVÄSKYLÄ  
RESEARCH REPORT SERIES

161. Pakkanen, Hannu: Characterization of organic material dissolved during alkaline pulping of wood and non-wood feedstocks. (76 pp.) 2012
162. Moilanen, Jani: Theoretical and experimental studies of some main group compounds: from closed shell interactions to singlet diradicals and stable radicals. (80 pp.) 2012
163. Himanen, Jatta: Stereoselective synthesis of Oligosaccharides by *De Novo* Saccharide welding. (133 pp.) 2012
164. Bunzen, Hana: Steroidal derivatives of nitrogen containing compounds as potential gelators. (76 pp.) 2013
165. Seppälä, Petri: Structural diversity of copper(II) amino alcohol complexes. Syntheses, structural and magnetic properties of bidentate amino alcohol copper(II) complexes. (67 pp.) 2013
166. Lindgren, Johan: Computational investigations on rotational and vibrational spectroscopies of some diatomics in solid environment. (77 pp.) 2013
167. Giri, Chandan: Sub-component self-assembly of linear and non-linear diamines and diacylhydrazines, formylpyridine and transition metal cations. (145 pp.) 2013
168. Riisiö, Antti: Synthesis, Characterization and Properties of Cu(II)-, Mo(VI)- and U(VI) Complexes With Diaminotetraphenolate Ligands. (51 pp.) 2013
169. Kiljunen, Toni (Ed.): Chemistry and Physics at Low Temperatures. Book of Abstracts. (103 pp.) 2013
170. Hänninen, Mikko: Experimental and Computational Studies of Transition Metal Complexes with Polydentate Amino- and Aminophenolate Ligands: Synthesis, Structure, Reactivity and Magnetic Properties. (66 pp.) 2013
171. Antila, Liisa: Spectroscopic studies of electron transfer reactions at the photoactive electrode of dye-sensitized solar cells. (53 pp.) 2013
172. Kemppainen, Eeva: Mukaiyama-Michael reactions with  $\alpha$ -substituted acroleins – a useful tool for the synthesis of the pectenotoxins and other natural product targets. (190 pp.) 2013
173. Virtanen, Suvi: Structural Studies of Dielectric Polymer Nanocomposites. (49 pp.) 2013
174. Yliniemelä-Sipari, Sanna: Understanding The Structural Requirements for Optimal Hydrogen Bond Catalyzed Enolization – A Biomimetic Approach. (160 pp.) 2013
175. Leskinen, Mikko V: Remote  $\beta$ -functionalization of  $\beta'$ -keto esters. (105 pp.) 2014
176. 12<sup>th</sup> European Conference on Research in Chemistry Education (ECRICE2014). Book of Abstracts. (166 pp.) 2014
177. Peuronen, Anssi: N-Monoalkylated DABCO-Based N-Donors as Versatile Building Blocks in Crystal Engineering and Supramolecular Chemistry. (54 pp.) 2014
178. Perämäki, Siiri: Method development for determination and recovery of rare earth elements from industrial fly ash. (88 pp.) 2014

DEPARTMENT OF CHEMISTRY, UNIVERSITY OF JYVÄSKYLÄ  
RESEARCH REPORT SERIES

179. Chernyshev, Alexander, N.: Nitrogen-containing ligands and their platinum(IV) and gold(III) complexes: investigation and basicity and nucleophilicity, luminescence, and aurophilic interactions. (64 pp.) 2014
180. Lehto, Joni: Advanced Biorefinery Concepts Integrated to Chemical Pulping. (142 pp.) 2015
181. Tero, Tiia-Riikka: Tetramethoxy resorcinarenes as platforms for fluorescent and halogen bonding systems. (61 pp.) 2015
182. Löfman, Miika: Bile acid amides as components of microcrystalline organogels. (62 pp.) 2015
183. Selin, Jukka: Adsorption of softwood-derived organic material onto various fillers during papermaking. (169 pp.) 2015
184. Piisola, Antti: Challenges in the stereoselective synthesis of allylic alcohols. (210 pp.) 2015
185. Bonakdarzadeh, Pia: Supramolecular coordination polyhedra based on achiral and chiral pyridyl ligands: design, preparation, and characterization. (65 pp.) 2015
186. Vasko, Petra: Synthesis, characterization, and reactivity of heavier group 13 and 14 metallylenes and metalloid clusters: small molecule activation and more. (66 pp.) 2015
187. Topić, Filip: Structural Studies of Nano-sized Supramolecular Assemblies. (79 pp.) 2015
188. Mustalahti, Satu: Photodynamics Studies of Ligand-Protected Gold Nanoclusters by using Ultrafast Transient Infrared Spectroscopy. (58 pp.) 2015
189. Koivisto, Jaakko: Electronic and vibrational spectroscopic studies of gold-nanoclusters. (63 pp.) 2015
190. Suhonen, Aku: Solid state conformational behavior and interactions of series of aromatic oligoamide foldamers. (68 pp.) 2016
191. Soikkeli, Ville: Hydrometallurgical recovery and leaching studies for selected valuable metals from fly ash samples by ultrasound-assisted extraction followed by ICP-OES determination. (107 pp.) 2016
192. XXXVIII Finnish NMR Symposium. Book of Abstracts. (51 pp.) 2016
193. Mäkelä, Toni: Ion Pair Recognition by Ditopic Crown Ether Based bis-Urea and Uranyl Salophen Receptors. (75 pp.) 2016
194. Lindholm-Lehto, Petra: Occurrence of pharmaceuticals in municipal wastewater treatment plants and receiving surface waters in Central and Southern Finland. (98 pp.) 2016
195. Härkönen, Ville: Computational and Theoretical studies on Lattice Thermal conductivity and Thermal properties of Silicon Clathrates. (89 pp.) 2016
196. Tuokko, Sakari: Understanding selective reduction reactions with heterogeneous Pd and Pt: climbing out of the black box. (85 pp.) 2016
197. Nuora, Piia: Monitapaustutkimus LUMA-Toimintaan liittyvissä oppimisympäristöissä tapahtuvista kemian oppimiskokemuksista. (171 pp.) 2016

DEPARTMENT OF CHEMISTRY, UNIVERSITY OF JYVÄSKYLÄ  
RESEARCH REPORT SERIES

198. Kumar, Hemanathan: Novel Concepts on The Recovery of By-Products from Alkaline Pulping. (61 pp.) 2016
199. Arnedo-Sánchez, Leticia: Lanthanide and Transition Metal Complexes as Building Blocks for Supramolecular Functional Materials. (227 pp.) 2016
200. Gell, Lars: Theoretical Investigations of Ligand Protected Silver Nanoclusters. (134 pp.) 2016
201. Vaskuri, Juhani: Oppiennätyksistä opetussuunnitelman perusteisiin - lukion kemian kansallisen opetussuunnitelman kehittyminen Suomessa vuosina 1918-2016. (314 pp.) 2017
202. Lundell Jan, Kiljunen Toni (Eds.): 22<sup>nd</sup> Horizons in Hydrogen Bond Research. Book of Abstracts. 2017
203. Turunen, Lotta: Design and construction of halogen-bonded capsules and cages. (61 pp.) 2017
204. Hurmalainen, Juha: Experimental and computational studies of unconventional main group compounds: stable radicals and reactive intermediates. (88 pp.) 2017
205. Koivistoinen Juha: Non-linear interactions of femtosecond laser pulses with graphene: photo-oxidation, imaging and photodynamics. (68 pp.) 2017
206. Chen, Chengcong: Combustion behavior of black liquors: droplet swelling and influence of liquor composition. (39 pp.) 2017
207. Mansikkamäki, Akseli: Theoretical and Computational Studies of Magnetic Anisotropy and Exchange Coupling in Molecular Systems. (190 p. + included articles) 2018.
208. Tatikonda, Rajendhraprasad: Multivalent N-donor ligands for the construction of coordination polymers and coordination polymer gels. (62 pp.) 2018
209. Budhathoki, Roshan: Beneficiation, desilication and selective precipitation techniques for phosphorus refining from biomass derived fly ash. (64 pp.) 2018
210. Siitonen, Juha: Synthetic Studies on 1-azabicyclo[5.3.0]decane Alkaloids. (140 pp.) 2018
211. Ullah, Saleem: Advanced Biorefinery Concepts Related to Non-wood Feedstocks. (57 pp.) 2018
212. Ghalibaf, Maryam: Analytical Pyrolysis of Wood and Non-Wood Materials from Integrated Biorefinery Concepts. (106 pp.) 2018

1. Bulatov, Evgeny: Synthetic and structural studies of covalent and non-covalent interactions of ligands and metal center in platinum(II) complexes containing 2,2'-dipyridylamine or oxime ligands. (58 pp.) 2019. JYU Dissertations 70.
2. Annala, Riia: Conformational Properties and Anion Complexes of Aromatic Oligoamide Foldamers. (80 pp.) 2019. JYU Dissertations 84.
3. Isoaho, Jukka Pekka: Dithionite Bleaching of Thermomechanical Pulp - Chemistry and Optimal Conditions. (73 pp.) 2019. JYU Dissertations 85.
4. Nygrén, Enni: Recovery of rubidium from power plant fly ash. (98 pp.) 2019. JYU Dissertations 136.
5. Kiesilä, Anniina: Supramolecular chemistry of anion-binding receptors based on concave macromolecules. (68 pp.) 2019. JYU Dissertations 137.
6. Sokolowska, Karolina: Study of water-soluble p-MBA-protected gold nanoclusters and their superstructures. (60 pp.) 2019. JYU Dissertations 167.
7. Lahtinen, Elmeri: Chemically Functional 3D Printing: Selective Laser Sintering of Customizable Metal Scavengers. (71 pp.) 2019. JYU Dissertations 175.
8. Larijani, Amir: Oxidative reactions of cellulose under alkaline conditions. (102 pp.) 2020. JYU Dissertations 217.
9. Kolari, Kalle: Metal-metal contacts in late transition metal polymers. (60 pp.) 2020. JYU Dissertations 220.
10. Kauppinen, Minttu: Multiscale computational investigation of catalytic properties of zirconia supported noble metals. (87 pp.) 2020. JYU Dissertations 231.
11. Ding, Xin: Halogen Bond in Crystal Engineering: Structural Studies on Crystals with Ruthenium Centered Complexes and 1-(4-Pyridyl)-4-thiopyridine Zwitterion as Halogen Bond Acceptors. (59 pp.) 2020. JYU Dissertations 323.
12. Neuvonen, Antti: Toward an Understanding of Hydrogen-Bonding Bifunctional Organocatalyst Conformations and Their Activity in Asymmetric Mannich Reactions. (77 pp.) 2020. JYU Dissertations 336.
13. Kortet, Sami: 2,5-Diarylpiperidines and Pyroglutamic-Acid-Derived 2-Diarylmethyl-5-Aryl-Piperidines: Their Synthesis and Use in Asymmetric Synthesis. (221 pp.) 2020. JYU Dissertations 337.
14. Saarnio, Ville: Fluorescent probes, noble metal nanoparticles and their nanocomposites: detection of nucleic acids and other biological targets. (80 pp.) 2021. JYU Dissertations 361.
15. Chernysheva, Maria:  $\sigma$ -hole interactions: the effect of the donors and acceptors nature in selenoureas, thioureas, halogenated species, substituted benzenes, and their adducts. (72 pp.) 2021. JYU Dissertations 370.
16. Bulatova, Margarita: Noncovalent interactions as a tool for supramolecular self-assembly of metallopolymers. (62 pp.) 2021. JYU Dissertations 377.



17. Romppanen, Sari: Laser-spectroscopic studies of rare earth element- and lithium-bearing minerals and rocks. (66 pp.) 2021. JYU Dissertations 393.
18. Kukkonen, Esa: Nonlinear optical materials through weak interactions and their application in 3D printing. (58 pp.) 2021. JYU Dissertations 441.
19. Kuosmanen, Riikka: The Effect of Structure on the Gel Formation Ability and the Properties of Bile Acid Based Supramolecular Organogels. (68 pp.) 2021. JYU Dissertations 465.
20. Reuna, Sini: Development of a Method for Phosphorus Recovery from Wastewaters. (67 pp.) 2022. JYU Dissertations 486.
21. Taipale, Essi: Synthetic and Structural Studies on the Effect of Non-Covalent Interactions on N(*sp*<sup>2</sup>)-Heterocyclic Molecules. (67 pp.) 2022. JYU Dissertations 496.
22. Järvinen, Teemu: Molecular Dynamics View on Matrix Isolation. (143 pp.) 2022. JYU Dissertations 544.
23. Kumar, Parveen: Synthesis and Structural Studies on Halogen(I) Complexes. (160 pp.) 2022. JYU Dissertations 549.
24. Forsblom, Samu: Design and Construction of Metal-Organic Polyhedra. (212 pp.) 2022. JYU Dissertations 569.
25. Korpelin, Ville: Computational Studies of Catalytic Active Site Properties and Reactions at the Metal–Oxide Interface. (78 pp.) 2022. JYU Dissertations 578.
26. Vuori, Hannu: Extending Benson Group Increment Theory to Compounds of Phosphorus, Silicon, and Boron with Computational Chemistry. (59 pp.) 2022. JYU Dissertations 581.